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 Each year approximately 600,000 and 2.2 million bone graft procedures are performed 
worldwide with 600,000 of them performed only in the United States. With a high success rate of 
osteo-integration and limited activation of the immune response, autografts are currently 
considered the gold standard for bone grafting. However, autografts are limited by the volume of 
bone tissue that can be harvested and by the threat of donor site morbidity. Allografts are 
alternatives to autografts since they are available in nearly unlimited supply and avoid donor-site 
morbidity and pain. However, allografts have been shown to be less frequently osteoinductive 
than autografts due to lack of biological factors, i.e., cells, growth factors. Limited 
vascularization, new bone formation and remodeling associated with large allograft healing are 
directly associated with clinical failure due to non-unions, late graft fractures and infections.  
 The objective of this thesis is to increase the functionality and subsequent incorporation 
of allograft into host bone by applying a thin polymeric coating to allografts that would be 
capable of carrying and delivering growth factors with quantitative precision in hopes of 
increasing the ability of allografts to heal large scale bone defects. It is hypothesized that loading 
the dual growth factors, bone morphogenetic protein-2 (BMP-2 ) and vascular endothelial 
growth factor (VEGF), onto a polymeric coating with two different techniques will result in short 
term and long term delivery kinetics. We also hypothesized that dual sequential delivery of 
BMP-2 and VEGF will show enhanced bone repair over BMP-2 delivered alone. We introduced 
a thin coating of poly(lactide-co-glycolide) (PLGA), that has been used for orthopaedic and 
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musculoskeletal applications, to functionalize rat femoral allografts. Allografts was coated and 
loaded with BMP-2 and VEGF independently and simultaneously using two different loading 
techniques, surface adsorption and encapsulation, each with distinct delivery kinetics. The rapid 
release of VEGF stimulated osteoclastogenesis and the sustained release of BMP-2 encouraged 
osteogenesis. The bioactivity of the growth factors, BMP-2 and VEGF was evaluated through 
different bioassays using Human Mesenchymal Stem Cells (hMSCs) and Bone Marrow 
Macrophages (BMMs), respectively. Healing of rat femoral segmental defect was assessed after 
4 and 8 weeks to determine the effect of controlled release of VEGF and BMP-2.  
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1. INTRODUCTION 
1.1. Biology of Bone 
 
 Bone is a metabolically active and highly organized connective tissue which constitutes 
an internal support for all higher vertebrates. The main functions of bone are: a) it is a major 
organ for calcium homeostasis and a significant store of phosphate, magnesium, potassium, and 
bicarbonate; b) bones provide mechanical support for the soft tissues; c) it provides protection of 
internal vital organs; and d) bone is the major site of hematopoiesis in the human adult. By mass, 
bone is 8% water, 22% protein, and 70% mineral [1]. The organic portion of bone is primarily 
type I collagen while the inorganic portion is mainly calcium phosphate. Like other connective 
tissues, the structural organization of bone is a robust ECM coupled with a relatively sparse 
distribution of cells. Bone cells have the ability to form and deposit calcium phosphate within 
their extracellular matrixes. 
1.1.1. Overview and Structure of Bone 
 
 The adult human skeleton has about 213 bones, excluding the sesamoid bones. The 
appendicular skeleton has 126 bones, axial skeleton 74 bones, and auditory ossicles six bones 
[2]. Each bone constantly undergoes remodeling during life to help it adapt to changing 
biomechanical forces, as well as remodeling to remove old, micro-damaged bone and replace it 
with new, mechanically stronger bone to help preserve bone strength. Cells penetrate throughout 
the mineralized tissue constantly facilitate new bone formation through the process of 
apposition, in which cells deposit new matrix on existing bone surfaces that eventually becomes 
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mineralized. At the same time, a distinctly different class of cell resorbs the old bone matrix to 
make the way for the fresh bone.  
 The four general categories of bones are long bones, short bones, flat bones, and irregular 
bones. Long bones include the clavicles, humeri, radii, ulnae, metacarpals, femurs, tibiae, 
fibulae, metatarsals, and phalanges. Short bones include the carpal and tarsal bones, patellae, and 
sesamoid bones. Flat bones include the skull, mandible, scapulae, sternum, and ribs. Irregular 
bones include the vertebrae, sacrum, coccyx, and hyoid bone. The adult human skeleton is 
composed of 80% cortical bone and 20% trabecular bone overall. Cortical bone, the outer, denser 
envelope of most bones, plays a major role in the support function and trabecular or cancellous 
bone, which is metabolically more active and is highly vascular and is responsible for blood cell 
production. 
 The long bones are composed of a hollow shaft, or diaphysis; flared, cone-shaped 
metaphyses below the growth plates; and rounded epiphyses above the growth plates (figure 
1.1.1.1). The diaphysis is composed primarily of dense cortical bone, whereas the metaphysis 
and epiphysis are composed of trabecular meshwork bone surrounded by a relatively thin shell of 
dense cortical bone. The diaphysis contains the medullary cavity filled with bone marrow. 
Cortical bone is a very dense material with 5% to 10% porosity. Trabecular bone, commonly 
found in the end of long bones is highly porous with 50-90% porosity. The periosteum is a 
fibrous connective tissue sheath that surrounds the outer cortical surface of bone, contains blood 
vessels, nerve fibers, and osteoblasts and osteoclasts. Periosteum bone formation remains active 
during our lifespan. In case of bone fracture, periosteum promotes formation of cartilaginous 
callus, followed by ossification. It also provides vascular and nerve supply to bones and serves as 
attachment sites for surrounding tendons and muscles. The endosteum is a membranous structure 
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covering the inner surface of cortical bone, trabecular bone, and the blood vessel canals 
(Volkman’s canals) present in bone. The endosteum is in contact with the bone marrow space, 
trabecular bone, and blood vessel canals and contains blood vessels, osteoblasts, and osteoclasts. 
Both cortical and trabecular bones are composed of osteons [3].   
 
 
In cortical bone the osteons are known as Haversian systems. In cortical bone, 3-8 lamellae of 
continuous collagen fibril (50-500 nm) arrange in a concentric manner around a central 
harversian canal to form osteon or harversian systems. These canals are occupied by blood 
vessels to supply nutrients. 
Figure 1.1.1.1 : Diagrams of cortical and trabecular bones in long bone and bone matrix arranged in the form of concentric rings, 
lamellae, centered around Harversian canals to form osteons [3].  
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1.1.2. Bone cells and their functions 
 
 Mature bone tissue consists of three primary cell types: osteoblasts, osteocytes, and 
osteoclasts (figure 1.1.2.1).  
 
Figure 1.1.2.1: Bone cell types and organizations. Osteoblasts, osteoclasts and bone lining cells 
reside on the surface of the bone whereas osteocytes are in the interior matrix of the bone. 
Mesenchymal stem cells differentiate into osteoblasts whereas osteoclast stem from 
hematopoietic cells [4]. 
 
Osteoblasts and osteoclasts are present on the surfaces of bone, while osteocytes permeate the 
mineralized interior. Osteoblasts are fully differentiated bone cells, present on bone forming 
surfaces and are responsible for synthesis and regulation of matrix mineralization. Osteocytes are 
terminally differentiated osteoblasts that are incased by the mineralized matrix and support 
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overall bone structure. Osteoclasts are large, multinucleated cells that are derived from different 
cellular precursors (hematopoietic stem cells), and are responsible for bone resorption. Mature 
bone cells, lacking the ability to divide and proliferate, are formed from proliferative 
mesenchymal stem cells. During embryonic development, three germ layers are formed; the 
ectoderm, the mesoderm, and the endoderm. The mesoderm is the middle germ layer consisting 
of multipotent mesenchymal stem cells that eventually give rise to (among other things) the 
entire vascular and lymphatic systems and all connective tissue. Several classes of mesoderm-
derived stem cells exist and are distinguished according to the types of cells they may become. 
Mesenchymal stem cells found in the bone marrow or periosteum are capable of being induced 
to differentiate into osteoprogenitors that can then become osteoblasts, osteocytes, and bone 
lining cells, whereas osteoclasts originate from the hematopoietic stem cells in blood [5]. 
1.1.2.1. Osteoblast 
 
 Osteoblasts are cuboidal cells that are located along the bone surface comprising 4–6% of 
the total resident bone cells and are largely known for their bone forming function. Osteoblasts 
are derived from mesenchymal stem cells (MSC). The commitment of MSC towards the 
osteoprogenitor lineage requires the expression of specific genes, following timely programmed 
steps, including the synthesis of bone morphogenetic proteins (BMPs) and members of the 
Wingless (Wnt) pathways. The expressions of Runt related transcription factors 2 (RUNX2), 
Distal-less homeobox 5 (Dlx5), and osterix (Osx) are crucial for osteoblast differentiation. 
Additionally, Runx2 is a master gene of osteoblast differentiation, as demonstrated by the fact 
that Runx2-null mice are devoid of osteoblasts. Runx2 has demonstrated to upregulate 
osteoblast-related genes such as ColIA1, ALP, BSP, BGLAP, and OCN. Once a pool of 
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osteoblast progenitors expressing Runx2 and ColIA1 has been established during osteoblast 
differentiation, there is a proliferation phase. In this phase, osteoblast progenitors show alkaline 
phosphatase (ALP) activity, and are considered preosteoblasts. The transition of preosteoblasts to 
mature osteoblasts is characterized by an increase in the expression of Osx and in the secretion of 
bone matrix proteins such as osteocalcin (OCN), bone sialoprotein (BSP) I/II, and collagen type 
I. Moreover, the osteoblasts undergo morphological changes, becoming large and cuboidal cells. 
The synthesis of bone matrix by osteoblasts occurs in two main steps: deposition of organic 
matrix and its subsequent mineralization. Osteoblasts are very rich in ALP, which participates in 
the mineralization process. Osteoblasts deposit about ~0.5 μm of matrix per day and their 
forming period lasts about 100 days [6-8]. Some of the osteoblasts are then entrapped within the 
matrix which they formed and are called osteocytes; others become flattened cells on the surface 
of the bone, and are called lining cells.  
1.1.2.2. Osteoclast 
 
 Osteoclasts are terminally differentiated multinucleated cells, which originate from 
mononuclear cells of the hematopoietic stem cell lineage, under the influence of several factors. 
Among these factors the macrophage colony-stimulating factor (M-CSF), secreted by 
osteoprogenitor mesenchymal cells and osteoblasts, and RANK ligand, secreted by osteoblasts, 
osteocytes, and stromal cells, are included. Together, these factors promote the activation of 
transcription factors and gene expression in osteoclasts. M-CSF binds to its receptor (cFMS) 
present in osteoclast precursors, which stimulates their proliferation and inhibits their apoptosis. 
RANKL is a crucial factor for osteoclastogenesis and is expressed by osteoblasts, osteocytes, and 
stromal cells. When it binds to its receptor RANK in osteoclast precursors, osteoclast formation 
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is induced. On the other hand, another factor called osteoprotegerin (OPG), which is produced by 
a wide range of cells including osteoblasts, stromal cells, and gingival and periodontal 
fibroblasts, binds to RANKL, preventing the RANK/RANKL interaction and, consequently, 
inhibiting the osteoclastogenesis. Thus, the RANKL/RANK/OPG system is a key mediator of 
osteoclastogenesis. Parathyroid hormone (PTH) inhibits OPG and thus helps in enhancing 
RANKL expression (Figure 1.1.2.2.1). 
 
Figure 1.1.2.2.1: Mechanisms of osteoclast formation and bone resorption. Stromal cells and 
osteoblasts express RANKL and M-CSF, which are up-regulated by osteoclastogenic molecules 
such as PTH. RANKL and M-CSF, interacting with their receptors on monocyte/macrophage cells, 
induce osteoclast formation. As these osteoclasts mature and form ruffled membrane, they 
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acidifies an extracellular microenvironment. Cathepsin K, a lysosome protease cause the 
degradation of demineralized organic matrix [9]. 
 Osteoclasts are bone dissolving cells that carry out the resorption of mineralized tissue. 
During bone resorption, osteoclasts attach to the active site of bone surface. They have two distinct 
plasma membrane regions: a ruffled border where the active resorption occurs and a clear or 
sealing zone that attaches the osteoclasts to the underlying matrix. Binding of osteoclasts to bone 
matrix causes them to become polarized, with the bone resorbing surface developing a ruffled 
border that forms when acidified vesicles that contain matrix metalloproteinases and cathepsin K 
are transported via microtubules to fuse with the membrane. The ruffled border secretes H+ ions 
via H+ -ATPase and chloride channels and causes exocytosis of cathepsin K and other enzymes in 
the acidified vesicles. The sealing zone surrounds the ruffled border and forms the resorption 
lacuna. In the sealing zone, the osteoclasts secrete hydrochloric acid to acidify and dissolve the 
hydroxyapatite crystals which constitute the mineral portion of extracellular matrix. The matrix 
degradation products ae removed from the resorption lacuna and transported into the extracellular 
space through the basolateral membrane of the osteoclasts. It has recently been demonstrated that 
the osteoclastogenic potential may differ depending on the bone site considered. It has been 
reported that osteoclasts from long bone marrow are formed faster than in the jaw. This different 
dynamic of osteoclastogenesis possibly could be, due to the cellular composition of the bone-site 
specific marrow [10, 11].  
1.1.2.3. Osteocytes 
 
 Osteocytes, which comprise 90–95% of the total bone cells, are the most abundant and 
long-lived cells, with a lifespan of up to 25 years [12, 13]. The morphology of embedded 
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osteocytes differs depending on the bone type. For instance, osteocytes from trabecular bone are 
more rounded than osteocytes from cortical bone, which display an elongated morphology. 
Osteocytes are derived from MSCs lineage through osteoblast differentiation. In this process, 
four recognizable stages have been proposed: osteoid-osteocyte, preosteocyte, young osteocyte, 
and mature osteocyte. At the end of a bone formation cycle, a subpopulation of osteoblasts 
becomes osteocytes incorporated into the bone matrix. Once the stage of mature osteocyte totally 
entrapped within mineralized bone matrix is accomplished, several of the previously expressed 
osteoblast markers such as OCN, BSPII, collagen type I, and ALP are downregulated. On the 
other hand, osteocyte markers including dentine matrix protein 1 (DMP1) and sclerostin are 
highly expressed. Within the matrix, osteocytes residing in lacunae provide the communication 
network between adjacent osteocytes, osteoblasts and bone lining cells on the external surfaces 
of bone by extending out processes within the canaliculi and establishing contact to adjacent 
cells via gap junctions. Such an extensive network of canaliculi also allows the diffusion of 
nutrients and metabolites through the mineralized matrix and blood vessels. Moreover, osteocyte 
apoptosis has been recognized as a chemotactic signal to osteoclastic bone resorption. In 
agreement, it has been shown that during bone resorption, apoptotic osteocytes are engulfed by 
osteoclasts. In addition, osteocytes act as mechanosensors in bone. Osteocytes can sense and 
signal transport functions and promote the translation of mechanical stimuli into biochemical 
signals to initiate formation or resorption responses [14]. 
1.1.2.4. Bone lining cells 
  
 Bone lining cells are thin, flat and elongated inactive cells that line with bone surfaces. 
They are originated from osteoblasts but have fewer cytoplasm and organelles. Recent studies 
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have shown that bone lining cells are able to communicate with the entrapped osteocytes and 
contribute to the anchorage of hematopoietic stem cells and their subsequent differentiation into 
osteoclasts. These lining cells secrete matrix metalloproteinase to remove the thin layer of 
osteoid covering the bone matrix and aid in the attachment of osteoclasts to specific bind sites 
and initiate bone resorption. After remodeling, a collagen layer is secreted by the bone lining 
cells to cover the bone surfaces [12].   
1.1.3. Bone Matrix and Markers 
 
  Bone matrix is composed of both organic (35%) and inorganic components 
(65%). The inorganic material of bone consists predominantly of phosphate and calcium ions; 
however, significant amounts of bicarbonate, sodium, potassium, citrate, magnesium, carbonate, 
fluorite, zinc, barium, and strontium are also present. Calcium and phosphate ions nucleate to 
form the hydroxyapatite crystals, which are represented by the chemical formula 
Ca10(PO4)6(OH)2. Together with collagen, the non-collagenous matrix proteins form a scaffold 
for hydroxyapatite deposition and such association is responsible for the typical stiffness and 
resistance of bone tissue. The inorganic phase is comprised of 65% of the bone matrix and play 
important roles in conferring compression resistance. The non-collagenous proteins contribute to 
the regulation of hydroxyapatite crystal size, orientation and mineral deposition by binding to 
calcium or releasing phosphate ion [16, 17,18].  
The organic phase is primarily consisted of type I collagen (90% of organic phase). The non-
collagenous proteins (10% of organic phase) include: glycoproteins (osteonectin, osteopontin, 
bone morphogenetic proteins and bone sialoprotein), proteoglycans (hyaluronan, decorin, 
biglycan and chondroitin sulfate) and a few protein with γ-carboxyglutamic acid (Gla) 
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(osteocalcin). These proteins regulate the cell differentiation and matrix mineralization via 
temporal and spatial expression. Figure 1.1.3.1 shows the cellular production of various 
osteoblastic markers including calcium, osteocalcin (OCN), osteopontin (OPN), alkaline 
phosphatase (ALP), and collagen type I (collagen I) relative to culture time and their effect on 
osteoblastic differentiation, proliferation and matrix mineralization.  
 
Figure 1.1.3.1: Expression of osteoblast markers shown relative to culture time and their 
contribution in different phases of f bone matrix formation [15]. 
 Osteopontin (OPN) is a secreted glycoprotein that was originally found in osteoblasts. It 
is produced by a variety of cells, including preosteoblasts, osteoblasts, osteocytes, endothelial 
cells, and macrophages, and its synthesis is stimulated by vitamin D3. The role of OPN in 
mineralization process attributes to 1) inhibition on apatite formation and growth; 2) regulation 
on the shape of hydroxyapatite crystal. It is also believed that OPN is important in recruiting 
osteoclast precursors and binding them to the mineralized bone matrix.  
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 Osteocalcin (OCN) is a calcium-binding protein that is the most abundant non-
collagenous protein in bone tissue. It is known to have a role in the process of bone 
mineralization, during which it binds to calcium phosphate in the ECM of osteoblasts.  It is 
primarily synthesized during the matrix mineralization stage of osteoblastic development, but 
may be marginally produced at earlier stages of matrix maturation. It has been suggested that 
OCN acts as a chemoattractant for osteoblasts, osteoclasts, and blood monocytes. Most of an 
organism’s OCN is localized within the bone cell matrices, however, when osteoblasts are 
producing large amounts of OCN during the mineralization phase of osteoblastic development, 
some OCN is also emitted into the blood. It is for this reason that serum levels of OCN are 
considered to be indicative of new bone formation. 
 Alkaline phosphatase (ALP) is an enzyme that is associated with cell plasma membrane. 
ALP is found in several other non-mineralized tissues including liver, kidney, intestine and 
placenta. ALP gene expression generally begins when a cell transitions from the proliferative to 
the matrix maturation stage, peaks during matrix maturation, and then decreases upon entrance 
of the osteoblastic mineralization stage. The role of ALP in mineralization can be summarized: 
1) ALP hydrolyzes phosphate ester and results in the increase of local phosphate concentrate 
ultimately promoting bone mineral formation; 2)ALP hydrolyzes pyrophosphate, a calcification 
inhibitor, into phosphate molecules; 3) ALP transfers phosphate groups from the extracellular 
fluid and binds calcium to facilitate calcium phosphate precipitation [16,17].  
 Bone resorption markers include an enzyme, tartrate resistant acid phosphatase (TRAP), 
and products of bone breakdown, which include calcium and bone matrix degradation products 
such as hydroxyproline, pyridinium cross-links, and telopeptides [16].   
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1.1.4. Bone Fracture and Repair  
  
 There are two different mechanisms of ossification in normal bone healing: 
intramembranous and endochondral ossification. In either case, mesenchymal cellular 
condensation first occurs and serves as a template for the subsequent bone formation. 
Intramembranous bone formation involves mesenchymal progenitor cells differentiating directly 
into osteoblasts, and the subsequent development of parts of the mandible and clavicle, and many 
cranial bones. Most bones in the body (i.e., all long bones and vertebrae), however, are formed 
through endochondral bone formation. This process involves mesenchymal progenitor cells first 
differentiating into chondrocytes, which are responsible for depositing a cartilaginous template 
that is later, mineralized and replaced by bone. 
 Fractured cortical bone is repaired by a callus formation mechanism, in which new bone 
(callus) composed of fibrous tissue, blood vessels, cartilage, and bone forms in order to bridge 
the gap between the two fractured bone fragments. This fracture healing process involves four 
sequential stages: hematoma formation (inflammation), soft callus formation, hard callus 
formation and bone remodeling (figure 1.1.4.1). These stages often overlap with each other 
temporally [18,19].  
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Figure 1.1.4.1: A four-stage model of fracture repair. (A) Histological images of fracture healing 
showing soft callus is systematically remodeled; (B) Repair of fractures by callus production 
occurs in four overlapping phases; (C) Cellular contribution to the fracture healing process 
[18,19]. 
 
1.1.4.1. Inflammation 
 
 The first stage of cortical bone healing is inflammation. Following the fracture, disruption 
of blood vessels and normal vascular function causes the activation of non-specific wound 
A 
B 
C 
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healing pathways. The bleeding results in formation of hematoma between fractured fragments. 
Degranulated platelets, macrophages, and other inflammatory cells (granulocytes, lymphocytes, 
and monocytes) infiltrate the hematoma between the fractured fragments and combat infection, 
secrete cytokines and growth factors, and advance clotting into a fibrinous thrombus. Over time, 
capillaries grow into the clot, which is reorganized into granulation tissue. Macrophages, giant 
cells and other phagocytic cells clear degenerated cells and other debris. Eventually, hemostasis 
is achieved within the hematoma as platelets bind to the fibrillar collagen that forms throughout 
the site. These platelets release various vasoactive mediators and growth factors in order to 
influence cell migration, proliferation, and differentiation. New blood vessels are formed from 
preexisting ones through the process of angiogenesis within the hematoma as inflammatory cells, 
fibroblasts, and preosteoblasts are recruited by growth factors and cytokines that are released by 
the inflammatory response. The increased cellular proliferation throughout the injury site is seen 
within the first 8 hours of post injury and reaches its maximum around 24 hours. In the next few 
days, the cellular activity subsides and confines to the fracture area. This stage can last up to a 
month.  
1.1.4.2. Soft Callus Formation 
 
 The second stage of cortical bone healing is soft (or primary) callus formation, in which a 
fibrocartilagous callus forms. In this stage, chondrocytes and fibroblasts produce a semi-rigid 
soft callus that is able to provide mechanical support to the fracture, as well as act as a template 
for the bony callus that will later supersede it. The growth of the separated cartilaginous regions 
continues until they unite to generate a big fibrocartilaginous callus bridging the fracture.  
Finally, chondrocytes become hypertrophic and mineralize the cartilaginous matrix. At the same 
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time, intramembranous ossification occurs at the periosteum and an external callus is created 
along the periphery of the fracture.  
1.1.4.3. Hard Callus Formation 
 
 This stage of bone healing is also known as primary bone formation stage, which is the 
most active osteogenesis period. It is characterized by high levels of osteoblast activity and the 
formation of mineralized bone matrix, which arises directly in the peripheral callus. In order for 
bridging new hard callus to form, the insecure soft callus is gradually removed, followed by 
revascularization. The new bone is known as the hard callus and it is typically irregular and 
under-remodeled. However, it has an increased diameter compared to the original cortex and 
thus provides sufficient stability to the defect site. In summary, the primary bone formation 
phase displays the most rapid osteogenesis, involving (1) bone cell recruitment and woven bone 
formation; (2) chondrocyte apoptosis, osteoclast recruitment, and mineralized cartilage 
resorption; and (3) continued neo-angiogenesis. 
1.1.4.4. Bone Remodeling  
  
 In the final stage of bone remodeling (over 12 weeks), the woven bone hard callus is 
gradually remodeled to lamellar bone and the size of the callus is decreased to that of pre-
existing bone.  During this renewal process small pockets of old bone are replaced by new bone. 
It has been estimated that in humans, as much as 25% of trabecular bone and 3% of cortical bone 
is resorbed and replaced each year [20]. A remodeling site is initiated by the appearance of 
osteoclasts (and precursors) following any of several humoral or local stimuli to resorption. The 
osteoclasts proceed to resorb an amount of bone which produces a small resorption pit 
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(Howship’s lacuna), following which, they move to another site. This resorptive phase is 
followed by an active reversal phase when the cement line is deposited. During the subsequent 
formative phase, actively synthesizing cuboidal osteoblasts appear and begin to deposit 
uncalcified matrix (osteoid) which is later mineralized. Resorption and formation always occur 
successively in the same location and always in the same order [21]. This sequence of resorption 
and formation has been referred to as a basic multicellular unit of bone turnover (BMU) as 
illustrated in figure 1.1.4.4.1. The process of bone resorption followed by an equal amount of 
formation has been termed coupling. This remodeling phase may take 3 months to several years 
to complete [20].  
 
Figure 1.1.4.4.1: The remodeling cycle in bone. Representation of Bone Multicellular Units 
(BMUs) showing the various stages of cellular activity including resorption of old bone by 
osteoclasts and the subsequent formation of new bone by osteoblasts. For simplicity of 
illustration, the cartoon shows remodeling in only two dimensions, whereas in vivo it occurs in 
three dimensions, with osteoclasts continuing to enlarge the cavity at one end and osteoblasts 
beginning to fill it in at the other end [22]. 
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1.2. Growth Factors Associated with Healing Process 
  
 A cell receives information from a growth factor through the binding of the factor to its 
receptor, which is integrated in the cell’s plasma membrane. Each factor is associated with a 
specific receptor to which it binds with a high affinity in order to stimulate an intercellular 
response. The signal from the factor-binding may be transmitted to the cell in several different 
ways, depending on the specific factor-receptor pair. Many growth factors have been purified 
and their amino acids sequenced, enabling researchers to isolate the corresponding human 
cDNA. With the cDNA sequences, it is possible to achieve recombinant growth factor 
expression in pharmaceutical amounts. 
As discussed in the previous section bone healing is a very intricate phenomenon that 
involves many different steps and components throughout its process.  Following a fracture, a 
blood clot is formed at the injury site, causing platelets to release granules to transform the clot 
into a hematoma.  The ECM created allows for inflammatory cells such as neutrophils, 
monocytes, and lymphocytes to access the hematoma.  Along with these inflammatory cells, 
mesenchymal stem cells (MSC’s) are recruited within a couple hours of the fracture. This 
cellular response is coordinated by and involves the secretion of a range of cytokines and growth 
factors including transforming growth factor-β(TGF-β), platelet-derived growth factor (PDGF), 
fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), macrophage 
colony stimulating factor (MCSF), interleukins-1 and -6 (IL-1 and -6), bone morphogenetic 
proteins (BMPs), and tumor necrosis factor-α(TNF-α). These factors facilitate the recruitment of 
additional inflammatory cells in a positive feedback loop, and also the migration and invasion of 
multipotent mesenchymal stem cells. In the second stage of healing, the differentiation of these 
MSC’s into chondrocytes causes the formation of cartilage. Fibroblast proliferation and 
 19 
 
chondrocyte proliferation/ differentiation are stimulated by the coordinated expression of growth 
factors including TGF-β2 and -β3, PDGF, fibroblast growth factor-1 (FGF-1), and insulin-like 
growth factor (IGF). Additionally, members of the BMP family assist in promoting cell 
proliferation and chondrogenesis. Invasion of the soft callus by vascular endothelial cells, 
angiogenesis, and capillary in-growth is stimulated by pro-angiogenic factors including VEGF, 
BMPs, FGF-1 and TGF-β.  In addition, angiopoietin I and II regulate vascular morphogenesis of 
larger vessels and development of collateral branches from existent vessels. In the primary bone 
phase formation, there’s an increase in TNF-α, receptor activator of nuclear factor kappa B 
ligand (RANKL) and macrophage colony-stimulating factor (MCSF), associated with 
mineralized cartilage resorption, the recruitment of mesenchymal stem cells and induces 
apoptosis of hypertrophic chondrocytes. Activity of BMP-3, BMP-4, BMP-7, and BMP-8 
increase in association with the resorption of calcified cartilage and promote recruitment of cells 
in the osteoblastic lineage. VEGFs are upregulated to stimulate neo-angiogenesis. In the 
remodeling phase, osteoblasts and osteoclasts work in combination to create secondary bone and 
through the process of remodeling restore the bone to its original size, shape, and structure. 
During this stage the activity of IL-1 and IL-6 increase, whereas RANKL, MCSF, and TGF-β 
activity slowly diminish. This cascade of events is caused by the presence and activation of 
different growth factors and cytokines at specific time points.  A list of the major growth factors 
during the different stages of bone healing is shown in table 1.2.1 [23, 24]: 
Table 1.2.1: Growth factors associated with fracture healing [23, 24] 
Cytokines/Growth 
Factors 
Bone healing stages  Overall action 
 IL-1, 6 1.Inflammation    Hematoma 
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 TNFα 
 PDGFs 
 GDF-8 
 RANKL, M-
CSF 
 OPG 
 Inflammation 
 MSCs recruitment 
 VEGFs 
 BMPs 
 TGFβs 
 Angiopoietin 
 FGF-I 
 IGF 
2.Soft callus 
(fibrocartilagous 
callus) Formation 
   Chondrogenesis 
 Endochondral 
ossification 
 Osteoblast/Osteoclast 
precursors 
recruitment 
 Vascular ingrowth 
 New angiogenesis 
 VEGFs 
 BMP-2, 7 
 RANKL and M-
CSF 
 Angiopoietin 
3.Cartilage resorption 
and primary bone 
formation 
   Chondrocyte 
apoptosis 
 Cartilage resorption 
 Osteoblast/Osteoclast 
precursors 
differentiation 
 Woven bone 
formation 
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 IL-1, IL-6 
 RANKL and M-
CSF 
4.Secondary bone 
formation and 
remodeling 
   Bone remodeling 
 Osteoblast activity 
 Marrow 
establishment 
 
1.2.1. Bone Morphogenetic Protein-2 (BMP-2) 
 
 Bone morphogenetic proteins (BMPs) are members of the transforming growth factor β 
(TGFβ) family. They are involved in numerous mechanisms of organogenesis, notably in 
skeletogenesis. Thus far, around 20 different proteins have been named BMP in humans, but not 
all members are truly osteogenic. The bone-inducing BMPs can be divided into several 
subgroups, according to homology of their amino acid sequences. BMP-2 and BMP-4 comprise 
one subgroup; the second group consists of BMP-5, BMP-6, BMP-7 and BMP-8, while BMP-9 
and BMP-10 form the third osteogenic group. The other members of the BMP family do not 
possess osteogenic properties. BMP-1 is actually a metalloprotease and not a member of the 
superfamily, whereas BMP-3 and BMP-13 function as BMP antagonists/inhibitors rather than as 
BMPs [25]. In bone, BMPs are produced by osteoprogenitor cells, osteoblasts, chondrocytes and 
platelets. After their release, the extracellular matrix functions as a temporary storage for BMPs. 
The regulatory effects of BMPs depend upon the target cell type, its differentiation stage, the 
local concentration of BMPs, as well as the interactions with other secreted proteins. BMPs 
induce a sequential cascade of events leading to chondrogenesis, osteogenesis, angiogenesis and 
controlled synthesis of extracellular matrix. Of all BMPs, BMP-2 is essential for fracture healing. 
The BMP-2 signal transduction pathway is complex, but in brief, once BMP-2 has bound to its 
 22 
 
receptor complex, a signaling cascade is activated in which the Type II receptor kinase 
phosphorylates the Type I receptor, which then phosphorylates the intracytoplasmic signaling 
molecules, Smads 1, 5, and 8. Smads 1, 5, and 8 bind to Smad 4 and then translocate into the 
nucleus of the cell to activate transcriptional factors for certain osteoblastic genes [26]. Activated 
transcription factors enhance the expression of the osteoblastic mRNA and ultimately lead to 
increased production of proteins such as osteocalcin and alkaline phosphatase required for 
osteoblastic phenotype development, bone remodeling and mineralization. BMP-2 has shown 
strong osteoinductive activity both in vitro and in vivo. In vitro effects of BMPs are observed at 
very low dosages (5-20 ng/mL). Normal bone has been estimated to contain about 0.002 mg of 
BMP per kilogram of pulverized bone. However, current commercially available rhBMPs are 
used in large dosages (up to 40 mg of some products), probably because of their intense 
proteolytic consumption during the early stages of post-surgical repair, especially for orthopedic 
spinal fusion procedures [27]. Animal studies have shown a half-life of 7-16 min systemically, 
and up to 8 days locally when implanted on a collagen sponge [28]. The possible negative side 
effects for patients due these high doses of BMP-2 may result in vertebral osteolysis, ectopic 
bone formation, radiculitis and cervical soft tissue swelling [30]. 
1.2.2. Vascular Endothelial Growth Factor (VEGF) 
 
 Vascular endothelial growth factor (VEGF) is a potent mitogen, which increases the 
number of capillaries in a given network and is essential for angiogenesis, the mechanism to 
remodel initial vascular network. VEGF acts as a chemotactic factor for the proliferation of 
endothelial cells. Under hypoxic conditions, VEGF is upregulated by HIF-1, which stimulates 
vessel permeability, proliferation/survival, migration and differentiation into mature blood 
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vessels [30, 31]. It is well known that VEGF is required for effective coupling of angiogenesis to 
endochondral and membranous bone formation during skeletal development. VEGF plays 
significant role in osteoblast functionality. Studies have shown that VEGF has dose-dependent 
chemoattractive effect on primary human osteoblasts and human mesenchymal progenitor cells. 
Human-derived mesenchymal cells express VEGF and VEGFR-1, a VEGF receptor, during their 
differentiation and VEGF increases ALP activity in primary human osteoblastic cells [32, 33]. In 
endochondral ossification, an essential process for formation and growth of long bones, VEGF is 
responsible for regulating blood vessel invasion (neovascularization) into hypertrophic cartilage. 
The entering blood vessels bring undifferentiated mesenchymal cells into the mineralization 
front and later differentiate into osteoblasts and engage in osteogenesis. VEGF also plays a vital 
role in osteoclast differentiation and bone resorption. Studies showed that VEGF can directly 
enhance osteoclastic bone resorption. Nakagawa et al., demonstrated VEGF caused a dose- and 
time-dependent increase in the area of bone resorption pits excavated by the purified rabbit 
mature osteoclast. They detected two distinct VEGF receptors, KDR/Flk- 1 and Flt-1, in 
osteoclasts at the gene and protein levels, and VEGF induced tyrosine phosphorylation of 
proteins in osteoclasts. Thus, osteoclastic function and angiogenesis are upregulated by a 
common mediator, VEGF [34]. Yang et al. also reported that VEGF regulates survival of mature 
osteoclasts via VEGFR-2 signaling [35]. Liu et al. showed in a recent in vivo study with mutant 
mice that VEGF can stimulate osteoclast differentiation [36]. They suggested VEGF stimulates 
osteoclast formation in a paracrine mechanism. Helmrich et al. investigated a cell-based gene 
therapy approach to generate osteogenic grafts with an increased vascularization potential in an 
ectopic nude rat model in vivo. The study showed that the expression VEGF in the defect site not 
only improved vascularization but also increased the recruitment of the TRAP and Cathepsin K-
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positive osteoclasts [37]. Henriksen et al. conducted a combination of ex vivo bone culture and 
in vitro cell migration assays to study the role of Receptor activator of nuclear factor kappa-B 
ligand (RANKL) and VEGF in osteoclast recruitment through chemotactic properties during 
bone regeneration. Results demonstrated that RANKL and VEGF stimulate osteoclast 
recruitment and induce bone resorption through a signaling pathway different from M-CSF, a 
well characterized chemoattractant for osteoclasts. Addition of the antagonists of RANKL and 
VEGF led to reduced recruitment of osteoclasts in ex vivo cultures of embryonic bones [38]. 
When introduced intravenously, VEGF has a half-life of less than 30 minutes, requiring many 
doses or massive amounts of growth factor, which can lead to detrimental vessel formation in 
non-target areas [39]. It is essential to deliver the proper dosage of the growth factor to grow 
quality neo-vasculature. 
1.3. Bone Grafts and bone graft substitutes 
  
 A bone graft is surgery to place new bone or bone substitutes into spaces around a broken 
bone or bone defects. Currently, the United States, as well as other countries worldwide, are 
experiencing an exceedingly high demand for functional bone grafts, as the statistics have risen 
above half a million recipient patients and costing over $2.5 billion annually in the United States. 
This figure not only doubles on a global basis, but is also expected to double by 2020 due to a 
variety of factors, including the growing baby boomer population and increased life expectancy 
[40]. Bone grafts are utilized in a wide array of clinical settings to augment bone repair and 
regeneration. There are four broad clinical situations in which bone grafting is performed: (1) to 
stimulate healing of fractures, either fresh fractures or fractures that have failed to heal after an 
initial treatment attempt; (2) to stimulate healing between two bones across a diseased joint. This 
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situation is called “arthrodesis” or “fusion”; (3) to regenerate bone which is lost or missing as a 
result of trauma, infection, or disease. Settings requiring reconstruction or repair of missing bone 
can vary from filling small cavities to replacing large segments of bone up to 12 inches in length; 
(4) to improve the bone healing response and regeneration of bone tissue around surgically 
implanted devices, such as artificial joints replacements (e.g. total hip replacement or total knee 
replacement) or plates and screws used to hold bone alignment [41]. Autografts are considered as 
the gold standard for bone graft procedure as they contain osteogenic bone cells, marrow cells, 
and an osteoconductive collagen matrix suitable for new and existing bone cell attachment and 
migration, as well as osteoinductive proteins and factors endogenous to bone. However, the 
autograft requires a second surgery at the tissue harvest site, which increases post-operative pain 
and the possibility of surgical complications at the site. The best alternative to autograft is 
allograft, tissue taken from a donor or cadaver. Although secondary surgery or donor site 
morbidity is less of a problem, there is a minimal but real risk of disease transmission from donor 
to recipient with allografts [42, 43], and there have been reports of additional allograft-associated 
complications in which as many as 30%-60% of allograft implants encounter some complication 
when evaluated at the 10-year mark. Bone graft substitutes have been proposed as alternatives to 
allografts but they have also shown limited tissue ingrowth. Traditional scaffold design supports 
bone formation through intramembranous ossification with limited to no vascularization leading 
to graft core necrosis and, thus, poor bone formation. Therefore there is a need to develop a 
biocompatible scaffold that (i) closely mimics the natural bone extracellular matrix niche, (ii) 
recruit osteogenic cells to lay down the bone tissue matrix, (iii) contain morphogenic signals to 
help direct the cells to the phenotypically desirable type, and (iv) allow sufficient vascularization 
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to meet the growing tissue nutrient supply and clearance needs. Table 1.3.1 demonstrates various 
bone grafts and graft substitutes and their advantages and limitations [44]. 
Table 1.3.1: List of graft options for bone repair [44] 
Bone Graft 
Structural 
Strength 
Osteo-
conduction 
Osteo-
induction 
Osteo-
genesis 
Autograft 
Cancellous No +++ +++ +++ 
Cortical +++ ++ ++ ++ 
          
Allograft 
Cancellous No ++ + No 
Cortical +++ + + No 
De-mineralized Bone Matrix 
(DBM) 
No + + No 
Bone graft substitutes 
Coralline HA + ++ No No 
Collagen-based matrices No + No No 
Calcium phosphate +++ ++ No No 
Calcium sulfate No + + + 
Bioactive silicate + ++ ++ ++ 
Biodegradable Polymers (e.g., 
PLGA) 
+ ++ No + 
 
1.3.1. Autograft 
 
 Autografts are currently the gold standard method of bone grafting in which the donor 
tissue is harvested from the recipient’s own body. As autografts intrinsically possess optimal 
biocompatibility, three-dimensional pore structure, and biological components, they represent the 
most ideal bone grafting option and boast an 80-90% success rate. In short, the autograft 
possesses all the requirements for an ideal bone substitute; osteoconductivity, osteogenicity, and 
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osteoinductivity. However, although the grafted tissue may be optimal at the defect site, the 
threat of donor-site morbidity and the limited supply of donor tissue impose restrictions on 
autograft procedures. In fact, there are relatively few bones in the human body that can be 
harvested without incurring significant morbidity, for example the iliac crest, rib, and fibula. A 
retrospective study by Silber et al followed the healing of 187 patients who had undergone 
autologous anterior iliac crest bone graft harvest for anterior cervical discectomy and fusion 
procedures, all of which were performed by the same surgeon. Patients were interviewed an 
average of 48 months post-surgery, and reported that although there was a 92.5% degree of 
satisfaction with the cosmetic result, 26.1% of the patients reported pain at the donor site [45]. 
Recovery time depends on the injury or defect being treated and the size of the bone graft. 
Patient recovery may take 2 weeks to 3 months. The bone graft itself will take up to 3 months or 
longer to heal. 
1.3.2. Allograft 
 
 Allograft procedures, in which the grafting tissue is harvested from a cadaver, are 
common alternatives to autografts. The advantages of using structural allografts are: (1) the 
patient does not have to donate the bone graft, so the surgery is shorter, and there may be less 
postoperative pain (2) biologic constructs (3) mechanically strong (e.g., cortical allograft) (3) 
simple to use; grafts can be customized in operating room (4) easily available and inexpensive 
(vs. synthetic spinal devices) (5) easy radiographic fusion assessment (vs. radiopaque devices). 
Allograft, removed from organ donor is usually kept in bone banks. The bone bank follows 
procedures intended to sterilize the bone graft and perform tests on the bone for diseases such as 
hepatitis and AIDS. The earliest collections of allograft tissue, or bone banks, were established in 
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the beginning of the 20th century when Bauer refrigerated bone samples for 3 weeks and then 
implanted them in dogs [44]. Allografts were prepared for storage at this point by chilling or 
heating, but it was soon determined that boiling the bone samples rendered them inferior in 
healing to autografts because the endogenous proteins and factors were undoubtedly destroyed 
during heating. The big leap forward in bone banking came during World War II when new 
methods of bone storage preparation were studied, including freezing, freeze-drying, 
deproteinating, irradiating, autoclaving, demineralizing, and chemically treating the harvested 
bone [46]. The challenge that exists with allografts is to ensure their sterility while imparting 
appropriate biologic and biomechanical properties to the defect. In order to provide disease-free 
bone grafts that will not elicit an immune response in the host, the donor tissue must be 
processed with treatment solutions and/or radiation methods in order to remove cellular and viral 
components. As a result of sterilization process allograft, void of osteoinductive components 
show decreased revascularization and graft incorporation. Therefore, an allograft does not 
always heal as well or as quickly as an autograft. In addition to the loss of osteoinductivity, 
processing techniques may also alter the mechanical properties of the allograft. Studies have 
shown the compressive modulus of allographic bone to decrease by 30% after undergoing 
lyophilization and 10-20% after exposure to gamma radiation [47]. The allograft also carries a 
risk of transferring infectious diseases, although it is rigidly tested. 
 Demineralized bone matrix (DBM) is a commonly used allographic form in which 
donated tissue is morcellized and exposed to a demineralizing agent such as hydrochloric acid in 
order to remove the mineral content of the bone. This process makes DBM much safer than 
mineralized allographic tissue, which is more likely to retain viral components in the intact blood 
spaces such as the marrow and blood vessels. After the decalcification step, all blood elements 
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are removed from the DBM with subsequent treatment solutions. Depending on the type of 
demineralizing agent used, DBM has the potential to retain osteoinductive properties from native 
extracellular matrix that induce cellular differentiation. Morcellized allograft tissue and 
demineralized allograft tissue (demineralized bone matrix or DBM) have demonstrated better or 
faster incorporation than intact large allograft bone but neither of these tissue types is load-
bearing, considerably reducing their indications and applications [48]. 
1.3.3. Bone Graft Substitutes 
 
 Synthetic bone graft substitutes offer alternative grafting methods that avoid the 
difficulties associated with conventional autografts and allografts. A variety of commercial 
implants approved by the U.S. Food and Drug Administration are currently available for clinical 
use. Materials used to construct synthetic bone grafts range from natural (collagen) and synthetic 
(poly(lactide-co-glycolide)) polymers to ceramics such as calcium phosphates and sulfates and 
may be used alone or in combination. Although synthetic bone graft options offer virtually 
unlimited supply and minimal disease transmission possibilities, they do not incorporate every 
component of the ideal autologous bone graft. A list of commercially available bone grafts is 
shown in table 1.3.3.1 [49]. 
Table 1.3.3.1: List of bone graft substitutes that are commercially available [49] 
 
Company 
Commercially 
available 
product 
Composition 
Commercially  
available form 
Claimed mechanisms of 
action 
DePuy Spine HEALOS® 
Mineralized 
collagen matrix 
Variety of strip 
sizes 
• Osteoconduction 
    • Creeping substitution 
    • Osteoinduction 
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• Osteogenesis when 
mixed 
    
with bone marrow 
aspirate 
Optecure® 
DBM suspended 
in a 
Dry mix kit 
delivered • Osteoconduction 
hydrogel carrier 
with buffered 
saline • Bioresorbable 
   • Osteoinduction 
    • Osteogenesis when 
    
mixed with autogenous 
bone graft 
Integra 
Orthobiologics 
Integra 
MozaikTM 
80% highly 
purified 
Strip and putty 
• Osteoconduction 
b-TCP/   • Bioresorbable 
20% highly 
purified  Type-1 
collagen 
  
  
     
Medtronic Spinal 
& Biologics 
INFUSE® 
Bone Graft 
 
rhBMP-2 protein 
 
• Bioresorbable carrier 
on an absorbable 
Multiple kit 
sizes  • Osteoinduction 
collagen sponge   • Chemotaxis of 
    stem cells; indirect 
    Osteogenesis 
NovaBone NovaBone® 
Bioactive silicate 
Particulate, 
putty and • Osteoconduction 
  Morsels • Bioresorbable 
    • Osteostimulation 
Biomet 
Osteobiologics 
ProOsteon® 
500R 
Coralline-derived 
Granular or 
block • Osteoconduction 
HA/CC 
composite 
  
• Bioresorbable 
    • Osteoconduction 
Synthes  Calceon® 6  Calcium sulfate  Pellets  • Bioresorbable 
Stryker Biotech 
OP-1® 
Implant 
rhBMP-7 with 
Type-1 
Lyophilized 
powder • Bioresorbable scaffold 
bone collagen 
reconstituted 
with • Osteoinduction 
  
saline to form 
wet   
  
sand-like 
consistency   
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1.3.4. Challenges Associated with Allograft Healing 
  
 Massive bone allografts have been used primarily for limb salvage in orthopaedic 
oncology and remain an option for reconstructing large bony defects. The primary function of 
the structural allograft is to provide immediate structural support. Implanted bone allograft can 
transmit disease, therefore, safety is a prime consideration in the use of allograft transplant. It is 
reported that fresh allograft can be immunogenic. From least to most immunogenic, rank order 
is, freeze-dried allograft, fresh- frozen allografts, fresh non vascularized allograft and fresh 
vascularized allograft. It is necessary to inactivate and remove any harmful agents from the bone 
to reduce the risk of disease transmission, since only unprocessed, fresh-frozen allografts have 
been documented as sources of viral infection in recipients of bone grafts. Procedures designed 
to ensure the supply of safe bone include guidelines on donor selection, tissue quarantine and 
tissue processing. Long bones are procured under sterile conditions in the operating theatre after 
organ ex-plantation. The mechanical properties of the bone are excellent as the donors are young. 
Bone allograft tissue can be processed under strict aseptic conditions or be sterilized at the final 
stage, usually with irradiation. Some of the processing techniques include demineralization, 
freeze- drying, fresh- freezing, cryopreservation, and sterilization. Ethanol, acetone and ether are 
often used, as they have been shown to inactivate coated viruses such as HIV and the hepatitis 
viruses [50]. Large intact allograft are usually procured sterile from organ donors and stored at -
80˚C. All these tissue processing steps eliminates cellular and viral components, growth factors 
and proteins that were present in the native allograft tissue. As a result, the graft become very 
desirable for immunity but undesirable for bone repair. The graft completely loses its ability to 
make bone because of the absence of viable osteogenic cells. 
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 An allograft serve primarily as a spacer that allows osteoconduction of the host cells into 
its mass, resulting in progressive incorporation of the graft into the host bone. Five-year follow-
up studies have demonstrated substantial concerns with allograft incorporation into host bone 
particularly with intact allograft tissue [51, 52]. Incorporation is a series of events leading to 
gradual replacement of the old necrotic bone by living new bone as a result of creeping 
substitution, a mechanism of osteoclastic resorption followed by deposition of new bone. A bone 
graft is considered to be incorporated when there is no abrupt histological change between the 
host bone and the graft. Stevenson et al defined successful incorporation as the graft uniting with 
the host, with the graft-host bone construct able to tolerate physiological loads without fracture 
or pain. From the perspective of basic science, the complete incorporation is defined as rapid 
vascularization and substitution of original graft bone with new host bone without substantial 
loss of strength. The process of bone graft incorporation involves an initial hemorrhage and 
hematoma within and around the graft that serves to nourish the graft until distinct capillaries 
and vasculature develops. With the initial injury from surgery, there is an inflammatory response, 
resulting in granulation tissue ingrowth into the graft. This process of tissue ingrowth will serve 
to revascularize the tissue and bring osteoprogenitor cells into the graft. Once revascularization is 
complete, viable cells within the graft and the recipient osteoprogenitor cells will begin to resorb 
the old bone and form new bone via creeping substitution [53]. After new bone is formed, it is 
mineralized and remodeled. In cortical bone, or cortical-cancellous grafts for that matter, the 
revascularization and resorption process follows along peripheral haversian canals. Unlike 
cancellous grafts that incorporate by creeping substitution initiated by osteoblasts, cortical graft 
incorporation is initiated by osteoclast resorption in a process often called reverse creeping 
substitution. Extensive resorption occurs as early as 2 weeks and increases up to 6 weeks, 
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resulting in relative weakness that can persist for 6 to 12 months [54]. Incorporation of the 
cortical bone begins at the graft/recipient junction and proceeds to the center of the graft. 
However, this intricate process of incorporation is very limited in large segmental allograft and 
there remains a final bulk of dead bone that has been poorly substituted by new bone. Efforts 
have been made to overcome this limited substitution by improving the revascularisation of the 
bone via perforation and the introduction of stem cells and growth factors. Despite this, no major 
progress in clinical series using massive allografts has been accomplished so far.  This reduced 
incorporation has secondary manifestations that influence the overall healing capacity of the 
defect site such as poor mechanical integrity at the interface, poor mechanical properties of the 
allograft. Intact allografts exhibit limited creeping substitution, delayed non-union of the host 
allograft/implant interface, bone callus bridging of the allograft/implant segment, and limited 
bone remodeling with increased frequency of fatigue fracture. Each secondary manifestation may 
lead to failure of the structural allograft and does so as often as 60% of the time according to ten 
year follow-up studies [55]. Cortical allografts remain significantly weaker than cortical 
autografts for considerable time after surgery. Given enough time and a weight bearing, stable 
construct, most segmental cortical allografts eventually resemble autografts biomechanically and 
structurally, although significantly more un-remodeled necrotic bone remain present in 
allografts. In autograft healing, both graft and host bones contribute toward healing whereas, 
large allografts do not contain living cells, therefore, graft incorporation relies only on host cells 
and tissues. In summary the complications associated with intact allograft healing are: (1) 
inadequate vascularization; (2) micro-fractures occur in graft areas in which no bony apposition 
is found and in areas of bone without subchondral resorption; (3) lack of creeping substitution, 
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osteoclastic resorption of dead bone from the allograft and its replacement by new living bone 
made by osteoblasts from the host.  
1.4. Bone Tissue Engineering 
  
 Tissue engineering (TE) aims to replace or facilitate the regrowth of damaged or diseased 
tissue by utilizing biomaterials, cells, and bioactive molecules alone or in combination with one 
another. The need for TE stems from the limited availability of autologous tissue and the potential 
for immunorejection of allogeneic sources and is bolstered by the numerous and growing 
availability of advanced material fabrication methods of novel biocompatible biomaterials. The 
strategies involved in designing and building engineered scaffolds are diverse but often focus on 
the biomaterial as a synthetic extracellular environment to organize cells into a three-dimensional 
architecture and to present stimuli that can direct the growth and formation of a desired tissue. The 
promise of TE would empower scientists to grow tissues and organs in the laboratory and safely 
implant them when the host body is incapable of self-healing. This possibly offers an alternative 
to organ transplantation, which, although an important clinical tool, has its limitations. The goals 
of TE integrate so well with the goals of regenerative medicine that as each field progresses, the 
distinction between them becomes ever less clear.  
  Recently, a new field has evolved that seeks to unite TE and regenerative medicine with 
an additional focus on the integration of stem cells, developmental biology, and advanced materials 
science. This field, termed ‘regenerative engineering’, seeks to integrate these fields in pursuit of 
the current clinical challenge of complex tissue regeneration where more than one tissue type, 
often in direct proximity to another distinct tissue type, is regenerated [56]. The complexity of 
regenerating neighboring tissues with distinct structural and chemical requirements cannot be 
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underestimated, and mandates a renewed focus on these specific challenges. Regenerative 
engineering seeks to build on what has been accomplished thus far in TE and regenerative 
medicine, and move the field forward towards true clinical implementation. 
 A key moment in organ transplant history was in 1954 with the first successful kidney 
transplant. Development in the field continued into the 1960s with successful pancreas–kidney, 
liver, and later in the 1980s with heart–lung, single lung, double lung, and living-donor liver 
transplants [57].  Despite the utility of organ transplantation there is a real mismatch in supply and 
demand in respect of organs and tissues available for transplantation. Data published by United 
Network for Organ Sharing (UNOS) listed only 11,579 people receiving transplants from January 
2013 to May 2013, while 76,223 people were recorded as waiting-list candidates (Figure 1.4.1) 
[126]. While the simple hope of TE is that discrepancies like this would be obviated, its potential 
full impact is far broader than this: in addition to reducing the need for organ replacement TE, and 
now with advanced biomaterials science, developmental biology, and a focus on stem cell 
integration, regenerative engineering could, for instance, greatly accelerate the development of 
new drug delivery systems that may reduce the need for transplantation through novel drug 
delivery applications and other novel treatments. 
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Figure 1.4.1: UNOS organ transplant statistics for 2002 to 2012 [126]. 
 
 TE approach involves three main components: biomaterials to form a substrate onto which 
cells and biological molecules can reside; proteins and/or peptides that function to influence cell 
behavior; and, the cells to build the tissue (Figure 1.4.2). Designing the substrate or scaffold (the 
first of the three components) onto which new tissue may grow has become a critical part of the 
development process. Although some scaffolds simply involve the injection of a material into the 
defect site, those that are designed to provide structural support with a specific architecture require 
additional preparation prior to implantation. For instance, often the tissue engineer chooses to 
incorporate biological molecules (the second of the three components) like growth factors or 
peptides into the scaffold to control proliferation and/or differentiation of progenitor cells to 
increase the rate of tissue healing. The choice of cells (the third component) that are seeded onto 
the scaffold to supplement the process of cell migration from the host and therefore accelerate the 
overall tissue formation can greatly influence the success of the overall repair. These three 
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components – the design of the scaffolds, the use of growth factors and other biological molecules, 
and the cells chosen to seed onto the scaffold – are reviewed in depth below. This is not meant as 
an exhaustive survey of the field as that is beyond the scope of this chapter, but an update on select 
approaches to tissue regeneration. It will be noted that these three components exist neither alone 
nor always in combination toward whole tissue regeneration, but rather as a combination of one, 
two, or three elements.  
 
Figure 1.4.2: Tissue engineering paradigm. Cells isolated from donor/source.; seed cells in 
combination with appropriate growth factors onto scaffold; implant the engineered scaffold in 
the defect site [126].  
 
Natural biomaterials are widely available in nature and derived from natural sources, 
mostly from plants, animals, and microorganisms. Recent research has been focused on 
polysaccharide-derived polymers such as chitin and chitosan, hyaluronic acid (HA), alginate, 
 38 
 
starch, and cellulose-based polymers for the development of scaffolds for bone, cartilage, and skin 
regeneration [58]. Native collagens form the main structural components of the ECM of many 
tissues, such as bone, skin, teeth, tendons, cartilage, and ligaments. Twenty-seven types of 
collagens have been identified to date, but collagen type I is the most abundant and widely 
investigated. A broad range of collagen-based scaffolds have been developed and commercialized 
in recent times. For example, bi-layered collagen gels seeded with human fibroblasts in the upper  
layer and keratinocytes in the upper layer have been used as the dermal matrix, an artificial skin 
product commercialized by Organogenesis in the USA under the name of Apligraf in 1998 [59]. 
Collagen sponges have been used as an osteoconductive carrier of bone morphogenetic protein 
(BMP-2) for spinal fusion marketed by Medtronic in the USA [60] Collagraft, commercialized by 
Angiotech Pharmaceuticals, Inc., Canada, is a mixture of porous hydroxyapatite and tricalcium 
phosphate and animal derived collagen I, and has been used clinically for the treatment of long 
bone fractures for more than a decade. Healos Bone Graft Replacement by DePuy Orthopedics, 
USA, is an osteoconductive matrix constructed of crosslinked collagen fibers that are fully coated 
with hydroxyapatite. It has been approved recently for clinical use as a bone graft substitute in 
spinal fusions [62].  
 The application and use of synthetic polymers in tissue regeneration is relatively recent 
compared to natural polymers. In the past 50 years with the synthesis of novel synthetic 
biomaterials, scientists have been able to simulate many key aspects of the extracellular 
microenvironment [63]. Scaffolds can be produced from a variety of materials, including metals, 
ceramics, and polymers. Metallic alloys are popular for both dental and bone implants [64] while 
ceramics with good osteoconductivity have been used for bone tissue engineering [65]. However, 
both metals and ceramics have significant drawbacks. Metals are not biodegradable and do not 
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provide a biomimetic matrix for cell growth and tissue formation. Ceramics, meanwhile, also have 
limited biodegradability and are difficult to process into highly porous structures due to their 
brittleness. In contrast, polymers have great processing flexibility and their biodegradability can 
be imparted through molecular design. Therefore, polymers are the dominant scaffolding materials 
used in TE. In the process of developing scaffolds, synthetic polymers hold numerous advantages 
over natural materials. Key among those advantages is the ability to tailor mechanical properties 
and degradation kinetics for various applications. Synthetic polymers can be engineered into 
various shapes with optimum pore sizes and surface textures, conducive to tissue formation. 
Furthermore, polymers can be designed with chemical functional groups that can induce tissue 
ingrowth. Aliphatic polyesters, including poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and 
their copolymer poly[(lactic acid)-co-(glycolic acid)] (PLGA) are the most widely used synthetic 
polymeric materials in TE. These polymers are well characterized and have gained FDA approval 
for certain clinical application (e.g., sutures). PGA is a rigid thermoplastic material with high 
crystallinity making it less soluble in most organic solvents; a troublesome property if trying to 
form scaffolds. PGA is widely used in medical application as resorbable sutures (dexon, American 
Cyanamide Co). The degradation process of the material occurs in two stages: the first stage 
involves the diffusion of water into the amorphous (non-crystalline solid) regions of the matrix 
followed by the degradation of the crystalline structure of the polymer. The rapid degradation rate 
of PGA causes the weak mechanical integrity of the scaffolds [66]. Poly(lactic acid) (PLA) is more 
hydrophobic and stable against hydrolysis than PGA. PLA degrades to form lactic acid, naturally 
present in the body. No significant amounts of accumulation of harmful degradation products of 
PLA have been reported. Both in vitro and in vivo studies have been carried out to determine the 
biocompatibility of PLA and PGA. Many studies suggest that these polymers are sufficiently 
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biocompatible [67, 68]. Poly(lactide-co-glycolide) (PLGA), copolymer of PLA and PGA, has been 
used in many biomedical applications, for example, sutures, drug delivery devices, and TE 
scaffolds. Due to its good biodegradability, biocompatibility, and process ability, PLGA has been 
considered for many TE applications, such as the skeletal muscle [69], bone [70], cartilage [71], 
ligament/tendon [72], and nerve [73]. Synthetic polymers, such as Polycaprolactone (PCL) a 
semicrystalline polyester shows very low in vivo degradation rate up to 3–4 years. Therefore, it is 
used in long-term implant delivery devices. PCL films modified with arginine-glycine-aspartate 
(RGD) peptide (which promotes cell adhesion by acting as a binding site for integrins) served to 
promote the attachment and spreading of mesenchymal stem cells (MSCs) [74]. Other synthetic 
biodegradable polymers, including poly(3-hydroxybutyrate) (PHB) [75], polyurethanes (PU) [76], 
polycarbonate (PC) [77], poly(ortho ester) (POE) [78], poly(propylene fumarate) (PPF) [79], and 
polyphosphazenes (PP) [80] have also been used as scaffolding biomaterials. Biodegradable 
bioceramics are designed to aid in the self-repair processes of the living organism, and are 
subsequently resorbed. Tricalcium phosphates, calcium sulfates, HA, and certain compositions of 
glasses and glass-ceramics have been recently investigated as biodegradable bioceramics.  
Hydrogels can be used as space-filling scaffolds, for cell delivery, and for bioactive 
molecule delivery [81]. Gilbert et al. demonstrated how adult muscle stem cells on engineered 
hydrogel substrates can be proliferated in vitro with higher efficiency, leading to better host tissue 
integration. These stem cells would normally lose their pluripotency and undergo massive cell 
death within the first weeks of culture on rigid plastic culture dishes. However, when cultured on 
chemically crosslinked bioactive poly(ethylene glycol)  (PEG) hydrogels, the cells showed signs 
of self-renewal and were engrafted with substantially better integration in a muscle implant model 
[82].  Hydrogel-based products have been made available for patient care in the recent years. For 
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example, soft contact lenses are typically made from poly(hydroxyethylmethacrylic) acid 
[poly(HEMA)] while biological adhesives routinely used in surgical procedures have been made 
from reconstituted fibrin or albumin. Hydrogels are currently extensively investigated for bone, 
cartilage, intervertebral, and cardiac regeneration. Moreover, ‘smart’ hydrogels are raising 
significant interest due to their ability to change shapes. They can dynamically shrink, swell, or 
degrade based on exposure to changing stimuli such as pH, temperature, and other activators. They 
are often used for vascular applications, since their smart capabilities allow them to be maneuvered 
through small, tight pathways [83].  
 One of the most important aspects of regenerative engineering is to have cells that are able 
to differentiate and proliferate based not only on the cell type, but also the environment that 
surrounds them. The scaffold acts similarly to an ECM, creating an environment that is conducive 
to integration, differentiation, and cell growth. With that in mind, it is extremely important to select 
a cell source that not only matches the overall goal of the implantation, but that also integrates well 
with compatible scaffolding. Obtaining cells that are able to differentiate and proliferate to the 
correct degree is imperative in successful tissue regeneration, as many damaged tissues are not 
able to regenerate the native tissue to an acceptable extent. The most common types of stem cell 
used are progenitor stem cells. These cells, while having undergone some degree of differentiation, 
are still able to differentiate into multiple lineages.  They can also be isolated, cultured and 
differentiated into the appropriate lineage before being transplanted into the patient.  Human 
mesenchymal stem cells (MSCs) are of particular interest due to their multilineage potential, being 
able to differentiate into many different cell types like osteogenic, adipogenic, and chondrogenic 
[84]. They are used for vastly different functionalities, treating hundreds of symptoms from a wide 
spectrum of ailments [85]. Neural stem cells (NSCs) are used for differentiation into almost all 
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types of neural lineages, but there a large amount of difficulty has been encountered in creating 
the desired type and number of cells when expanding the NSCs.  Epithelial stem cells have been 
used for skin grafts, as well as things such as ocular regeneration. Considerable research efforts 
have been directed toward human induced pluripotent stem cells (hiPSCs) that are able to 
differentiate into many lineages, acting very similarly to ESCs [86]. These hiPSCs are capable of 
different functionalities and are also procured much more easily than most other stem cell types. 
They are created by inducing a forced expression of specific genes in order to cause a specific 
expression. Cells are often taken from bone marrow, hair keratinocytes, or skin fibroblasts to create 
an array of functions, as noted by Streckfuss-Bomeke et al [87]. Somewhat similar to MSCs, it has 
also been found that it is possible to extract stem cells from the amnion and amniotic fluid that 
have similar capabilities. Corradetti et al. showed that MSCs from the amniotic fluid are capable 
of many different functions from their original lineages [88]. With so many different types of stem 
cells to choose from for tissue regeneration procedures, steps must be taken to ensure the correct 
cell type is selected. Grompe et al. created a tracing system in order to show the differentiation 
process of stem cell systems [89]. This allowed for better selection of different cells for different 
functions. In order to harvest the stem cells for implantation, they must first be isolated and 
expanded in culture. Because it is difficult to harvest a large number of stem cells, expansion is 
important in order to have a viable level of cells for transplantation. The environment and methods 
to culture the stem cells is of particular importance, as it can result in changes to the growth rate 
and extent of the expansion. 
 Growth factors are therapeutic agents for tissue regeneration. Different growth factors are 
used in order to create differentiation of cells towards a specific phenotype. The following are 
some of the more commonly used growth factors given their efficacy and the tissue types they 
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have been found to repair and regenerate effectively: nerve growth factor (NGF), epidermal growth 
factor (EGF), vascular endothelial growth factor (VEGF), and bone morphogenetic proteins 
(BMPs).  Nerve growth factor is normally used to help with nerve damage and neurodegenerative 
disorders. NGF is used to maintain neuronal survival and promote axonal elongation. It has also 
been used to treat disorders such as Alzheimer’s disease or Huntington’s disease [90]. By 
promoting neuronal growth, NGF can be used for brain and spinal cord injuries. Bone 
morphogenetic proteins are used extensively and have been called the gold standard for enhancing 
bone formation and cell proliferation [91]. Due to their extensive osteoinductive properties and 
ability to stimulate osteoblast proliferation, BMPs are able to help form new bone, as well as help 
it continue to grow. They are applicable for bone defects almost anywhere within the body. 
Vascular endothelial growth factor is a growth factor that is used to form blood vessels. Its job is 
to not only induce endothelialization of existing vessels, but also to promote angiogenesis (the 
process of forming new blood vessels from pre-existing tissue). VEGF can also recruit endothelial 
cells to migrate to where they are needed.  Epidermal growth factor is a growth factor used for 
skin injuries such as incisions and burns. It supports epidermal cell growth, proliferation, and 
migration. It is also able to catalyze the creation of collagen to help with wound healing. It is used 
to engineer new skin, as well as heal existing skin [92]. Using these (or similar) growth factors, 
many different cell types can be proliferated and differentiated. Tissue engineered scaffolds 
incorporate these growth factors to ensure that the correct type of cells are created to treat the 
defect. In order to do this, it is important to know how the growth factor will react with the 
extracellular matrix of the scaffold, as well as to the material of the scaffold itself.  
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1.5. Poly(lactide-co-glycolide) (PLGA) and its Application in Tissue Engineering 
 Poly (lactide-co-glycolide) (PLGA) is the copolymer of poly-(lactic acid)/polylactide 
(PLA) and poly-(glycolic acid)/polyglycolide (PGA). Poly lactic acid contains an asymmetric α-
carbon which is typically described as the D or L form in classical stereochemical terms and 
sometimes as R and S form, respectively. The enantiomeric forms of the polymer PLA are poly 
D-lactic acid (PDLA) and poly L-lactic acid (PLLA). PLGA is generally an acronym for poly 
D,L-lactic-co-glycolic acid where D- and L- lactic acid forms are in equal ratio (figure 1.5.1) 
[93] 
 
Figure 1.5.1: Chemical formula of poly(lactide-co-glycolide) (PLGA) [93] 
PGA has highly crystalline structure and higher hydrophilicity and faster degradation rate, 
whereas PLA has less crystalline structure and shows poor hydrophilicity and slow degradation 
rate. Crystalline PGA, when co-polymerized with PLA, reduces the degree of crystallinity of 
PLGA and as a result increase the rate of hydration and hydrolysis. PLGA copolymers are 
amorphous in nature with glass transition temperature between 45 and 55°C.  Higher content of 
PGA leads to quicker rates of degradation with an exception of 50:50 ratio of PLA/PGA, which 
exhibits the fastest degradation, with higher PGA content leading to increased degradation 
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interval below 50%. For instance, PLGA 50:50 degrades at a faster rate as compared with PLGA 
85:15 due to the higher hydrophobic lactide content of the latter. PLGA undergoes hydrolytic 
degradation in aqueous environment where ester linkages present along the polymer backbone 
are randomly hydrolyzed to lactic and glycolic acids that are finally broken down to form energy, 
carbon dioxide and water by the normal metabolic pathways of the body. The degradation of 
PLGA copolymer is the collective process of bulk diffusion, surface diffusion, bulk erosion and 
surface erosion. The degradation time of the frequently used PLGA family of polymers ranges 
from 1 to 2 months for completely amorphous PLGA 50:50 and up to 1–2 years for the semi-
crystalline poly L-lactide (PLLA). As a drug delivery vehicle PLGA shows biphasic release 
pattern. The initial burst release of drug occurs as water penetrates into polymer matrix, causes 
random scission of PLGA and drug on surface of the polymer release through desorption. The 
sustain release of drug occur when the polymer breaks down by hydrolysis into soluble 
oligomeric and monomeric products and creates a passage for drug to be released by diffusion 
and erosion until complete polymer dissolved [94]. PLGA polymers are easy to process as they 
are soluble in wide range of solvents such as dichloromethane, tetrahydrofuran, ethyl acetate, 
chloroform, hexafluoroisopropanol, acetone and benzyl alcohol. Table 1.5.1 shows physical and 
chemical properties of PLGA, PLA and PGA [95]. 
Table 1.5.1: Physical and Chemical properties of PLGA compositions [95] 
Polymer 
Inherent 
viscosity 
(dl/g) 
Density 
(g/ml) 
Crystalline 
melt 
transition 
(°C) 
 Glass 
transition 
temp (°C)  
Solubility 
(at 5% w/w)  
Approx. 
degradation 
(months) 
50:50 DL-PLG 0.55–0.75 1.34 Amorphous 45–50 1 2 3 4 5 6 1–2 
65:35 DL-PLG 0.55–0.75 1.30 Amorphous 45–50 1 2 3 4 5 6 3–4 
75:25 DL-PLG 0.55–0.75 1.30 Amorphous 50–55 1 2 3 4 5 6 4–5 
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85:15 DL-PLG 0.55–0.75 1.27 Amorphous 50–55 1 2 3 4 5 6 5–6 
DL-PLA 0.55–0.75 1.25 Amorphous 50-60 1 2 3 4 5 6 12–16 
L-PLA 0.90-1.20 1.24 173–178 60-65 1 4 5  >24 
PGA 1.40-1.80 1.53 225–230 35-40 5 6–12 
Solvents: 1 = dichloromethane; 2 = tetrahydrofuran; 3 = ethyl acetate; 4 = chloroform; 5 = 
hexafluoroisopropanol; 6 = acetone. 
1.6. Growth-Factor Loading Techniques 
 
Incorporating growth factors to bone grafts/ substitutes can encourage osteoinductivity in 
the defect site. The growth factors are expected to be delivered to cells seeded on the scaffold or 
localized at the defect site and stimulate the differentiation of osteoprogenitors down the 
osteoblastic lineage. The choice of which growth factor to load depends on the inductive effects 
that one hopes to impart on the targeted cells. For example, growth factors such as insulin-like 
growth factor-1 (IGF-1), bone morphogenetic protein-2 (BMP-2), and vascular endothelial 
growth factor (VEGF) induce cellular differentiation towards adipose, osteoblast, and endothelial 
lineages, respectively. With the appropriate growth factor selected, the loading method is next to 
be considered. As proteins, the activity of growth factors depends on their conformation and 
ability to interact with their cellular receptors. Growth factors may be denatured if exposed to 
extremes in temperature or pH and must therefore be loaded under appropriate conditions. 
Therefore, while loading the protein it is imperative to consider that the loading method doesn’t 
denature the protein conformation and also maintains a sufficient concentration of the growth 
factors that mimics the physiological range for bone regeneration. In order to do this, the growth 
factor must be bound to the system in such a way that causes the desired release kinetics.  The 
timing and duration of release, as well as how it is administered, are very important to optimize 
healing.  Growth factors in vivo degrade due to denaturation, oxidation, or proteolysis.  These 
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challenges must be controlled if the factors are to be delivered from an implanted construct to 
achieve a release profile that can mimic that of the natural healing process.   
1.6.1. Non-Covalent Growth Factor Immobilization 
 
Strategies for non-covalent binding of growth factors into carrier matrix include physical 
encapsulation and surface adsorption.  Growth factors can be physically entrapped into scaffolds 
by dispersing the proteins into the scaffold material prior to scaffold construction. Scaffolds used 
for physical encapsulation can be designed to have specific mechanical properties, degradation 
rates, and porosity to elicit desired cellular responses.  These types of growth factor delivery 
systems can be created using techniques such as phase separation, solvent casting and particulate 
leaching, melt molding,   freeze drying, phase emulsion, and gas foaming. There are many 
different fabrication methods for physical encapsulation, all with different benefits and 
drawbacks that make them effective in certain applications. The table below outlines the most 
common techniques, along with their advantages and disadvantages. 
Table 1.6.1.1: Growth Factor Encapsulation Techniques [39] 
Technique Advantages potential disadvantages 
solvent 
casting/particulate 
leaching  
control over porosity, pore sizes 
and crystallinity; high porosity 
residual solvents and porogen 
materials; limited mechanical 
properties 
freeze drying  
high porosity and 
interconnectivity 
limited pore sizes range (15–
35 µm) 
phase separation  high porosity 
limited pore sizes, residual 
solvents (1–10 µm) 
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Technique Advantages potential disadvantages 
melt moulding  
control over macrogeometry, 
porosity and pore size; free of 
harsh organic solvents high temperatures 
high internal-phase 
emulsion  
control over porosity, pore size 
and interconnectivity 
limited polymer types and 
mechanical properties 
in situ polymerization  
injectable; control over 
mechanical properties 
residual monomers and cross-
linking agents, limited 
porosity 
gas foaming  
free of organic solvents; control 
over porosity pore interconnectivity 
 
Both natural and synthetic biomaterials can be to design three- dimensional scaffolds to 
load and deliver growth factors for bone regeneration. Synthetic polymers such as aliphatic 
polyesters, including poly (glycolic acid) (PGA), poly(lactic acid) (PLA), and their copolymer 
poly[(lactic acid)-co-(glycolic acid)] (PLGA), poly(ε-caprolactone) (PCL) and its copolymer are 
the most widely used for encapsulating growth factors into polymeric delivery systems. These 
scaffolds can be engineered into different shapes such as sphere, cylinder, thin-films etc. 
depending on the parameters necessary for the specific experiment. Gelatin, silk fibroin, 
cellulose, chitin and chitosan, hyaluronic acid (HA), alginate, and collagen are natural carrier 
materials that have been used for delivering bone growth factors due to their protein affinity, 
biocompatible byproducts, and mild processing conditions. Being fully encapsulated, the loading 
and release kinetics of the growth factors are controlled largely by the physical, chemical and 
biological properties of the polymers. In PLGA, polymer composition is the most important 
factor in hydrophilicity and degradation of the polymer and hence in controlling release rate of 
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the protein. PLGA 65:35 shows higher degradation than PLGA 75:25. Presence of higher ratio of 
highly crystalline PGA makes PLGA polymer more hydrophilic and thus exhibits faster 
degradation and drug release rate [94].  
The approach of loading proteins on pre-made scaffolds presents an attractive option for 
tissue engineered growth factor delivery. Furthermore, the surface area that the growth factor 
contacts is the same as that which cells eventually approach, making the proteins more accessible 
to the cells than if they were hidden within the material. Depending on the protein’s 
hydrophilicity, they tend to desorb from the scaffold too quickly upon implantation in a “burst” 
effect. Deluca et al. have reported a series of experiments in which they loaded BMP-2 on porous 
PLGA microspheres by soaking the spheres in the BMP-2 concentrated solution. Deluca et al. 
defined “bound” (adsorbed to the surface of the PLGA microsphere) and “free” (physically 
entrapped within the pores of the microsphere) proteins [96,97]. They reported that increasing 
NaCl and buffer concentrations decreased the amount of protein adsorbed to PLGA. It was 
suggested that relative to the pI of the BMP-2 (~9) and the pKa of the PLGA (~3), there exists an 
intermediate pH range in which the positively charged protein and the negatively charged 
carboxylic acid end groups on the polymer interact via isoelectric bonding. Increased number of 
ionic species in the buffer was determined to have caused charge shielding, which resulted in the 
decrease of attractive forces between the polymer and protein. A subsequent study by the Deluca 
group investigated the effect of different properties of the polymer on protein-loading [98]. 
Microspheres made from a range of hydrophilic and hydrophobic PLGA were constructed by 
varying the molecular weight (MW), polydispersity, and acid number of the polymer and BMP-2 
was incorporated. PLGA with various degrees of end-capping were used in order to adjust the 
polymer acid number of the microspheres, which was directly related to the number of free 
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carboxylic acid functionalities. Higher acid values showed an increase in BMP-2 binding. Also, 
hydrophilic PLGA, which had greater acid numbers and therefore greater ionic reactivity than 
the hydrophobic form, exhibited the greatest protein adsorption capacity. By increasing the 
polymer acid number, the group effectively provided more negative moieties per unit of scaffold 
surface area on which the positively charged protein could adsorb. The MW of the polymer is 
also linearly correlated with the protein binding.  
1.6.2. Covalent Growth Factor Immobilization 
 
  Covalent tethering of growth factors is another way of incorporating growth factor to 
scaffolds. This method allows prolong availability of growth factors, spatial control of growth 
factors and reduce the required doses of growth factors, subsequently reduce the cost and the 
efficacy of growth factor based devices. In order to load growth factor using the tethering 
method reactive groups need to be available both in the growth factors and substrates. Utilizing 
crosslinkers such as water-soluble carbodiimide (e.g., EDC), monoacrylated PEG-succinimidyl 
ester, and photo-immobilization to functionalize growth factors and then bind to polymers are 
commonly used methods for covalent immobilization of growth factors. Sulfosuccinimidyl- 4-
(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) is a heterobifunctional 
crosslinker that has been used to tether VEGF to agarose, collagen, PEG-dA hydrogel [99, 100] 
as well as PDGF-BB to demineralized bone [101] and BMP-2 to PCL, chitosan and collagen 
[102,103 ]. Scaffolds modified with immobilized VEGF and BMP-2 showed improved 
neovascularization and mature bone formation, respectively, in vivo [104].  
1.6.3. Growth Factor Loading and Delivery Systems 
 
 51 
 
Bone healing is a complex process where multiple growth factors play important role in 
concert. Therefore, it is imperative to obtain a delivery system that can maintain inherent ECM 
structure of bone as well as load and deliver multiple growth factors mimicking natural bone 
healing. To this end, Kolambkar et al. designed a growth factor delivery system consists of an 
electrospun nanofiber mesh tube for guiding bone regeneration combined with peptide-modified 
alginate hydrogel injected inside the tube for sustained rhBMP-2 release [105]. Kempen et al. 
fabricated a composite scaffold consisting of PLGA microsphere loaded with BMP-2 embedded 
in a poly(propylene) scaffold surrounded by a gelatin hydrogel loaded with VEGF to obtain 
sequential delivery of growth factors[106]. Following the same trend, dual release of TGF-b1 
and IGF-1 through gelatin-loaded microspheres incorporated in oligo(poly (ethylene 
glycol)fumarate) (OPF) hydrogels was evaluated for cartilage repair [107]. Richardson et al. 
engineered a PLG microsphere based system where PDGF were encapsulated into the polymer 
with lyophilized VEGF to promote angiogenesis in bone healing [108].  
Release kinetics of growth factors depend on the way protein is loaded on the scaffold, as 
well as on the environmental factors of the release medium. If a factor is released too quickly, it 
may diffuse away from the target site and not have enough time to interact with local cells. A 
burst release might even induce a toxic result if the protein is immediately presented to cells in 
too high of a concentration. Contrariwise, an overly slow release of growth factors may cause 
denaturation of the proteins. Since healing of bone is a complex multidimensional process, 
researchers are investigating scaffold systems that are capable of delivering multiple growth 
factors in a temporal and spatial manner. However, controlling the rate and dosage of growth 
factors is not a standardized procedure. In general, factor delivery is most important during the 
first few weeks following graft implantation. Reconstituted recombinant growth factors are most 
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active during this time, as their stabilities tend to decrease when exposed to temperatures above -
70°C. Furthermore, the first few weeks of healing are also the critical time for seeded precursor 
cells to differentiate towards the osteoblastic lineage. Drug release from 3D matrices is mostly 
driven by a pure diffusion mechanism, where free solutes very rapidly escape to the surrounding 
solution. Protein release can be also activated by external stimuli, including temperature changes, 
magnetism, ultrasound, electrical effect and irradiation. The size of the protein molecules also 
affects the release kinetics. Larger molecules may release more slowly from being bound to the 
surface by virtue of its larger physical size [109].  
1.6.4. Design Criteria for Growth Factors Delivery Systems 
 
A growth factor delivery system engineered for bone healing should be a combination of 
osteoinductive and osteoconductive properties, that way in the presence of an adequately porous 
shape 3D- matrix and biological stimulus cells can migrate, proliferate and differentiate and lead 
to the generation of ECM and vascular network osteo-integration. The materials for growth 
factor based delivery devices should be biocompatible, non-cytotoxic to the body. The device 
should degrade at a rate of few weeks to months according to the rate of tissue regeneration 
while maintaining appropriate release dose and profile of the incorporated growth factors. The 
delivery system should also be able to retain the bioactivity of the proteins during incorporation 
of the growth factors into the delivery systems and also over extended period of delivery time. 
The delivery system should have mechanical properties that are similar to those of the native 
bone. A weak scaffold may not have sufficient load-bearing capabilities, while an overly strong 
one may result in stress shielding that could lead to the resorption of the newly forming bone. 
Additionally, the delivery device should hold high loading protein efficiency and several growth 
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factors may be released sequentially in a manner that mimics the temporal profile of the healing 
process in vivo [110,111,112].  
1.6.5. Release Kinetics of Growth Factors: In Vitro and In Vivo 
 
Release kinetic is a function of the ability of the growth factors to diffuse out of the 
scaffold. In a purely diffusion-based system, release profile is often characterized by an 
initial burst; growth factors attached to the scaffold diffuse out to the defect site following 
concentration gradient. If the release of the growth factors is governed by the degradation of 
the scaffold, release profile depends on the molecular weight, concentration and 
hydrophobicity of the base polymer, degree of crosslinking and swelling, and the mode of 
degradation.  
The healing cascade of bone is administrated by temporally and spatially available 
growth factors which are produced by the cells and ECM at the defect site. However, in a 
non-union defect site the spatiotemporal action of the biological and mechanical cues is 
perturbed. Hence, it is imperative to achieve spatiotemporal release profile of growth factors 
to heal bone efficiently. Literatures indicate that simultaneous delivery of low doses of two 
growth factors, BMP-2 and TGF-β3 can induce more bone formation over single factor 
delivery [113,114].  It is important to consider the synergistic effect of the growth factors 
while designing a multiple delivery system. The growth factors should be able to maintain 
their respective bioactivity and work in concert. Selection of growth factors is also crucial. If 
not appropriately chose, the combination of growth factors can inhibit/stimulate the activity 
of each growth factor and affect overall healing. For instance, in a rabbit tibia model 
simultaneous delivery of osteogenic BMP-2 and angiogenic basic fibroblast growth factor 
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(bFGF) resulted in decreased bone formation [115]. However, sequential of BMP-2 and 
angiogenic VEGF is widely studied and have shown increased bone formation and 
regeneration [116,117]. Lee et al. evaluated knee meniscus repair upon spatially released 
human connective tissue growth factor (CTGF) and transforming growth factor–β3 (TGFβ3) 
from a three-dimensional (3D)–printed biomaterial. The group treated with CTGF followed 
by TGFβ3 delivered to the cell culture media showed fibrochondrogenic differentiation of 
human MSCs whereas the cells treated with combination/simultaneous delivery of CTGF and 
TGFβ3 failed to yield a substantial number of fibrochondrocyte-like cells [118]. Temporal 
control over the release kinetics can be obtained in different ways: designing hybrid scaffolds 
with polymers degrade at different rate, utilizing hydrogels as a layer in a polymeric scaffold, 
embedding multiple growth factors in charged mesh/film on scaffolds using layer-by-layer 
technology are explored by researchers. Delivering growth factors in a temporally controlled 
environment is beneficial as this allows to achieve desired cellular activity over the course of 
healing time without the need for repeated dosing of the proteins. 
Spatial control over growth factor release is an important issue in bone interfaces. 
Interfaces between bone and other tissues such as cartilage, ligament and tendon express 
various gene expressions which are tightly controlled in space. Mechanical and biochemical 
gradients are present at these interfaces. Releasing growth factors in a spatially controlled 
manner may influence cell phenotype, differentiation state and ECM production and 
organization which may have effect in tissue mechanical properties, mimicking those seen in 
vivo. A wide variety of technologies have been engineered to regulate the spatial organization 
of bioactive factors, and many of these have been applied for bone regeneration.  
Microcontact printing, non-contact technique, 2-D irradiation-based patterning, 3-D scaffolds 
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with microchannel, UV laser light treatment are widely studies techniques to create pattern 
on the scaffold to obtain spatially controlled growth factor release [119-121].   
1.6.6. Dose Response of Growth Factors: In Vitro and In Vivo 
 
Selecting the appropriate growth factors to regenerate the target tissue is only part of the 
solution of regenerative engineering. Optimal growth factor dose, carrier vehicle, and release 
kinetics all have to be assessed prior to the tissue scaffold implantation. Growth factors such as 
BMP-2 are considered to be dose dependent in vitro; that is the larger the dose of growth factor, 
the more bone tissue regeneration is observed. In vitro doses of BMP-2 at 1μg and larger were 
able to successfully bridge the defect site gap, with increasing doses resulting in an increase of 
bone formation, while doses at 0.5μg or lower were unable to sufficiently fill in the defect site 
[122]. The release of these doses in vitro often follows the pattern of a short burst release for the 
first week, followed by a more gradual increase, eventually leveling off after approximately 42 
days [106]. However, the dose-dependence of growth factors changes once evaluated in vivo. 
While the in vitro studies concluded that doses of 1μg and larger were able to bridge the defect 
site and regenerate bone, in vivo dose-dependence increased with the dose, but started to 
decrease after quantities of 1μg [122]. This had been hypothesized to be due to the saturation of 
BMP-2 receptors, or the fact that at higher doses, new bone formation has already filled the 
defect site. In vivo implantation must also take more careful consideration of the doses present, 
due to the physiological side effects of high doses. While it is important to maintain a dose 
significant enough to bridge the defect gap and regenerate new tissue, it is also important to 
ensure that the dose is not large enough to cause cell toxicity, an immune response, or excess 
bone or tissue formation.  
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1.7. Dual and Sequential Delivery of VEGF and BMP-2 in Fracture Healing 
  
 It has been observed that a combination of growth factors can result in a synergistic effect 
on the wound healing process, and lead to more advanced tissue regeneration. One of the more 
prevalent and understood growth factor combinations involves the delivery of both angiogenetic 
and osteogenic agents, which work together to establish vascularization and new bone formation 
respectively. Perhaps the most commonly used combination involves vascular endothelial 
growth factor (VEGF) and bone morphogenetic protein 2 (BMP-2). The synergy of these two 
growth factors is notable, as VEGF plays multiple roles in bone formation when combined with 
BMP-2. VEGF is known for ability to induce new blood vessel formation. Blood vessel 
formation is a key component in bone formation, as the blood vessels will transport blood, 
oxygen, cytokines, and other healing agents to the wound site, enhancing and sustaining the new 
bone formation. Additionally, VEGF also plays a role in ossification, further improving its 
synergistic effects with BMP-2. Peng et al., for instance, have shown that VEGF antagonists 
reduce the induction capacity BMP-2 to form bone, while BMP-2 in the presence of VEGF 
showed enhanced bone formation [117]. Further, the degree of bone formation after exposure to 
both factors was partially dependent on the ratio of one to the other, with higher amounts of 
BMP-2 compared to VEGF eliciting more bone formation than the reverse.  In another study of 
co-release of VEGF and BMP-2 examining the chemotactic role of each molecule, Ramazanoglu 
et al. examined expressions of collagen type I, Osteocalcin, and Osteopontin.  Increased collagen 
I from VEGF+BMP-2 groups confirmed the chemotactic migration behavior elicited by VEGF 
on osteoblasts.  At week 4, the VEGF+BMP-2 group showed higher osteopontin expression.  
Since osteopontin regulates bone remodeling by helping osteoclasts bind to bone, an increase in 
its expression was interpreted as an indication of bone remodeling [123]. Studies have been 
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reported where VEGF and VEGF receptor, VEGFR-1 have been expressed by human 
mesenchymal stem cells during their differentiation and that VEGF has increased the ALP 
activity in primary human osteoblastic cells. In intramembranous ossification during 
angiogenesis VEGF direct the surrounding blood vessels to invade the mesenchymal 
condensation and in endochondral ossification it helps to recruit the endothelial cells associated 
vasculature to invade the ischemic cartilaginous region. Invading vasculature allows the 
recruitment of osteoclasts, which subsequently remove the cartilaginous matrix and allow for 
osteoprogenitor cells to migrate and synthesize bone matrix.  Furthermore, in addition to 
osteoblast formation, VEGF has been shown to stimulate osteoclast formation as well, due to its 
increase of RANKL expression in osteoclast precursor cells. By upregulating RANKL 
expression in these cells, VEGF aids in the differentiation of these precursor cells in to 
osteoclasts [34, 35].These additional benefits have made the VEGF and BMP synergy a 
favorable combination of growth factors to use in bone healing, because they address new bone 
formation from multiple different pathways in the healing process. 
 The BMP family and VEGF is widely and commonly used, but other growth factors can 
also affect bone healing from multiple pathways. One example of such a growth factor is the 
fibroblast growth factor (FGF). FGF effects the bone regeneration process in a related way to 
VEGF, by increasing the differentiation and proliferation of precursor cells into osteoblasts, and 
it has also been observed to express type 1 collagen and osteoclast differentiation. Additionally, 
in vitro studies have shown that FGF directs endothelial cell migration as well as promotes 
VEGF expression, meaning FGF also has the potential to express both angiogenetic and 
osteogenic properties [125]. Platelet derived growth factor (PDFG) is another growth factor that 
is thought to effect both the angiogenetic and osteogenic pathways in wound healing. PDFG 
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plays a role in osteogenesis by inducing the formation of cartilage and other connective tissue by 
stimulating fibroblasts and chondrocytes. Similar to FGF, PDGF can increase VEGF expression, 
therefore making it an angiogenetic factor as well [125]. In fact, a small number of other growth 
factors have been shown to play a role in both osteogenesis and angiogenesis, including TGF-β, 
IGF and HGF, and perhaps the right combination of these growth factors with each other or other 
growth factors can prove to be as effective as the BMP-2 and VEGF synergy. 
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2. PROJECT OVERVIEW AND SPECIFIC AIMS 
 
 The objective of this thesis is to outline studies evaluating the efficacy of PLGA-coated 
cortical allografts capable of delivering both BMP-2 and VEGF, individually and simultaneously 
to enhance bone allograft incorporation and overall defect healing. We anticipate that our 
modified polymer coated- growth factor loaded allograft will demonstrate osteoinductive 
capacity and adequate remodeling during healing process. Coating will be applied to allografts to 
both maximize available surface area for coating and to retain the pore structure to support bone 
implant integration and growth factors will be loaded utilizing two different loading schemes to 
obtain short and long term delivery kinetics. The study is organized into the specific aims, 
detailed below.  
2.1. Specific Aim I: To optimize and characterize continuous coating on allografts using PLGA, 
an FDA polymer and examine the loading and delivery kinetics of VEGF and BMP-2 alone 
and simultaneously released from PLGA coated allografts.  
It is hypothesized that PLGA can be used to create a continuous coating of polymer on both 
the periosteal and intramedullary surfaces of the allograft while maintaining the native 
macroporous structure for host bone. It is further hypothesized that coated allografts will be 
capable of adsorbing and delivering growth factors in a controlled fashion.  
 
2.2. Specific Aim II: To determine the bioactivity of BMP-2 both in vitro and in vivo.  
It is hypothesized that loading and delivering the growth factors will not impact the 
bioactivity of the BMP-2. To test the bioactivity of the released BMP-2, differentiation 
ability of hMSCs into mature osteoblast will be assessed using hMSCs in the presence BMP-
2, released from PLGA coated allografts. Using a transwell, BMP-2 loaded, polymer coated 
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allografts will be cultured with human mesenchymal stem cells to determine the functionality 
of released BMP-2 from the allografts in supporting osteoblast differentiation.  
We also hypothesize that PLGA coated and BMP-2 loaded allograft will show more bone 
formation and osteointegration over coated allograft in a critical size rat femoral segmental 
defect. 
 
2.3. Specific Aim III: To investigate the role of VEGF in osteoclastogenesis in virto. 
We hypothesize that VEGF delivered will be viable to the extent that it can stimulate 
osteoclast differentiation. Using a transwell PLGA coated-VEGF loaded allograft will be 
cultured with Raw 267.4 cells and Bone Marrow derived Macrophages (BMM) cells and the 
ability of released VEGF to stimulate functional osteoclast differentiation will be evaluated. 
 
2.4.  Specific Aim IV: To evaluate the ability of PLGA coated and growth factors loaded 
allografts to repair large scale segmental defects in vivo.  
It is hypothesized that delivery of both VEGF and BMP-2 in a controlled way will increase 
healing over BMP-2 alone and uncoated-unloaded allografts. Specifically, given the nature 
of the bone defect to be used, segmental defects, it is anticipated that bone repair will occur 
via endochondral ossification as opposed to intramembranous. For this reason it is 
anticipated that an initial release of VEGF, followed by a more sustained release of BMP-2 
will result in more vascularization, better bone remodeling and overall healing. 
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3. LOADING AND DELIVERY OF BMP-2 AND VEGF FROM PLGA COATED 
ALLOGRAFT 
3.1. INTRODUCTION 
  
 Bulk allograft incorporation has been limited by a number of factors including diminished 
mechanical properties of the allograft, lack of remodeling of the allograft over time, fracture 
non-unions, and scant allograft vascularization.  This has led to high failure rates which has 
been as high as 60% in ten-year follow-up studies.1 Intact allografts, however, are the only 
subgroup suitable for load-bearing applications and indications, underscoring their importance 
in the clinical realm.  Given their importance clinically and their well-documented 
shortcomings enhancing allograft healing has become a well-studied topic.  Researchers are 
investigating several ways of improving allograft healing outcomes by combining them with 
cells, factors, proteins, and/or adenoviruses to revitalize the otherwise largely inert implant 
material,2-10 although for the most part these strategies have not investigated the nature with 
which these additives are delivered to the defect site nor sought to design delivery kinetics.   
 Studies on growth factors and bone repair have clarified the importance of controlling not 
only which factors to administer to a bone defect site but also the relative quantities and the 
temporal expression of factors as well.  Our hypothesis was that allografts could be made 
biologically active by combining the allograft with growth factors such as vascular 
endothelial growth factor (VEGF) and bone morphogenetic protein-2 (BMP-2).11 Our 
ultimate goal is to quantitatively and temporally control the delivery of these growth factors 
which has the potential to enhance the nature and extent of bone-allograft incorporation 
toward bone healing.  To accomplish this we introduced a thin coating of a biodegradable 
polymer to functionalize the exposed surface of the allograft as a delivery vehicle for the 
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growth factors, with the intention of delivering them simultaneously with short-term and 
long-term kinetics.  The primary aim of this study was to develop a methodology to apply a 
polymer coating onto the surface of the allograft thin enough to maintain its native 
architecture, specifically its inherent pore structure that facilitates new bone ingrowth, and to 
use the coating as a factor delivery modulator in which two growth factors, VEGF and BMP-
2, can be released from coated allograft in such a way that the VEGF is released rapidly, and 
prior to, the release of BMP-2. 
3.2. MATERIALS AND METHODS 
3.2.1. Allograft Harvest and Preparation 
 
For allograft samples, tibial and femoral bone samples were harvested from male and female 
Sprague-Dawley retired breeder rats (300-600g). The samples were cleaned of soft tissue and the 
bone marrow was aspirated. The bone segments were agitated in a chloroform solution overnight 
to reduce the residual fatty tissue and subsequently trimmed to 5 mm longitudinal segments. After 
a brief ethanol rinse, the allograft segments were autoclaved (121°C and 15 PSI for 30 minutes) to 
devitalize biological remnants. 
3.2.2. Allograft Coating with PLGA 
 
Polymer coating of sterilized allografts was based on prior studies12. Briefly, 50:50 PLGA 
(Lakeshore Biomaterials, Inc. Birmingham, AL) was dissolved in 1:8 (w/v) concentration of 
tetrahydrofuran (Fisher Scientific, Pittsburgh, PA). Each allograft was placed in the cylinder 
portion of a 3cc syringe and the polymer solution was drawn into the syringe by pulling the plunger 
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to fully submerge the allograft with the polymer and coat it through its endosteal and periosteal 
surfaces.  This process was repeated by moving the plunger up and down to effectively rinse the 
allograft with the polymer.  The pressure applied to the plunger in each direction was to force the 
polymer solution through the small pores found at the ends of the long bones to fully coat all 
surfaces.  Once coated the allografts were then lyophilized to remove any residual solvent. 
3.2.3. Coating Characterization of PLGA –coated Allograft 
 
Polymer coating was evaluated qualitatively using scanning electron microscopy (SEM) and 
microcomputed tomography (microCT).  SEM images were taken of allografts sputter-coated 
with gold using a JEOL 6700 scanning electron microscope (JEOL USA, Peabody MA) operated 
at 5.0 kV.  SEM was then performed to analyze the outer surface, as well as the cross section of 
the allograft.  Allografts were positioned on the SEM sample platform and sputter coated with a 
gold-palladium (Au-Pd) solution before being inserted into the SEM.  Images were taken to 
assess the thickness of the polymer coating. 
Additional images were taken with micro-focus X-ray computed tomography CT scans 
(µCT40; Scanco Medical AG, Bruttisellen, Switzerland) in 5 mm segments of the coated allograft 
to assess the volume of polymer coating.  Serial tomographic images were acquired at 45 kV and 
114 µA, collecting 1,000 projections per rotation at 300 msec integration time. Three-dimensional 
16-bit grayscale images were reconstructed using standard convolution back projection algorithms 
with Shepp and Logan filtering, and rendered at a discrete density of 244,141 voxels/mm3 
(isometric16-µm voxels).  Betadine was integrated into the polymer coating on the allografts to 
enhance contrast between the polymer coating and background.  Polymer coating volume was 
quantified by analyzing the microCT images. 
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3.2.4. Surface Adsorption of Growth Factor 
 
The growth factor VEGF was loaded onto the bone graft using surface adsorption.  
VEGF was purchased from Sigma Aldrich in 5 µg vials and stored in a -20ᵒ C freezer.  The 
VEGF was reconstituted using with 1 ml of deionized (DI) water to create a VEGF concentration 
of 5 µg/ml13. Allografts were coated with 1g/8ml (w/v) concentration of PLGA. .  After 
allografts were coated with the polymer solution and lyophilized, they were submerged in 500 µl 
of the VEGF solution with a concentration 5µg/ml.  The allografts were allowed to soak in the 
VEGF solution at room temperature for 15 minutes before the samples were frozen in a -20ᵒ C 
freezer.  Once frozen, they were lyophilized for 24 hours.  Control samples were created using 
the same procedure, being submerged in pure DI water instead of the reconstituted VEGF 
solution.  Studies were completed with a sample size of n = 6. 
Surface adsorption of BMP-2 was conducted following similar protocol as VEGF. 
Recombinant human BMP-2 was procured from Genscript Inc., NJ as a lyophilized powder in 
500 µg vials and stored at a temperature of -20ᵒ C before use.  Allografts were coated with a 
polymer solution containing a PLGA concentration of 1g/8ml.  Acetic acid was diluted with DI 
water to create a solution of 20 mM acetic acid.  1 ml of the solution was added to the 500 µg 
vial of BMP-2 to create a BMP-2 concentration of 500µg/ml13.  Coated allografts were 
submerged in 500 µl of the BMP-2 solution and incubated for 15 minutes at room temperature.  
The samples were then placed in a -20ᵒ C freezer until the BMP-2 solution had completely 
solidified.  The samples were then lyophilized for 24 hours.  Control samples were submerged in 
20 mM acetic acid rather than the BMP-2 solution.  A sample size of n = 6 was used.  
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3.2.5. Encapsulation of Growth Factor 
 
Release of BMP-2 was also tested using encapsulation of the protein in the polymer coating.  
PLGA was dissolved in THF at a concentration of 1g/8ml.  A 500 µg vial of BMP-2 from 
Genscript was reconstituted with 500 µl of 20 mM acetic acid.  This reconstituted solution was 
slowly mixed into the polymer solution until homogenized.  Allografts were then coated and 
lyophilized using the coating method stated previously. 
3.2.6. Incorporation of Multiple Growth Factors 
 
BMP-2 and VEGF were both loaded onto one coated allograft sample using one of two 
methods to obtain short-term and long-term release kinetics. Recombinant human BMP-2 
(Genscript, NJ) was loaded into polymer-coated allografts through encapsulation within the polymer 
coating and recombinant mouse VEGF (sigma Aldrich, MO) was loaded onto the same allograft 
sample through surface adsorption onto the polymer coating.  For factor encapsulation, 50:50 PLGA 
(Lakeshore Biomaterials, Inc. Birmingham, AL) was dissolved in 1:8 (w/v) concentration of 
tetrahydrofuran (Fisher Scientific, Pittsburgh, PA). BMP-2 was then added to the polymer solution 
(500μg/ml) prior to allograft coating. Each allograft was then placed in the barrel of a 3cc syringe 
and the polymer solution was drawn into the syringe by pulling the plunger to fully coat the allograft 
across its endosteal and periosteal surfaces. This process was repeated by moving the plunger up 
and down to effectively rinse the allograft with the polymer.  The allografts were then placed in a 
rotator at 40C overnight to achieve an even, continuous coating, followed by lyophilization to 
remove residual solvent. After lyophilization VEGF was adsorbed to the surface of the same coated 
allografts by placing them into a concentrated VEGF solution (5μg/ml) for a period of 15 minutes 
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to allow the protein to adsorb to the coating.  Coated allografts were subsequently frozen at -20°C 
for 20 hours, lyophilized for an additional 24 hours, and stored at -20°C until use. 
3.2.7. Release Protocols of Growth Factors 
 
Release kinetics of the growth factors were determined by placing the growth-factor-
loaded allografts in phosphate buffered saline (PBS) at 37°C under constant agitation for 42 
days. Samples were placed in well plates and submerged in 800 ul of phosphate-buffered saline 
(PBS).  Ion concentrations and osmolarity of PBS were equivalent to that of the human body, 
making it more similar to the environment of the body when the allograft is implanted.  The well 
plates were wrapped in parafilm and placed in a 37ᵒ C room to simulate the internal temperature 
of the human body.  Samples were taken by extracting the supernatant fluid in each well and 
freezing it in a -20ᵒ C freezer until it was ready to be analyzed.  The allografts were shifted to a 
new well at each time point and re-submerged in 800 ul of PBS. 800µl samples of buffer were 
taken at specific intervals: 2, 4, 6, 8, 12, and 24 hours, and 3, 5, 7, 10, 14, 21, 28, and 42 days. 
3.2.8. Growth factor Release Kinetics 
 
Protein release was analyzed using the enzyme-linked immunosorbent assay (ELISA) (R&D 
systems, Minneapolis, MN). To quantify the release of VEGF and BMP-2, 50 µl of each sample 
was added to an individual well, followed by 50 µl of Assay Diluent.  Two standard curves were 
also made using reconstituted VEGF diluted with PBS, as well as VEGF standards provided in 
the ELISA kit.  The well plate was covered with an adhesive strip and placed on a Thermo 
Scientific rocker to incubate for 2 hours with slight agitation at room temperature.  The wells 
were aspirated and washed with wash buffer 5 times before adding 100 µl of Mouse VEGF 
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conjugate to each well.  The well plate was then covered and incubated on the rocker for another 
2 hours.  The washing step was repeated, followed by 100 µl of Substrate Solution being added 
to each well.  The plate was covered in aluminum foil to protect from light and incubated on the 
rocker for 30 minutes. 100 µl of Stop Solution was then added to the Substrate Solution in each 
well.  The optical density of each well was read using a Biotek Synergy HT plate reader at 450 
nm and correction wavelength was set to 540 nm.  Using the optical densities of the wells, the 
concentration of VEGF in each sample was calculated, and cumulative release kinetics of the 
VEGF were calculated. 
3.2.9. Statistical Analysis 
 
 A student’s t-test (to compare two groups) or one-way analysis of variance with Tukey 
post-hoc testing, (for multiple group comparisons) was used to determine statistical significance 
with p<0.05.  Sample size for all protein release in vitro analysis was n=6. 
3.3. RESULTS 
3.3.1. Mass Analysis of Coating 
 
The weight of the allograft with and without factor-loaded polymer was measured and 
recorded (n=6) to quantify the extent of polymer coating. The mean recorded weight for 
uncoated allograft was 126.50 mg (± 38.88 mg) and the mean recorded weight for the coated and 
factor-loaded allograft was 158.16 (± 38.99 mg), a statistically significant mass increase of 27% 
(± 10.84%) (p<0.05, figure. 3.3.1.1).   
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Figure 3.3.1.1: Measurements of average weight of samples before and after polymer coating and 
protein loading (encapsulation scheme). Addition of growth factor and coating increased the 
mass of the allograft (p<0.05). 
3.3.2. Coating Thickness 
 
Scanning electron micrographs confirmed an even, continuous coating both on the 
endosteal and periosteal surface (figure. 3.3.2.1) that was between 30-100µm in thickness, thin 
enough to maintain open pores as small as 200µm but thick enough to minimally but evenly coat 
the entire surface area of the allograft.   
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Figure 3.3.2.1: SEM micrograph of the coated allograft at low magnification (right, 27X) and high 
magnification (left, 170X) represents 40 µm thick coating on the periosteal surface.  Coating 
thickness ranged from approximately 30µm-100µm.  
3.3.3. Coating Volume and Pore Size 
 
MicroCT analysis of the coated allografts confirmed an even continuous coating that 
maintained the small trabecular pore structure evident at the proximal and distal aspects of the 
allograft samples (figure 3.3.3.1) and demonstrated a trend toward a greater volume of coating on 
the periosteal surface of the allograft than the endosteal surface (figure 3.3.3.2).  It was anticipated 
that the periosteal surface would have a greater volume of polymer coating than the endosteal 
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surface given the overall uniformity of the coating along the allograft and the greater inherent  
surface area of the periosteal surface than endosteal surface.  
 
 
 
Figure 3.3.3.1: MicroCT image of allograft coating alone, with allograft removed from image (left) 
showing thin, continuous polymer coating on both the endosteal and periosteal surfaces. Scale bar 
=1 mm 
 85 
 
 
Figure 3.3.3.2: Distribution of polymer coating between periosteal and endosteal surfaces indicates 
a trend but no significant differences in volume. 
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Figure 3.3.3.3: Pore size measurement of allografts. No significant difference in pore size was 
depicted before and after coating 
 
3.3.4. Release of BMP-2 and VEGF (Single Release) 
 
 To determine the release kinetics of the single release of growth factors, one growth 
factor either BMP-2 or VEGF was loaded on one coated allograft.  
3.3.4.1. Release Kinetics Profile 
 
 In vitro factor release studies examining the rate at which the growth factors were 
released from the coated allografts (n=6) indicated that the implants with BMP-2 adsorbed to the 
surface of the polymer coating exhibited a burst release of 91.10% (± 24.16%) during the first 24 
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hours, followed by a more gradual release and eventual plateau over the next 7 days.  Almost the 
entire payload had been released within the first 7 days (figure 3.3.4.1.1).  For the BMP-2 
encapsulated within the polymer coating a more sustained release profile was noted (fig. 
3.3.4.1.1) with no initial growth factor burst release but rather a more sustained release over the 
entire study. 
 
Figure 3.3.4.1.1: Growth factor release profiles from polymer-coated allografts containing either 
surface adsorbed (black line) or encapsulated (grey line) BMP-2 show the rapid release of 
surface adsorption and the more sustained release of encapsulation. 
  
 The release profile of surface adsorbed VEGF depicted similar release kinetics as the 
surface adsorbed BMP-2, suggesting the burst release profile due to surface adsorption was 
independent of the molecule being released. VEGF release was most prominent within the first 
few days with 60% VEGF released within the first 24 hours and 82% released by day 7 (fig. 
3.3.4.1.2). 
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Figure 3.3.4.1.2: Growth factor release profiles from polymer-coated allografts containing VEGF 
(surface adsorbed). Release profiles indicate a rapid burst release of VEGF from the surface of 
the coated allograft.  This demonstrates the versatility of delivering of multiple growth factors 
from coated allograft with temporal control.   
3.3.4.2. Cumulative Protein Release 
 
In total, 52 µg/ml of BMP-2 was released from the surface of the allograft coating, with no 
further release after day 7 (Fig. 3.3.4.2.1) while 550ng/ml of BMP-2 was released from within 
the polymer coating over the 42-day release study (Fig. 3.3.4.2.2). In total, 170 ng/ml of VEGF 
was released from the surface of the allograft coating, with no further release after day 10 (Fig 
3.3.4.2.3). The surface adsorption of BMP-2 showed higher release of payload than VEGF 
because of the higher loading concentration in surface adsorbed BMP-2 (500 µg/ml) than surface 
adsorbed VEGF (5 ug/ml).  
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Figure 3.3.4.2.1: In vitro cumulative concentration of BMP-2 released from coated allograft 
constructs in phosphate buffered saline at 37 0C. BMP-2 was surface adsorbed onto the polymer 
coated allograft. Data are mean ±SD, n=6 independent experiments. 
 
 90 
 
 
Figure 3.3.4.2.2: In vitro cumulative concentration of encapsulated BMP-2 released from coated 
allograft constructs in phosphate buffered saline at 37 0C. Data are mean ±SD, n=6 independent 
experiments. 
Encapsulated BMP-2 released over 42 days 
 91 
 
 
Figure 3.3.4.2.3: In vitro cumulative concentration of VEGF released from coated allograft 
constructs in phosphate buffered saline at 37 0C. VEGF was surface adsorbed onto the polymer 
coated allograft. Data are mean ±SD, n=6 independent experiments. 
3.3.5. Release of Simultaneous Delivery of BMP-2 and VEGF 
  
 To determine release kinetics of simultaneous delivery of the growth factors, two growth 
factors were loaded concurrently on one coated allograft.  
3.3.5.1. Release Kinetics Profile 
 
 In vitro factor release studies showed the rate at which the growth factors were released 
from the coated allografts when VEGF was surface adsorbed onto the polymer coating and BMP-
2 was encapsulated within the coating of the coated/loaded allograft. The simultaneous release of 
Surface Adsorbed VEGF released over 28 days 
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the two growth factors exhibited a sequential release pattern where VEGF release was predominant 
at the earliest time points with 96.8% of the VEGF payload eluted between days 1 and 14 (Fig. 
3.3.5.1.1 grey line), while the BMP-2 release followed a more sustained profile with less of an 
initial burst release over the entire study (Fig. 2 black line).  
3.3.5.2 Cumulative Protein Release 
 
 In total, 145 ng/ml of VEGF was released from the surface of the allograft coating, with no 
measurable release after day 28 (Fig. 3.3.5.2.1) while 368ng/ml of BMP-2 was released from 
Figure 3.3.5.1.1: Growth factor release profiles from polymer-coated allografts containing both VEGF (surface 
adsorbed) and BMP-2 (encapsulated) simultaneously.  Release profiles indicate a rapid burst release of VEGF from 
the surface of the coated allograft and a more sustained, longer-term release profile of BMP-2 from the polymer 
coating.  This demonstrates the feasibility of delivering two growth factors from one coated allograft with temporal 
control.   
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within the polymer coating over the 42-day release study (Fig.3.3.5.2.2) Overall, this result 
demonstrated the ability to elicit short-term and long-term delivery kinetics with one growth factor 
released prior to another from the same construct by using surface adsorption and encapsulation, 
respectively. 
 
Figure 3.3.5.2.1: In vitro cumulative concentration of VEGF released from BMP-2+ VEGF loaded 
and PLGA coated allograft constructs in phosphate buffered saline at 37 0C. VEGF was surface 
adsorbed onto the polymer coated allograft. Data are mean ±SD, n=6 independent experiments. 
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Figure 3.3.5.2.2: In vitro cumulative concentration of encapsulated BMP-2 released from 
VEGF+BMP-2 loaded and PLGA coated allograft constructs in phosphate buffered saline at 37 
0C. Data are mean ±SD, n=6 independent experiments. 
3.4. DISCUSSION 
 
 Based on 5- and 10-year clinical follow-up studies large-scale bone allografts have a high 
failure rate from infection, fracture, and non-union associated with the poor healing and integration 
with host bone.14  Retrieval studies done by Wheeler and Enneking showed as much as a 50% 
decline in mechanical properties over time, which correlated with increased microfractures and 
decreased allograft bone mineral density.5  Data suggests that the allograft is less an active part of 
the repair process once implanted, a factor that most likely contributes to the overall failure of the 
allografts in the long term.  Given this, we imagined a system through which defect repair would 
be facilitated better by a functionalized allograft that delivers multiple bone growth factors with 
temporal precision rather than relying on it as a purely mechanical support.  Our strategy was to 
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apply a microscale thick coating of degradable polymer to all surfaces of the allograft to act as a 
delivery vehicle for multiple growth factors known to be relevant to bone healing (VEGF and 
BMP-2).  Further, we sought to evaluate whether the release kinetics of the loaded growth factors 
could be controlled to allow one to be delivered rapidly (VEGF) while the other remained 
sequestered and ultimately delivered over a more sustained period of time (BMP-2).  
 A study by Schrier et al. showed that the binding capacity of PLGA is affected by the 
molecular weight of the polymer, as well as the acid number of the polymer, which correlates to 
the hydrophilic/hydrophobic nature of the polymer.  It also showed that molecular weight linearly 
related to binding capacity, and hydrophobic PLGA showed a greater affinity for surface 
adsorption binding of proteins. The release of proteins from PLGA is biphasic, with an initial burst, 
as well as an extended release as the polymer degrades.  The burst release is caused by protein on 
the surface of the coating interacting with the medium surrounding it.  The extended release occurs 
through hydrolysis of the polymer to allow for drug release through diffusion and erosion.  The 
drug release is affected by the drug type and concentration, as well as the hydrophobicity and 
molecular weight of the polymer15. PLGA is very useful when creating drug delivery systems due 
to the way in which it is able to load and release growth factors.  Its biphasic release makes it an 
optimal polymer to deliver multiple growth factors due to the fact that it is capable of causing a 
burst effect or an extended release.  Using surface adsorption and encapsulation, it is able to exhibit 
a wide range of release kinetics.  Properties of PLGA can also be changed in order to optimize a 
system for specific applications.  PLGA, being a copolymer containing PLA and PGA, can be 
procured in many different variations, including molecular weight and ratio of the two polymers.  
PGA has been shown to be more hydrophobic than PLA, and a higher level of PGA also correlates 
to a faster degradation rate of the polymer. Therefore, PLGA can be procured in different forms 
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depending on the specific binding and release properties that are needed. BMPs have been 
administered to bone defects in a variety of ways; as a reconstituted protein that is dripped into the 
defect site, loaded into degradable structures that release the payload as they degrade, and directly 
onto allograft, both morcellized and intact, to assist with incorporation and healing to surrounding 
bone.  Baas et al. used morcellized canine allograft as both a mechanical strut and delivery vehicle 
by drip-coating the rhBMP-2 onto allograft chips and implanting them with titanium screws.  No 
means were taken to measure or control the rate of release of BMP-2 from the allograft chips, and 
healing was noted to have been hindered because the rhBMP-2 stimulated elevated metabolic 
activity of the surrounding cells. The allograft chips were completely resorbed prior to healing, 
leaving the implant site unstable.  Therefore this was not a failure of rhBMP-2 as a healing agent, 
but was an indication that this approach may not be suitable for small allograft samples.16 Indeed, 
Lieberman et al. authored the only clinical study of its kind investigating the utility of coating 
intact structural allograft with partially purified human BMP as both a mechanical strut and 
delivery vehicle in osteonecrotic femoral heads.17 BMP was coated on the surface of fibula 
allograft samples and lyophilized, and implanted with a gelatin capsule containing BMP.  Positive 
results indicated the potential value and utility of delivering BMP from an allograft to treat human 
osteonecrosis, but little was known about the uptake and release kinetics of BMP.  
 
 Others have sought to improve allograft healing by adding an external coating to try to 
recreate the periosteum by adding a cell layer to allografts via a submucosal membrane-coating,18-
21 or by adding a porous polymeric outer textured layer to increase osteoconductivity of the 
implanted allograft.22,23 While successful to an extent, these strategies presented additional 
challenges when considering long-term storage since they would require an environment capable 
of sustaining living cells.  Adding growth factors to a stable polymeric layer would not have the 
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same storage limitations.  Further, as these alternative approaches sought to coat the periosteal 
portion of an allograft it is unclear how endosteal surfaces would remodel and contribute to repair.  
The coating process described in this manuscript does not occlude any pore structure larger than 
100µm along the endosteal, periosteal, and cross-sectional regions of an implanted allograft while 
adding biofunctionality by delivering growth factors determined to be beneficial to new bone 
ingrowth. 
 Bone growth and repair has been attributed to many different growth factors including 
fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth 
factor-beta (TGF-β), and vascular endothelial growth factor (VEGF), to name a few.  BMP-2 and 
VEGF, two of the more commonly studied growth factors in bone repair, are critically important 
on their own but also have interconnected roles in the healing process.  VEGF has been shown to 
be involved in the conversion of soft callus to hard callus,24 contributes to cartilage resorption and 
subsequent ossification,25 and has also been found at very early stages of angiogenesis within the 
fracture hematoma after injury.  BMP-2 has been shown to stimulate osteoblast migration and 
differentiation,26 and its function has been intimately tied to the presence or absence of VEGF.24 
The function and timing of growth factor expression in bone repair has also been evaluated. Street 
et al. have uncovered subtle but measureable differences between intramembranous and 
endochondral ossification, where early angiogenesis may be required for the latter to convert 
chondrocytes to hypertrophic chondrocytes, stimulating their apoptosis and subsequent 
replacement with hard tissue.  Peng et al. have evaluated the response of BMP-2-mediated bone 
repair in the absence and presence of VEGF.  Their findings showed that BMP-2 in the presence 
of VEGF antagonists was reduced in its capacity to form bone, while BMP-2 in the presence of 
VEGF showed enhanced bone formation.27 
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 Our strategy was to be able to release one growth factor, VEGF, rapidly and prior to the 
release of another growth factor, BMP-2, over several weeks to mimic the sequence of release 
suggested by the literature. Using surface adsorption and encapsulation techniques, respectively, 
we were able to achieve this effect.  Evaluating the surface adsorption release kinetics of both 
BMP-2 and VEGF allowed us to determine if surface adsorption-mediated burst release was 
simply a function of the loading process or was also dependent on the molecule released.  It was 
found that while surface adsorption led to an overall burst release regardless of the molecule there 
were some slight differences in the kinetics of the burst release.  Each growth factor, VEGF and 
BMP-2, released over 90% of the payload within 7-10 days but about 70% of the BMP-2 had 
released within 24 hours while only 60% of the VEGF was released in the same time frame.  There 
are several factors that could explain the subtle difference like the hydrophobicity of the surface 
of the polymer, the 3-dimensional structure of the scaffold, the pKa and isoelectric point of the 
molecule,29,30 and the molecular weight of the polymer30.  Since the scaffold material and structure 
were the same for each growth factor those parameters were not relevant.  Both BMP-2 and VEGF 
have pI values of 8.5-9 so that is unlikely to have had a large impact.  Molecular weight, however, 
of BMP-2 is 26 kDa while VEGF is 45 kDa.  The larger size may have impacted the release of the 
VEGF from the surface since surface adsorbed proteins can either be considered free or bound, 
where the free molecules are dependent on the concentration of the molecule in solution and the 
bound molecules are physically entrapped within small pores on the surface of the microsphere28-
30.  The larger VEGF molecule may have released more slowly from being bound to the surface 
by virtue of its larger physical size. 
 The simultaneous and sequential delivery of VEGF and BMP-2 from the same 
coated allograft exhibited that surface adsorbed VEGF is released rapidly from the double loaded 
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allograft, with over 96% coming off in the first four days.  While BMP-2 release also begins in the 
short term its release is more gradual and extends over a longer period of time than the VEGF, 
with more than 50% of its payload still bound to the allograft after VEGF is almost completely 
eluted.  This demonstrates that we can deliver both VEGF and BMP-2 from the same construct, 
and preferentially have the vast majority of the VEGF elute first, a temporal specificity that has 
been shown in the literature to be important for bone repair and regeneration 31,32.  While the two 
growth factors do elute simultaneously at the earliest time points, VEGF elutes at 3x-5x that of 
BMP-2.  At later time points BMP-2 continues to elute after the entire VEGF payload has been 
released.  So while not perfectly sequential, the release is dominated in the earliest time points by 
VEGF and at the later time points by BMP-2. 
3.5. CONCLUSIONS & FUTURE DIRECTIONS 
 
 Studies on factors and bone repair have clarified the importance of controlling not only 
which factors to administer to a bone defect site but also the relative quantities and the temporal 
expression of factors as well.  In response, this study was an attempt to address each of these needs 
by modifying existing large scale bone allografts with a thin polymeric coating that would act as 
a delivery vehicle for growth factors in a temporal pattern designed to maximize bone-allograft 
incorporation.  In this study we have demonstrated the dual release of VEGF and BMP-2 with 
temporal precision from one polymer-coated cortical allograft.  Burst release of VEGF was 
confined to the first week while BMP-2 release was extended over several weeks of elution.  Our 
studies have resulted in a microscale thin polymer coating of PLGA capable of retaining and 
delivering growth factors, VEGF, and BMP-2 and releasing them in such a way that it is available 
at the defect site initially by a burst release or by a longer-term exposure.   
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 Further refinement of release kinetics for each growth factor is possible by functionalizing 
the surface of the polymer to modify its hydrophobicity, varying the polymer used (more slowly 
degrading materials may sustain long term release for longer periods of time) or by adding other 
materials like calcium phosphate to the coating, which may allow for a more sustained release of 
the surface adsorbed VEGF if desired. Further, we should develop protocol to measure the total 
amount of growth factors loaded onto the coated allograft. This will give us an indication of the 
total amount of proteins that will be released in vivo as the allografts break down and eventually 
proteins that are embedded within the bone matrix will be eluded. Additionally, this approach is 
not limited to VEGF and BMP-2.  Antibiotics, which may need to be released in a bolus after 
implantation could be surface adsorbed to provide both acute and chronic delivery. 
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4. INVESTIGATION OF BIOACTIVITY OF RELEASED BMP-2: IN VITRO & IN 
VIVO EVALUATION 
4.1. INTRODUCTION 
 
 Encapsulation of proteins or peptides within biodegradable and biocompatible polymers is 
a successful and well-documented method for their sustained or controlled-release. The benefits 
of sustained or controlled-release protein delivery systems include avoidance of resistance in 
bacteria [1–4] and pulsatile administration of vaccines to enhance immune response, etc [5, 6]. In 
general, during the protein encapsulation process an aqueous solution of the protein, or of protein 
and an additive, is added to an organic solution of the polymer of choice to form an emulsion. 
Because proteins are large hydrophilic molecules and difficult to encapsulate within hydrophobic 
polymers, a high rate of mixing is employed to entrap the protein into pockets of water solution 
inside the polymer, followed by freeze-drying. As discussed in the previous section the 
encapsulation of BMP-2 into the PLGA coated allograft showed sustained release of payload over 
42 days, which can be beneficial to mimic the healing of native bone. However, this method results 
in direct exposure of the protein molecule to water–oil interfaces, which can often result in protein 
denaturation. [2] Therefore the primary goal of this study is to confirm that the coating applied to 
the allograft did not diminish nor remove the bioactivity of the delivered proteins.  To this end the 
released growth factor bioactivity was assessed by both in vitro and in vivo studies. We performed 
in vitro cell studies with human mesenchymal stem cells (hMSCs) to test the osteoinductivity of 
the released BMP-2. A pilot in vivo study was also conducted to further verify the bioactivity of 
released BMP-2 to heal a critical sized defect. 
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4.2. MATERIALS AND METHODS 
4.2.1. Cell Culture 
 To study the bioactivity of the released BMP-2, human mesenchymal stem cells (hMSCs) 
isolated from human bone marrow, cell culture growth medium, and cell culture osteogenic 
medium were obtained from Lonza (Lonza Walkersville Inc, Maryland).  hMSCs were expanded 
per vendor protocols in growth medium, after which they were trypsinized and seeded into 24 well 
culture plates at a seeding density of 50,000 cells/well and maintained in osteogenic medium.  
Cellular viability and phenotypic expression was evaluated after 7, 14, and 21 days (and 28 for 
mineralization studies). Three different groups were tested for the in vitro study: 1) Test Group: 
Cells were treated with BMP-2 that was released from polymer-coated and growth-factor-loaded 
(coated-loaded) allografts that were placed into transwell inserts so the seeded cells would be 
exposed to released BMP-2 but not the allograft itself, 2) Positive Control: cells were cultured as 
above but without the coated-loaded allografts added.  Rather 1.5l of a stock solution of 
reconstituted rhBMP-2 (100g/ml) was added directly to wells every three days for a final 
concentration of 100ng/ml, and 3) Negative Control: cells were cultured as the control group but 
vehicle (reconstitution solution with no BMP-2) was added every three days.  
4.2.1.1. Cytotoxicity Assay 
 Potential cytotoxicity of the released BMP-2 was assessed using an MTS assay (CellTiter 
96® Aqueous One Solution, Promega Corp, WI) at specific intervals (7, 14 and 21 days). For 
MTS assay study the cells were treated with basal media. Assays were performed by adding a 
small amount of the CellTiter 96® AQueous One Solution Reagent directly to culture wells at 
designated time points ( 7, 14 and 21 days), incubating for 2 hours and then recording the 
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absorbance at 490nm with a micro plate reader. The absorbance values were normalized to the 
background readings. A standard curve relating cell number to MTS activity was plotted for the 
specific hMSCs used in the current study. 
4.2.1.2. Alkaline Phosphatase (ALP) Activity 
 Alkaline phosphatase (ALP) activity was analyzed using an Alkaline Phosphatase 
Substrate kit (Bio-Rad Laboratories, Inc., Hercules, CA), which measured the catalytic activity 
of ALP via the conversion of p-nitrophenyl phosphate to p-nitrophenol + phosphate and assumed 
that the rate of reaction was proportional to the enzyme activity. Prior to conducting the ALP 
activity assay, cells were rinsed with PBS and lysed with 1% Triton X-100. Next, 100 μL of each 
cell lysate sample was incubated with 100 μL of the working ALP substrate solution (p-
nitrophenyl phosphate tablets dissolved in 1X diethanolamine buffer) for 30 minutes at 37°C. 0.4 
N NaOH was then added to each sample to stop the ALP-catalyzed reaction. Finally, the 
absorbance of each sample was immediately measured at a wavelength of λ = 405 nm using a 
SpectraFluor Plus Tecan plate reader (Männedorf, Switzerland). ALP data was normalized to cell 
number by BCA protein assay. 
4.2.1.3. Mineralized Matrix Production 
 Alizarin red was used to stain calcium deposits to measure the capacity and extent of 
mineralization of the cell cultures. At each culture time point (7, 14, 21 and 28 days) cells were 
fixed with 70% ethanol. Following fixation, cells were stained with 40 mM alizarin red (pH 4.23) 
for 10 minutes and then thoroughly rinsed with ddH2O until all excess stain was removed. Stain 
was quantified (562 nM) after solubilizing in 10% cetylpyridinium chloride (10 mM sodium 
phosphate, pH 7.0). Mineralization data was normalized to cell number by BCA protein assay. 
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4.2.2. In Vivo Femoral Critical-Sized Defect 
 Allografts were placed in critical size segmental femoral defects in 14 week-old male 
Lewis rats (n=1). Two groups were evaluated; one of which received BMP-2 loaded allografts 
(both surface adsorbed and encapsulated) and one of which received polymer coated but non-
factor-loaded allografts. All procedures were done in accordance with approved Institutional 
Animal Care and Use Committee guidelines. Briefly, the femur was approached anterolaterally, 
the periosteum incised, and then removed circumferentially. A small plate was fixed to the femur 
with four Kirschner wires and two surgical steel cerclage wires and a 6mm critical-sized full-
thickness defect was created in the central third of the diaphysis. The allografts were shaped to 
final size intraoperatively and placed into the defects to achieve a press-fit, and maintained in place 
using a single 4-0 Vicryl (Ethicon, Somerville, NJ) cerclage stitch that was tied around the graft 
and plate.  A three-layered closure of the muscle, subcutaneous tissue, and skin was performed 
with 4-0 Vicryl.   
4.2.2.1. Radiological Analysis 
 Bone formation on rat femur was analyzed at 26 kV for 6 seconds using the Faxitron X-
ray machine, and the Faxitron DX-Beta SR v1.4 software. Radiographic images were taken at 1, 
2, 4, and 8 weeks after surgery to track bone formation as indicated by radiographic opacity. 
4.2.2.2. Microcomputed Tomography (MicroCT) 
 MicroCT provides an efficient method to measure the distribution and density of 
mineralized tissue throughout the scaffold. Limbs harvested at week 12 were imaged using cone 
beam micro-focus X-ray computed tomography to render three-dimensional models for direct 
quantitation of sample bone density and volume, and to provide a three-dimensional 
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reconstruction of the defect (μCT40, Scanco Medical AG, Bassersdorf, Switzerland). 
Segmentation of bone and allograft provided direct volumetric quantification of new bone 
formation  
4.2.2.3. Histological Analysis 
 Limbs were embedded in methyl methacrylate using a plastic methylmethacrylate 
processing, infiltration and embedding techniques as described by Kecena et al., [7] and then 
was sectioned as undecalcified, and mounted onto glass slides. These sections were then be 
stained with hematoxylin and eosin to evaluate cellular events, and with Masson’s Trichrome to 
evaluate the osteoid, or new unmineralized bone being deposited at bone forming sites. All 
staining was performed according to protocols described by Kecena et al. [7]. 
 
4.2.3. Statistical Analysis 
 A student’s t-test (to compare two groups) or one-way analysis of variance with Tukey 
post-hoc testing, (for multiple group comparisons) was used to determine statistical significance 
with p<0.05.  Sample size for in vitro cell culture analysis was n=3. 
4.3. RESULTS 
4.3.1. Cell Viability 
 
 The cell viability assay showed significant increase in cell number over the 21 days 
(Figure 4.3.1.1) where the cells were treated with BMP-2 released from the loaded-coated 
allografts (n=3). The result shows that the released dose of BMP-2 and the byproducts of the 
scaffold are not toxic to the cultured hMSCs. 
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Figure 4.3.1.1: Effect of released BMP-2 dose on human mesenchymal stem cell viability 
determined by MTS mitogenic assay. (A) There is no significant difference between the groups 
in each time point. (B)Increasing cell numbers in the group treated with released BMP-2 over 21 
days confirm the biocompatible released dose of the protein. Significance between groups is 
designated with * = p<0.05. 
MTS reading of cells treated with 
released BMP-2 
A 
B 
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4.3.2. ALP Activity: Bioactivity of Released BMP-2 
 
 Alkaline Phosphatase (ALP) activity, well know osteoblastic phenotype marker was 
assessed in cells treated with BMP-2 released from allografts. The control for this study was cells 
treated in osteogenic media without any added BMP-2. Due to the presence of osteogenic 
component in the media the cells with no BMP-2 showed some ALP activity in the early stage of 
the time point, however as time progressed and the allograft started to release BMP-2, the group 
with BMP-2 showed significant increase in ALP activity over the control group (Figure 
4.3.2.13.1).  
 
Figure 4.3.2.1: ALP activity on cells treated with released BMP-2 and cell alone over a period of 
28 days (A). Significant increase in the cellular ALP activity at day 21 and 28 between cells 
exposed to released BMP-2 compared to cells not exposed to BMP-2 confirms the intact 
bioactivity of the protein (B). Significance between groups is designated with (*)= p<0.05. 
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4.3.3. Mineralization: Bioactivity of Released BMP-2 
 
 The quantitative results of the alizarin red calcium staining assay, an indicator that the cells 
are differentiating into mature osteoblasts, showed that at day 28 there was a significant increase 
in cellular mineralization from cells not exposed to released BMP-2 to cells exposed to released 
BMP-2 (Figure 4.3.3.11). The positive control where BMP-2 solution was added manually to the 
culture also demonstrated similar trend as the experimental group (n=3). The data revealed that 
the BMP-2 released from the scaffold aids in differentiation of hMSCs into osteoblasts and is as 
effective when loaded and released as it is when added directly to culture wells.  
 
 
A 
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Figure 4.3.3.1: Alizarin red staining on cells treated with released BMP-2, added BMP-2 and cell 
alone over a period of 28 days (A). Significant increase in the cellular mineralization activity at 
day 28 between cells exposed to released BMP-2 compared to cells not exposed to BMP-2 
confirms the intact bioactivity of the protein (B). Significance between groups is designated with 
(*)= p<0.05. 
4.3.4. In Vivo Bone Formation 
  
 Radiograph, microCT and histological analysis revealed robust bone formation over an 8-
week period.  Evidence of mineralized callus was first evident by day 14 radiographs of allografts 
loaded with BMP-2 and continued to develop over the 8-week period as compared to polymer-
coated allograft without growth factors (see fig. 4.3.5.1). MicroCT detected total volume through 
Defect Region as 76.0787 mm 3 and new bone volume through defect region as 41.3817 mm3. 
BV/TV was calculated as 54.4 % (fig. 4.3.5.2). Histological sections performed 8 weeks after the 
procedure confirm the healing noted in radiographs.  Coated allografts with no BMP-2 loading 
Mineralization at day 28 B 
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show evidence of osteoid formation along the length of the allograft but no mineralized tissue, and 
incomplete bridging surrounding the implant (figure 4.3.5.3 A, B). The coated and BMP-2 loaded 
allograft, however, showed dramatically different results at the same time interval.  Dense, 
organized bone was formed along the length of the allograft, fully encapsulating the coated 
allograft.  
  
 
 
Figure 4.3.4.1: In vivo analysis bioactivity of the released BMP-2 utilizing critical size segmental femoral defects in (2) 14 week-
old male Lewis rats, one of which received BMP-2 loaded allografts (both surface adsorbed and encapsulated) and one of which 
received polymer coated BMP-2 loaded allografts (both surface adsorbed and encapsulated) and one of which received polymer 
coated but non-factor-loaded allografts. Representative radiographs of the rat femoral segmental defect at 1, 2, 4, and 8 weeks. 
Continuing formation of the mineralized callus observed in the BMP-2 loaded coated allograft, confirm the bioactivity of the 
released protein and bone union at the host site.  
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 A 
B 
Figure 4.3.4.2: MicroCT analysis of femoral bone defect 8 weeks post-implantation. Representative longitudinal section 
images, cross section images and three-dimensional reconstructed images are shown for control (A) and experimental group 
(B).  No evidence of new bone growth was detected through the defect site in the control group (A), whereas new bone 
formation was identified around the BMP-2 loaded coated allograft. Scale bar = 5 mm. 
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Figure 4.3.4.3 : Longitudinal histological sections of allograft and surrounding femoral bone and 
tissue after 8 weeks of healing.  Masson’s trichrome stain (A,C) and Hematoxylin and Eosin 
stain (B,D) show limited healing around polymer coated/unloaded allograft indicated as “ca” in 
the figures (A,B).  Figure A shows evidence of unmineralized osteoid within the defect site, 
peripheral to the allograft while Figure C shows mineralized bone bridging the defect and 
surrounding the coated/BMP-2 loaded allograft.   
 
4.4. DISCUSSION  
 
 BMP-2 released from polymer coated allograft showed Human mesenchymal stem cells 
exposed to BMP-2 released from polymer-coated allografts were noted to show no reduced 
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metabolic activity over 21 days of culture, and to produce mineralization at levels exceeding 
those of hMSCs exposed to osteogenic media with no BMP-2, and at levels comparable to BMP-
2 added directly to culture media (vs released from scaffolds), suggesting the enhanced 
osteoinductive effect of BMP-2 was neither eliminated nor reduced as a consequence of being 
encapsulated within the polymeric layer.  Enhanced Alkaline Phosphatase (ALP) expression in 
the group treated with released BMP-2 at day 21 and 28, indicates matrix maturation [12]. In 
clinical studies high doses of BMP2 were needed to be effective (1.5–2.0 mg/mL) [13-15], 
raising concerns about bone overgrowth and the potential subsequent risks of neural compression 
and oncogenic effects. High concentrations also make these treatments expensive. Therefore, 
more specific and controlled strategies for administration of BMP-2 for bone reconstruction is 
necessary.  Human bone marrow–derived mesenchymal stem cells (hMSCs) have long been 
considered promising candidates for bone regeneration due to their capability to differentiate into 
osteoblasts when appropriately induced in vitro, allowing the use of these cells for engineering of 
implantable bone constructs [16,17]. BMP-2 has been shown to stimulate the osteogenic activity 
in rodent cell cultures, [18–20] whereas the osteogenic effects are less pronounced in human 
cells. Some studies indicated that continuous stimulation with BMP2 (0.1–800 ng/mL) affects 
the differentiation but not the proliferation of hMSCs [21–25] whereas other studies did not 
demonstrate an osteogenic effect of 100 ng/mL BMP-2 [26, 27]. It is noted that in our study we 
developed a delivery system that can release sustain payload of BMP-2 significantly lower (300 
ng/ml from dual release) than what is currently being used clinically (1.5–2.0 mg/mL). This 
work suggests that delivering BMP-2 from coated allograft can promote osteoinduction of 
hMSCs in vitro and can serve as controlled delivery vehicle for new bone formation utilizing a 
reduced dose of BMP-2.  
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Our pilot in vivo study has shown feasibility of this approach for enhancing allograft 
repair. The robust bone formation was a strong indication that the BMP-2 that was loaded and 
subsequently delivered was bioactive and resulted in enhanced bone/allograft incorporation when 
compared to the control, coated allografts containing no BMP-2. Allograft fracture do not initiate 
the repair processes seen in normal fracture healing. Under normal circumstances, growth factors 
released from freshly injured bone send stimuli to the osteoprecursor cells in the periosteum and 
endosteum and induce formation of osteoblast which eventually cause callus formation. In 
devitalized allograft healing process the host bone only contribute to the healing process as the 
devitalized allograft doesn’t contain any biological factors. Numerous growth factors are 
responsible for orchestrating cellular proliferation, differentiation, chondrogenesis, and 
osteogenesis have been identified. BMP-2 is well recognized for its osteoinduction ability. In our 
study the robust bone formation and union at the host-graft junction occur due to BMP-2 
released from the allograft stimulate osteoinductive signaling and regulation of a number of 
gene-expression pathways involving the recruitment and differentiation of host mesenchymal 
progenitor cells into osteoblasts and eventually callus formation around the defect zone. 
 Literature supports our findings that a burst release followed by sustained release 
promotes enhanced new bone formation [28, 29]. The burst release of BMP-2 triggers early and 
fast cellular response and initiates the fracture healing cascade, also enhanced the recruitment of 
osteoprogenitor cells into the allograft [30], whereas, the sustained delivery of BMP-2 enhances 
bone regeneration, which has been attributed to by stimulating a larger population of 
osteoprogenitor cells at the fracture site at later stages following the original injury [31-33], as 
well as its role in promoting vasculogenesis [34]. Overall, an appropriate growth factor dose, 
timing and sequence of growth factor delivery, and the physical–chemical and three-dimensional 
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attributes of the scaffold are crucial to mimic the physiological repair process in bone. 
Interestingly in both the allograft implant with and without BMP-2 the allograft remained largely 
intact suggesting that, while BMP-2 delivery results in robust bone formation, it does not 
necessarily aid in the resorption of the allograft itself.   
4.5. CONCLUSIONS & FUTURE DIRECTIONS 
 The in vitro and preliminary in vivo data strongly suggests the utility of a growth factor-
loaded polymeric coating on massive allografts to enhance bone repair. These biologically active 
structural allografts may be effective in treating fracture non-unions and revision total joint 
arthroplasties with large bone defects [35].  There is great potential for the coated allograft as an 
“off-the-shelf” option for treating bone defects given that once the coating and growth factors are 
applied they are somewhat stable if stored appropriately.  That is to say there is no requirement for 
rehydration or special storage as there can be for hydrogel-based or cell-based bone graft 
substitutes.   
Future in vivo studies will include the delivery of VEGF (along with BMP-2) to determine its 
role in allograft resorption, a key component in complete allograft healing. These studies confirm 
the ability to deliver growth factors essential for bone repair from polymer-coated allografts 
without modifying the general physical structure of the allograft itself.  Implications of this work 
are great as many other proteins and pharmaceuticals could seemingly be delivered in a similar 
manner, depending on the particular need.  
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5. IN VITRO CELLULAR EVALUATION OF BIOACTIVITY OF RELEASED VEGF 
BY INVESTIGATING OSTEOCLAST PHENOTYPE 
5.1. INTRODUCTION 
 
 Bone grafting procedures are on the rise in the US, with an estimated 2 million 
grafting procedures performed annually.1 Autografts, donor tissues harvested from the patient’s 
own body, are considered the gold standard for their optimal biocompatibility, osteoconductivity, 
ideal biomechanical properties, biological components and subsequent osteoinductivity, leading 
to an 80-90% success rate clinically.2,3  Autografts are typically harvested from the iliac crest for 
its porous trabecular bone, relative ease of access, and the high marrow content taken with the 
bone because of its abundant cells, blood, and associated proteins.  Autograft incorporation follows 
a similar sequence of events as typical fracture repair including inflammation, repair, and 
remodeling 4.  During these three stages multiple cell types including macrophages, monocytes, 
lymphocytes, osteoclasts, and fibroblasts infiltrate the autograft from the host bone while 
granulation tissue begins to form.  Vascularization continues as a collagen matrix is formed and 
slowly mineralized.  Remodeling of the healed defect, often in response to mechanical loading, 
occurs through both bone resorption and subsequent new bone formation.  
While autografts are the clinical gold standard for bone grafting the hazard of donor-site 
morbidity and a limited supply requires a feasible alternative. Allografts, tissue harvested from a 
donor or cadaver, are common alternatives to using autografts but to reduce the likelihood of a 
host immune response or disease transmission the donor tissue must be devitalized through a 
process that removes cellular and viral components.5 This process removes the cells, blood, and 
proteins that are present with autografts, leaving the allograft as a largely structural implant with 
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little to no inherent bioactivity and diminished local vascularity. Therefore, in allograft healing 
graft incorporation relies only on cells, proteins, and tissues available from host bone and at the 
defect site.  For trabecular allografts this lack of bioactivity does not prevent adequate healing as 
the inherent pore structure of the tissue allows the host to infiltrate the allograft and heal but 
devitalization does impact more dense, cortical allografts.6  
Large-scale structural allografts (typically cortical bone taken from the diaphysis of long 
bones) have limited healing where mineralized tissue usually forms along the cortex of the host 
bone and allograft.  The lack of osteoclast-mediated allograft resorption or bone remodeling, leaves 
large segments of necrotic bone, weakening the defect site over time. The repetitive loading at 
these sites makes them vulnerable to destabilization and generation of small microfractures.7,8 As 
these allografts become less stable non-unions (27%-34%), late graft fractures (24%-27%), and 
infections (9%-16%) occur which ultimately result in clinical failure.9  In the hopes of improving 
large scale defect healing we have developed a technique to “revitalize” allografts by incorporating 
molecules known to stimulate implant resorption and enhance new bone formation.  The literature 
reports that delivering bone morphogenetic protein 2 (BMP-2) and vascular endothelial growth 
factor (VEGF) simultaneously yields better bone healing over either growth factor alone, and 
delivering them sequentially yields even better healing 10-13. The literature also suggests that VEGF 
may influence osteoclast precursor differentiation to mature osteoclasts14-17 which, when, 
delivered from devitalized allografts may increase the local osteoclast population to facilitate 
implant resorption thereby paving the way for subsequent new bone formation.  Given this, we 
have developed a method through which a thin, polymeric coating capable of retaining and 
delivering growth factors is applied to all surfaces of large-scale structural allografts, with the 
intention of delivering therapeutic molecules capable of enhancing bone-allograft healing.  In the 
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previous chapters we have demonstrated the ability to deliver either VEGF or BMP-2 with two 
distinct delivery kinetics; short- and long-term.18 Our studies demonstrated that BMP-2 released 
from the polymer-coated allograft resulted in robust bone formation in a rat segmental defect. 
However, the release of BMP-2 alone failed to show any significant bone resorption in vivo18 
substantiating the need to stimulate osteoclastogenesis.  
We hypothesized that the delivery of VEGF which is traditionally associated with 
angiogenesis would induce differentiation of osteoclast precursors into mature, bone-resorbing 
osteoclasts, in vitro.  
5.2. MATERIALS AND METHODS 
5.2.1. Culture of RAW 264.7 Cells 
 
 RAW264.7 cells were obtained from the American Type Culture Collection 
(ATCC; Rockville, USA) and cultured in 25 cm2 tissue culture flasks in ATCC-formulated RPMI-
1640 culture medium with 10% FBS, 1% penicillin/streptomycin at 370C in a humidified 
atmosphere containing 5% CO2. After 24–48 h of culture, RAW264.7 cells were detached using a 
cell scraper and seeded into 24-well plates at a density of 2.6 x104 cells/cm2 in α-MEM culture 
media with 10% FBS, 1% penicillin/streptomycin.  Four groups were evaluated in this study: 1) 
negative control: cells cultured in α-MEM; no additives, 2) positive control: cells cultured in α-
MEM with receptor activator of nuclear factor kappa-B ligand (RANKL 50ng/ml) which is 
available endogenously and is added to culture to replicate the in vivo environment, 3) cells 
cultured in α-MEM treated with RANKL (50 ng/ml) and 10 ng/ml VEGF added directly to the 
culture, and 4) cells cultured in α-MEM treated with RANKL (50 ng/ml) and 100 ng/ml VEGF 
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added directly to the culture.  Cells from each group were cultured for 7 days and then fixed in 
3.7% formalin. Cells were then stained with tartrate-resistant acid phosphatase (TRAP) using a 
commercial kit (Sigma).  Cells that both stained positive for TRAP and contained three or more 
nuclei were considered osteoclasts, and were visualized with a Zeiss observer Z.1 light microscope 
(Carl Zeiss, USA) and analyzed using NIH ImageJ software.  
5.2.2. Isolation of Bone Marrow Macrophages (BMMs) from mice 
   
 Primary bone marrow derived mononuclear cells (BMMs) were exposed to VEGF that was 
either added to cell culture wells as described above (to assess the functionality of osteoclast-
precursors differentiated with VEGF) and eluted directly from coated/loaded allografts (to confirm 
the bioactivity of the VEGF after it is released from the coated allograft) (see Figure 5.2.2.1).  
BMMs were isolated from long bones of wild type mice aged 4- to 9-week-old, according to 
published protocols.10 Briefly, long bones were excised from the mice, cleaned of soft tissue and 
stored in PBS.  The bone marrow of each bone was flushed out with -MEM media that was 
supplemented with 10% FBS and 1% penicillin/streptomycin.  Flushed marrow was centrifuged 
for 5 minutes at 1200 rpm.  Cells were then resuspended in ACK buffer to lyse red blood cells and 
the suspension was then centrifuged for 5 minutes at 1200 rpm. Finally cells were resuspended in 
complete media.  Cells were then seeded on a petri dish (1x108 cells/10 cm dish). Macrophage 
colony-stimulating factor (M-CSF) (30ng/ml) was added to the BMM for macrophage 
differentiation and cells were cultured for 48 hours in 5% CO2.  Cells were then detached and 
seeded onto 24-well plates at a concentration of 50,000 cells/well. To support osteoclast 
differentiation all cells were cultured in complete -MEM media supplemented with 10% FBS, 
1% penicillin/streptomycin and M-CSF (30ng/ml) to assess the following five experimental 
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groups: 1) negative control: cells cultured in media  (no additional additives), 2) positive control: 
cells cultured in media with RANKL added (50ng/ml), 3) cells cultured in media with 100 ng/ml 
VEGF added (no RANKL), 4) cells cultured in media with RANKL (50 ng/ml) and VEGF (100 
ng/ml) added, and 5) cells cultured in media with RANKL (50 ng/ml) and ~120 ng/ml VEGF 
eluted directly from coated/loaded allograft using a transwell with pore size 0.4 μm insert setup 
(Figure 5.2.2.1). Each group was cultured for 7 days and numbers of TRAP stained osteoclasts 
were counted as described above. 
 
 
Figure 5.2.2.1: Schematic representation of the cell study to evaluate the bioactivity of VEGF, 
adsorbed onto the surface of the PLGA coated allograft. Osteoclast precursors (RAW264.7 and 
BMMs) were seeded onto the cell culture plate and the allografts were placed in the corning 
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transwell inserts on the permeable membrane. VEGF released from the coated allograft filtered 
through the membrane and came in contact with the cells seeded on the plate. 
5.2.3. TRAP Staining Assay 
 
 TRAP (+) cells were identified as osteoclasts for both RAW264.7 cell studies (on day 7 of 
culture) and BMM cell studies (on day 5 of culture) through histochemical staining using a 
commercially available kit (Sigma-Aldrich) as per manufacturer’s instruction.  
5.2.4. Resorption Assay by Utilizing Osteo-Assay Microplates 
 
 Osteoclasts differentiated from BMM cell isolations were assessed for in vitro functionality 
using two different methods: quantification of resorbed hydroxyapatite coating, and identification 
of resorption pits from bone slices.  
Hydroxyapatite Resorption Assay: BMM cells were plated in hydroxyapatite-coated Corning 
Osteo-Assay Surface 24-well plates (Corning Life Sciences, USA) using the same culture media 
and cell density used in cell culture (see above). After 14 days of culture hydroxyapatite coated 
plates were washed with 1.2% sodium hypochlorite solution for 5 min to remove cells, rinsed 
with distilled water, and air-dried. For staining, plates were treated in dark at ambient 
temperature with 5% (w/v) silver nitrate solution for 30 min.  Wells were then aspirated and 
washed for 5 min in distilled water. Wells were aspirated again, and 5% (w/v) sodium carbonate 
in 10% formalin was added. After a 5-min incubation at ambient temperature plates were 
aspirated and air-dried at 370C prior to imaging. The resorption pits were imaged using a light 
microscope Zeiss observer Z.1 microscope (Carl Zeiss, USA) and percent resorption area was 
calculated using NIH ImageJ software. 
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Dentin Resorption Assay:  Bovine bone slices were used to assess resorption pits formed by 
mature osteoclasts. Briefly, the diaphyses of bovine femurs were cut transversely into 2-3 cm 
cylinders with a hacksaw. The cylinder was then cut into three segments and the marrow lifted 
out. Any adherent muscle, marrow or periosteum was cleaned with a scalpel. The segments were 
then sonicated in warm water. The bone was given a final cleaning of any adherent tissue with a 
scalpel. Transverse slices 200 µm thick were made on the Isomet Low Speed Saw (Buehler, 
Lake Bluff, IL) with a wafering blade. The bone was then clamped tightly and slices cut at 200 
µm intervals using 10% ethanol in Milli-Q water. These 200 µm slices were trimmed to produce 
the final 4.4 mm x 4.4 mm x 0.2 mm bone slices. The bone slices were stored in 70% ethanol 
until use, then sterilized overnight with UV light in a sterile hood. On the day of experiment, 
bone slices were placed in 24 well plates (1 bone slice/well). BMMs (100,000 cells/bone slice) 
were plated and cultured according to the 5 different groups described above for 14 days. Culture 
medium was changed and every 2-3 days.  Bone slices were then fixed with 2.5% glutaraldehyde 
in PBS for 30 minutes at RT.  Cells were then TRAP stained (Sigma kit #387A-1KT) and 
examined microscopically to observe TRAP-positive osteoclasts.  Bone slices were sonicated for 
5-15 minutes in distilled water to dislodge attached cells and then stained for 30-60 seconds with 
1% Toluidine blue in 1% Borax buffer, rinsed in distilled water, air dried, and examined for the 
presence of resorption pits using light microscope.  The dentin slices were also imaged using 
scanning electron microscopy. Allografts were sputter-coated with gold/palladium for 60 sec 
using a JEOL JSM-5900LV scanning electron microscope (JEOL USA, Peabody MA) operated 
at 10.0 kV and imaged for evidence of resorption pits. 
5.2.5. Statistical Analysis 
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 A student’s t-test (to compare two groups) or one-way analysis of variance with Tukey 
post-hoc testing, (for multiple group comparisons) was used to determine statistical significance 
with p<0.05. Sample size for cell studies was n=3. 
5.3. RESULTS 
5.3.1. Effect of VEGF in Formation and Differentiation of Osteoclast: Bioactivity of 
VEGF 
 
 To assess the efficacy of VEGF as a stimulator of osteoclastogenesis, and to see whether 
this effect was dose-dependent, RAW 264.7 cells were cultured in the presence of both RANKL 
and a low or high concentration of VEGF.  While mononuclear cells can exhibit TRAP-positive 
staining, in this study a cell had to stain positive for TRAP and also be multinucleated (three or 
more nuclei) to be considered osteoclast-like.   There was a statistically significant increase in the 
number of multinucleated TRAP-positive cells when comparing cultures with RANKL alone and 
RANKL + 10ng/ml VEGF (Figure 5.3.1.1), indicating that combining VEGF and RANKL further 
stimulates osteoclastogenesis over RANKL alone.  Data showed trend toward a dose-dependent 
effect as cultures containing RANKL + 100ng/ml VEGF showed an increase in TRAP-positive 
cells over RANKL+ 10ng/ml VEGF cultures (Figure 5.3.1.1). 
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Figure 5.3.1.1: Percentage of TRAP positive multinucleated cells in different groups. (*) indicates 
statistical significance between groups treated with RANKL alone and groups treated with 
RANKL and 100ng/ml VEGF.  A dose-dependent trend was observed in osteoclast differentiation 
on RAW264.7 cells from VEGF 10 ng/ml to 100 ng/ml (each with RANKL solution (50 ng/ml) 
added directly to the media). Data are mean ±SD, n=3 independent experiments. B) Micrograph 
of TRAP positive stained cells.  Only TRAP positive cells with 3 or more nuclei were considered 
osteoclast-like for quantification (circled in red). Scale bar represents 50 μm. 
 
 To evaluate the functionality of VEGF-differentiated osteoclasts BMMs were cultured with 
VEGF similarly to RAW264.7 cells and then assessed with TRAP staining and for bone resorption 
capability.  To confirm the bioactivity of eluted VEGF from the allograft BMMs were also placed 
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below transwell inserts to allow culture in the VEGF released from the allograft, as depicted in 
Figure 5.3.1.1.  TRAP assay results confirmed the efficacy of released VEGF to induce osteoclast 
formation of BMMs (Figure 5.3.1.1) and showed similar results to that of RAW264.7 cell lines. 
Groups treated with VEGF had significantly higher TRAP-positive multinucleated osteoclasts than 
those treated without VEGF (figure 5.3.1.8).  Further, data demonstrated no significant difference 
in the number of TRAP-positive multinucleated cells between the cultures where VEGF was added 
directly (100ng/ml) and where it was released from the coating, confirming that the process of 
coating and releasing VEGF from coated allografts did not alter its bioactivity.  
 
Figure 5.3.1.2: Micrograph of TRAP positive stained cells.  Only TRAP positive cells with 3 or 
more nuclei were considered osteoclast-like for quantification. 
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Figure 5.3.1.3. BMM cells treated with MCSF. No sign of multinucleated osteoclast was 
demonstrated. Scale bar=100 μm. 
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Figure 5.3.1.4: BMM cells treated with VEGF (~140 ng/ml) released from polymer coated 
allograft. No multinucleated osteoclast cell was observed. Scale bar=100 μm 
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Figure 5.3.1.5: BMM cells treated with RANKL (50ng/ml). In the presence of RANKL BMM 
differentiate into TRAP positive multinucleated osteoclasts. Scale bar=100 μm. 
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Figure 5.3.1.6: BMM cells treated with RANKL (50 ng/ml) and VEGF (100 ng/ml) added directly 
to the cell medium. Multinucleated TRAP positive osteoclasts were observed on day 5 of culture. 
Scale bar=100 μm 
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Figure 5.3.1.7: BMM cells in the presence of RANKL (50ng/ml) and VEGF (~140 ng/ml) released 
from coated allograft. Presence of TRAP positive multinucleated cells verifies the bioactivity of 
released VEGF. Scale bar=100 μm. 
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Figure 5.3.1.8: Effect of released VEGF on osteoclastogenesis of bone marrow-derived 
mononuclear cells as determined by TRAP-positive cell counts.  All wells were treated with 
MCSF. An increase in cell numbers confirmed the effectiveness of the released protein. There was 
a significant increase in osteoclast differentiation between the groups with or without VEGF, 
which confirms the bioactivity of the protein. There is no effect of VEGF alone on osteoclastic 
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differentiation. Significance between groups is designated with (*) = p<0.05. Data are mean± SD, 
n=3 independent experiments.  
5.3.2. Functionality of VEGF induced Osteoclasts: Bioactivity of VEGF 
  
 The ability of the osteoclasts differentiated from BMM cells to resorb bone was 
confirmed by staining osteo-assay plates with Von Kossa stain.  Figure 5.3.2.1 shows 
photomicrographs of synthetic hydroxyapatite mineral surfaces as black while white regions are 
areas where resorption has occurred due to active acid secretion by differentiated osteoclasts. 
Our results showed that the group with VEGF released from the allografts revealed a 
significantly (p <0.05) higher percent of resorption area over both positive and negative control 
groups (RANKL alone and no RANKL, respectively). These data suggests that the released 
VEGF from PLGA coated allograft enhances the differentiation of bone marrow derived 
monocytes into functional osteoclasts in vitro (Figure 5.3.2.1).    
 143 
 
 
Figure 5.3.2.1: Von Kossa staining on hydroxyapatite coated Corning osteo-assay plate. Cells in 
culture were treated with MCSF, RANKL, and VEGF that had eluted from coated allografts.  The 
white regions of the plates indicate osteoclastic resorption, which was quantified using image J 
software. Scale bar represents 100 µm 
 
 144 
 
 
Figure 5.3.2.2: A significant increase in the resorption activity between the group with and without 
VEGF confirms that the released VEGF not only increased osteoclast differentiation but that cells 
were functional as well. Significance between groups is designated with (*) = P<0.05. Data are 
mean± SD, n=3 independent experiments.  
 We also tested functionality of BMMs that were differentiated to osteoclasts via released 
VEGF on bovine bone chips to assess true bone resorption (fig. 5.3.2.3-5). SEM images revealed 
formation of resorption pits on bovine bone surface (fig. 5.3.2.3-4). The bone slices were also 
stained with TRAP, to confirm the presence of osteoclasts, and toluidine blue to visualize 
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resorption pits. Multinucleated TRAP positive cells were observed on the surface of the bone 
slices and the resorption pits developed a blue to purple color (fig. 5.3.2.5).  These results 
strongly support the notion that incorporating VEGF into coated and loaded allografts will not 
only help stimulate angiogenesis and early vascularization11, but also may likely facilitate 
allograft resorption via osteoclast precursor differentiation, which may encourage bone 
remodeling of the allograft. 
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Figure 5.3.2.3: VEGF induced osteoclast resorption activity on bovine bone slices. SEM images 
of untouched bone slices at different magnifications, indicate the appearance of bone with no 
resorption pits. 
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Figure 5.3.2.4: SEM images of bone slices where cells cultured with VEGF released from coated 
allograft constructs were seeded for 14 days. Cells were removed from the surfaces and SEM 
images were taken at 25x (A), 700x (B) and1800x (C). The resorption lacunae are indicated with 
yellow arrows. 
C 
A 
B 
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Figure 5.3.2.5: The same bone slices shown in figure 5.3.2.3 were also treated with TRAP and 
toluidine blue staining. (A) TRAP staining shows multinucleated osteoclasts on the surface of the 
bone slices (red arrows). (B) Toluidine blue staining depicted the presence of resorption pits (red 
arrows).  
5.4. DISCUSSION 
 
 Autografts are still considered the gold standard for bone grafting because of their 
biocompatibility and propensity to form bone, but limited supply and donor-site morbidities 
A 
B 
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restrict their utility and mandate a viable alternative12.  Allografts are either used alone or in 
combination with autografts and bone graft substitutes and, depending on the specifics of the 
defect site and the nature of the allograft, have a wide range of success. Since allografts are 
commonly harvested from cadavers they are traditionally processed before use to remove or 
minimize any biological activity, thereby lessening any host immune response but also any 
inherent graft bioactivity.  So the degree to which the host tissue heals depends more on non-
biological properties of the allograft like defect-size and graft architecture than inherent 
biological capabilities it may have possessed prior to processing.  It is clear, however, that 
devitalizing allografts to render them safer for transplant hinders their functionality and results 
in inferior healing8,13.   One solution to this has been to add back this functionality or revitalize 
the allografts.  Different approaches to revitalizing devitalized allografts have included, 1) 
creating a synthetic periosteum of cells14, 15, 2) binding and releasing genetic vectors to induce 
host cells to overexpress important growth factors for bone repair and remodeling16, 17, 3) 
modifying the physical structure of the allograft to encourage better host cell migration18, 19, 
and 4) adding a bioactive ceramic coating to the allograft itself 20, 21.  Each attempt has been 
moderately successful but also somewhat complex and challenging when considering scale-up 
and the requirements of large-scale manufacturing.   
 To address these concerns we have developed a novel procedure where a very thin coating 
of degradable polymer has been added to the surface of long bone allografts and loaded with 
relevant growth factors such that they elute with a temporal precision shown to benefit bone 
repair9.  By modifying an implant that is clinically viable and currently used in regular practice, 
and using materials and molecules that have long track records of safety and efficacy, we 
believe our approach may be accepted in the clinic, and by applying this to a known clinical 
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challenge by directly addressing the issues at the heart of the challenge we believe this 
approach has the potential to be an important tool to the orthopaedic surgeon.  This coated 
loaded allograft has been shown here to deliver both VEGF and BMP-2 from the surfaces of 
the long bone allograft such that the VEGF releases in a burst over the first few days after 
implantation and is followed by BMP-2 release over an extended period of time, up to 4 weeks 
longer.  In the previous chapters we established a methodology to apply a polymer coating 
onto the surface of the allograft thin enough to maintain its inherent pore structure (which 
facilitates revascularization and bone formation) and still act as a vehicle to deliver growth 
factors, VEGF and BMP-2, to the defect site. We examined both the release kinetics of each 
growth factor independently from polymer-coated allografts and the osteogenicity of the 
allograft through the bioactivity of the released BMP-2 in vitro and in vivo 9.  We showed how 
VEGF and BMP-2, when loaded individually, and on same coated allograft can be released 
with two distinct delivery kinetics depending on how they are loaded onto the allograft.   
BMP-2 and VEGF, two of the most commonly studied growth factors in bone repair, are 
critically important on their own but also have interconnected roles in the healing process. 
However, less well known are the roles of VEGF in regulating both bone formation and resorption 
through their respective cell types. VEGF plays a significant role in osteoblast functionality. 
Studies have shown that VEGF has a dose-dependent chemoattractive effect on primary human 
osteoblasts and human mesenchymal progenitor cells 22, 23 and is responsible for regulating blood 
vessel invasion (neovascularization) into hypertrophic cartilage.  VEGF also plays a vital role in 
osteoclast differentiation and bone resorption14-17.  Nakagawa et al., found that VEGF caused a 
dose- and time-dependent increase in the area of bone resorption pits excavated by the purified 
rabbit mature osteoclast via two distinct VEGF receptors, KDR/Flk- 1 and Flt-1, in osteoclasts at 
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the gene and protein levels, and VEGF induced tyrosine phosphorylation of proteins in osteoclasts. 
Thus, osteoclastic function and angiogenesis are upregulated by a common mediator, VEGF14. 
Helmrich et al. showed that VEGF in a defect site not only improved vascularization but also 
increased the recruitment of the TRAP and Cathepsin K-positive osteoclasts15. Kaku et al. showed 
in osteopetrotic op/op mice with a severe osteoclast deficiency that injection of VEGF induced 
osteoclast formation during experimental tooth movement16.  In this study we have substantiated 
the osteoclastogenic capacity of VEGF and verified that when released from the coated allograft 
its capacity is retained.  VEGF released from coated allografts resulted in enhanced differentiation 
of osteoclast progenitors in a dose dependent manner, and bone resorption studies verified that the 
differentiated osteoclasts were fully functional as bone resorbing cells.  While in our studies we 
were careful to isolate VEGF release when assessing osteoclastic precursor response, we do 
acknowledge that future studies should be done to fully understand how the overlap of VEGF and 
BMP-2 delivery that we see may impact this response given the design of our delivery system.  
Given that allografts, particularly large scale cortical allografts, have a failure rate of 30-60% at 
the 10-year mark9 in part due to lack of vascularization and limited remodeling via creeping 
substitution22, it is the belief that the early release of VEGF from the coated allografts will both 
encourage neovascularization at the defect site and also differentiate osteoclast precursors to fully 
functional osteoclasts so the implanted allograft becomes a temporary strut that is resorbed to make 
way for new bone rather than a semi-permanent necrotic tissue that is destined to fail years down 
the line. 
5.5.  CONCLUSIONS & FUTURE DIRECTIONS 
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 In this study we have demonstrated released VEGF, traditionally tasked with 
neovascularization, was shown to effect osteoclast progenitor cells and induce them to mature, 
functional osteoclasts capable of resorbing bone.  While in our studies we were careful to isolate 
VEGF release when assessing osteoclastic precursor response, we do acknowledge that future 
studies should be done to fully understand how the overlap of VEGF and BMP-2 delivery that we 
see may impact this response given the design of our delivery system.  
5.6. REFERENCES 
 
(1) Singh H, Levi AD. 2014. Bone Graft and Bone Substitute Biology. In: Patel V, Patel A, Harrop 
J., et al., editors. Spine Surgery Basics, 1st ed. Springer-Verlag Berlin Heidelberg; p 147-152. 
(2) Fleming JE, Cornell CN, Muschler GF. 2000. Bone cells and matrices in orthopedic tissue 
engineering. Orthop Clin North Am 31:357-374. 
(3) Cook SD, Baffes GC, Wolfe MW, Sampath TK, Rueger DC, Whitecloud TS, 3rd. 1994. The 
effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects. J 
Bone Joint Surg Am 76:827-838. 
(4) Kalfas IH. 2001. Principles of bone healing. Neurosurgical focus 10:1-4. 
(5) Mikhael MM, Huddleston PM, Zobitz ME, Chen Q, Zhao KD, An K. 2008. Mechanical 
strength of bone allografts subjected to chemical sterilization and other terminal processing 
methods. J Biomech 41:2816-2820. 
(6) Burchardt H. 1983. The biology of bone graft repair. Clin Orthop Relat Res 174:28-42.  
 153 
 
(7) Enneking WF, Mindell ER. 1991. Observations on massive retrieved human allografts. J Bone 
Joint Surg Am 73:1123-1142. 
(8) Gouin F, Passuti N, Verriele V, Delecrin J, Bainvel JV. 1996. Histological features of large 
bone allografts. J Bone Joint Surg Br 78:38-41. 
(9) Wheeler DL, Enneking WF. 2005. Allograft bone decreases in strength in vivo over time. Clin 
Orthop 435:36-42. 
(10) Peng H, Usas A, Olshanski A, Ho AM, Gearhart B, Cooper GM, et al. 2005. VEGF 
improves, whereas sFlt1 inhibits, BMP2‐induced bone formation and bone healing through 
modulation of angiogenesis. Journal of Bone and Mineral Research 20:2017-2027. 
(11) Kempen DH, Lu L, Heijink A, Hefferan TE, Creemers LB, Maran A, et al. 2009. Effect of 
local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. 
Biomaterials 30:2816-2825. 
(12) Patel ZS, Young S, Tabata Y, Jansen JA, Wong ME, Mikos AG. 2008. Dual delivery of an 
angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model. 
Bone 43:931-940. 
(13) Ramazanoglu M, Lutz R, Rusche P, Trabzon L, Kose GT, Prechtl C, et al. 2013. Bone 
response to biomimetic implants delivering BMP-2 and VEGF: an immunohistochemical study. 
Journal of Cranio-Maxillofacial Surgery 41:826-835. 
 154 
 
(14) Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, et al. 2000. Vascular 
endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of 
mature osteoclasts. FEBS Lett 473:161-164. 
(15) Helmrich U, Di Maggio N, Güven S, Groppa E, Melly L, Largo RD, et al. 2013. Osteogenic 
graft vascularization and bone resorption by VEGF-expressing human mesenchymal progenitors. 
Biomaterials 34:5025-5035. 
(16) Kaku M, Kohno S, Kawata T, Fujita I, Tokimasa C, Tsutsui K, et al. 2001. Effects of 
vascular endothelial growth factor on osteoclast induction during tooth movement in mice. J 
Dent Res 80:1880-1883. 
(17) Stolina M, Kostenuik PJ, Dougall WC, Fitzpatrick LA, Zack DJ. 2007. RANKL inhibition: 
from mice to men (and women). Adv Exp Med Biol. 602:143-50. 
(18) Sharmin F, Adams D, Pensak M, Dukas A, Lieberman J, Khan Y. 2015. Biofunctionalizing 
devitalized bone allografts through polymer‐mediated short and long term growth factor delivery. 
Journal of Biomedical Materials Research Part A DOI: 10.1002/jbm.a.35435. 
(19) Adapala NS, Barbe MF, Tsygankov AY, Lorenzo JA, Sanjay A. 2014. Loss of Cbl–PI3K 
Interaction Enhances Osteoclast Survival due to p21‐Ras Mediated PI3K Activation Independent 
of Cbl‐b. J Cell Biochem 115:1277-1289. 
(20) Street J, Bao M, deGuzman L, Bunting S, Peale FV,Jr, Ferrara N, et al. Vascular endothelial 
growth factor stimulates bone repair by promoting angiogenesis and bone turnover. 2002. Proc 
Natl Acad Sci 99:9656-9661. 
 155 
 
(21) Stevenson S, Horowitz M. 1992. The response to bone allografts. J Bone Joint Surg Am 
74:939-950. 
 (22) Street J, Bao M, deGuzman L, Bunting S, Peale FV,Jr, Ferrara N, et al. 2002. Vascular 
endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. 
Proc Natl Acad Sci USA 99:9656-9661. 
(23) Liu Y, Olsen BR. 2014. Distinct VEGF functions during bone development and 
homeostasis. Arch Immunol Ther Exp (Warsz ) 62:363-368. 
  
 156 
 
6. IN VIVO EVALUATION OF PLGA COATED-GROWTH FACTOR LOADED 
ALLOGRAFT FOR BONE REGENERATION IN A RAT FEMORAL SEGMENTAL 
MODEL 
6.1. INTRODUCTION 
 
 The repair and incorporation of bone graft is a regulated process that is very similar to 
fracture healing. The initial phase is characterized by inflammation and vascular invasion from 
the host, which enables recruitment of mesenchymal stem cells (MSC). These MSCs in the 
presence of growth factors like BMPs differentiate into the bone-forming osteoblast cells [1]. In 
the case of autografts, both graft and host bones contribute to the migration of osteoprogenitor 
cells [2]. In contrast, since allograft does not contain any live cells, healing relies exclusively 
upon host cells and tissues. Due to the lack of growth factors that are present in allograft, the host 
MSCs fail to receive essential stimuli to contribute in bone formation and overall healing. During 
healing process, autografts continue to remodel through osteoclastic resorption of necrotic bone 
followed by osteoblastic formation of new woven bone, later remodeled into stronger lamellar 
bone. In this way, autografts retain its sustainability through normal bone homeostasis. In 
contrast, due to insufficient revascularization, osteoinduction and remodeling of the graft, 
allograft tissue often shows limited healing, leaving a large segment of necrotic bone that is 
unable to respond to normal mechanical loading. Thus, structural allografts have a limited life 
span because microfractures that occur in them over time cannot be remodeled and repaired, and 
they demonstrate a 25–35% failure rate from infection, nonunion and fracture [3,4]. Therefore 
there is a high demand for revitalizing this devitalized allografts by modulating vascular 
ingrowth, osteogenesis, and remodeling. In order to facilitate allograft healing it is imperative to 
recognize the growth factors that contribute to autograft healing and are absent in allografts and a 
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method to introduce these factors onto allografts. In the introduction chapter of this thesis we 
discussed the important growth factors in bone healing and the two most notable factors were 
identified to be vascular endothelial growth factor (VEGF) and bone morphogenetic protein-2 
(BMP-2), which are known to dominantly regulate angiogenesis and osteoblastic bone 
formation, respectively, during skeletal repair. Our in vitro cell studies indicate that VEGF can 
also stimulate osteoclastogenesis in combination with RANKL. In the previous chapters we 
developed a polymeric system that can deliver VEGF and BMP-2 simultaneously from structural 
cortical allograft. Furthermore, we evaluated the bioactivity of the released growth factors via 
cellular assessment.  
 In our preliminary in vivo study we delivered BMP-2 utilizing short and long term delivery 
kinetics. Utilizing the dual delivery method we released approximately 50 µg of BMP-2 in total at 
the defect site. The results indicated dense, organized bone formation along the length of the 
allograft, fully encapsulating the coated allograft. However, the allograft showed no sign of 
resorption, hence no remodeling of the graft. BMP-2 is a very expensive molecule and high dose 
of BMP-2 can cause numerous adverse effects including ectopic bone formation, cyst-like bone 
void formation, and life-threatening cervical swelling [5,6]. Although proven to be an effective 
osteoinducer, the aforementioned adverse effects, along with the possibility of structurally 
abnormal and mechanically unstable bone tissue formation, currently limit the overall clinical 
efficacy of BMPs. The ability to define upper and lower bounds for BMP doses that would both 
form high-quality bone and avoid swelling, void formation, and other side effects would improve 
the prospects of BMP as a tissue engineering adjunct and as a clinical product.  Therefore, in this 
in vivo study we decided to deliver low dose of BMP-2 (at nanograms level) with simultaneous 
delivery of VEGF to enhance allograft healing. During normal bone healing, VEGF expression 
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was shown to peak during the early days while BMP expression peaked at a later time point [7,8]. 
Therefore we anticipate that a sequential delivery of VEGF and BMP-2 will show better allograft 
resorption and bone formation over BMP-2 alone. 
 The primary objective of this chapter is to evaluate the efficacy of coated-loaded 
bioactive allografts to repair large scale critical sized segmental defects in vivo. The femoral non-
union bone defect is a segmental defect model in which a section of the femur is removed. 
Commonly this defect is used to form a critical sized defect (CSD) to ensure non-union, as 
critical sized defects will not heal spontaneously and thus are a good measure of the ability of an 
implant to promote healing where healing would not otherwise occur [9]. A CSD has been 
defined as “the smallest intraosseous wound that would not heal spontaneously throughout the 
lifetime of an animal” [10]. For long bones this is defined as those defects having a length 
greater than or equal to a distance twice the diameter of the bone itself [11]. In a male Sprague-
Dawley rat weighing 300-325 g, this length is approximately 6mm [12-14]. It is hypothesized 
that coated allografts containing BMP-2 will show enhanced bone formation over uncoated 
allografts. It is also hypothesized that delivery of both VEGF and BMP-2 in a temporally 
controlled way will increase healing over either BMP-2 alone. Specifically, given the nature of 
the bone defect to be used, segmental defects, it is anticipated that bone repair will occur via 
endochondral ossification. For this reason it is anticipated that an initial release of VEGF will 
encourage angiogenesis and osteoclastogenesis, followed by sustained release of BMP-2 will 
result in bone formation and overall better bone repair. 
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6.2. MATERIALS AND METHODS 
6.2.1. In Vivo Femoral Critical-Size Segmental Defect 
 
 Allografts were placed in critical size segmental femoral defects in 10 week-old male 
Sprague-Dawley rats (weights 300-325 g). All procedures were done in accordance with 
approved Institutional Animal Care and Use Committee guidelines. Briefly, the right hindlimb of 
the rat were shaved, and prepped with betadine and 70% ethanol. The femur was approached 
anterolaterally, the periosteum incised, and then removed circumferentially. A small plate was 
fixed to the femur with four Kirschner wires and two surgical steel cerclage wires and a 6mm 
critical-sized full-thickness defect was created in the central third of the diaphysis. The allografts 
were shaped to final size intraoperatively and placed into the defects to achieve a press-fit, and 
maintained in place using a single 4-0 Vicryl (Ethicon, Somerville, NJ) cerclage stitch that was 
tied around the graft and plate.  A three-layered closure of the muscle, subcutaneous tissue, and 
skin was performed with 4-0 Vicryl.  After 4 and 8 weeks post-implantation animals were 
sacrificed and the femur was harvested, the metals were removed from the limbs and the femurs 
were kept fixed in 70% ethanol (fig. 6.2.1.1). 
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Figure 6.2.1.1: Steps involved in implantation of allografts into a rat femur bone defect model. (A) The right hindlimb of 
the rat is shaved, and prepped with betadine and 70% ethanol. (B) An incision is made in the right hindlimb of the rat and 
the surrounding muscle is dissected to expose the femoral bone. (C) A custom made polyethylene plate is placed against 
the bone. (D, E) The plate was secured using four Kirschner wires and two surgical steel cerclage wires. (F) A sterile 
surgical ruler is used to measure the length of the allograft. (G) A 6 mm defect is created in the bone using a dremel cutting 
burr. (H) The construct is secured in the defect by press fit. (I) Graft was maintained in place using a single 4-0 Vicryl and 
(J) A three-layered closure of the muscle, subcutaneous tissue, and skin was performed. 
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The groups that were evaluated in this study are stated in table 6.2.1.1. 
Table 6.2.1.1: Allograft treatment groups for animal study 
Healing Time Rats required to test the treatment method 
 BMP-2 encapsulated 
PLGA coated 
allografts 
VEGF surface adsorbed  and 
BMP-2 encapsulated PLGA 
coated allografts 
Uncoated 
allografts 
4 weeks 4 4 4 
8 weeks 4 4 4 
 
6.2.2. Radiological Analysis 
 
 Bone formation on each rat femur was analyzed at 26 kV for 6 seconds using the Faxitron 
X-ray machine and the Faxitron DX-Beta SR v1.4 software. 
6.2.3. MicroCT Analysis 
 
 Limbs harvested at week 4 and 8 weeks were imaged using cone beam micro-focus X-ray 
computed tomography to render three-dimensional reconstruction of the defect (μCT40, Scanco 
Medical AG, Bassersdorf, Switzerland). Serial tomographic images were acquired at 55 kV and 
145 μA with a 300 msec integration time. A set length of the distance between the two proximal 
pin holes of the Kirschner wires was analyzed within the defect. Using image J software new 
bone area was measured using the radiographs from MicroCT. 
6.2.4. Histological Analysis & Histomorphometry 
 
 Limbs were embedded in methyl methacrylate using a slow methylmethacrylate (sMMA) 
processing, infiltration and embedding techniques as described by Kecena et al., [33] and then 
sectioned at 5 μm thickness with a diamond saw microsectioning system., and mounted onto 
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glass slides. Undecalcified tissue sections were stained with Goldner’s Trichrome stain to 
visualize areas of new osteoid formation (which stains red) and new mineralized tissue (which 
stains deep green). It is also possible to visualize red blood cells with the Trichrome stain as they 
appear yellow-orange. Toluidine blue stain was used to detect osteoblasts and osteoclasts based 
on location of cells and shape, size, and number of nuclei of the cells. All staining was performed 
according to protocols described by Kecena et al. [33]. Histomorphomerty analysis was 
performed using a Nikon Eclipse E600 microscope (Nikon, Tokyo, Japan) coupled with a digital 
camera DN100 NIKON (magnifications of 4, and 10 lens). Osteomeasure software was used to 
quantify new bone area in each sample within the region of interest (ROI).  
6.2.5. Statistical Analysis 
 
 For quantification analysis, a two-way analysis of variance (ANOVA) was preformed to 
compare data. Error is reported in figures as the standard deviation (SD) and significance was 
determined using a probability value of p < 0.05 (n=4). 
6.3. RESULTS 
6.3.1. Radiographic and MicroCT Analysis 
 
 Radiographs of rats representing each implant type were taken throughout the healing 
process. Figure 6.3.1.1 shows healing in the control group (allografts with no growth factor) after 
4 weeks. Radiographs show virtually no evidence of callus formation or mineralization. Figure 
6.3.1.2 shows progression of healing during 8-week in allografts loaded with BMP-2 alone and 
allografts with VEGF and BMP-2. There is radiographic evidence of mineralized callus 
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formation in allografts loaded with BMP-2 and VEGF after 4 weeks of healing and at 6 weeks 
the grafts demonstrated increased opacity with approaching bridging, suggesting more healing at 
this time point. At week 8 almost complete bridging between the ends of the defect is seen along 
the length of the graft. Allograft loaded with BMP-2 alone showed less callus formation than 
VEGF+BMP-2 group with partial bridging at 8 weeks, indicating loading of dual growth factors 
not only show more bone formation over single growth factor but can also accelerate the healing 
process.  
 
 
 
Figure 6.3.1.1: Healing of the control (allograft without growth factor) after 4 weeks. No visible 
healing is evident on the radiograph. 
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Figure 6.3.1.2: Sample radiographs taken of limbs at every two weeks demonstrating the 
progression in healing within allograft treated with BMP-2 alone and BMP-2 and VEGF. Allograft 
treated with dual growth factors showed increased radiopacity within the defect site at week 4 and 
approaching complete bridging of the implant at week 8, whereas the group with single growth 
factor showed less radiopacity throughout the healing period. 
 
 To further confirm our X-ray findings, we performed microCT analysis using samples 
from 4- and 8-weeks post-surgery. Micro-CT analyses demonstrated that the size of the external 
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callus at the host/allograft junction in both BMP-2 and BMP-2 +VEGF group were larger and 
contained more mineralized bone than the allograft alone groups (fig. 6.3.1.3) at 4 and 8 weeks 
post-transplantation. MicroCT 3-D rendered images for the entire repair region further 
demonstrated that a bony union was achieved only in the BMP-2+VEGF groups at 8 weeks post-
surgery , while the gap between allograft and host bone was still visible in both allograft alone 
and BMP-2 groups (fig. 6.3.1.4 ).  
 
Figure 6.3.1.3: Representative radiographs (from MicroCT) of the dissected limbs after 
sacrificing the animals at 4 and 8 weeks. Groups include allograft with no treatment (control), 
BMP-2 encapsulated polymer coated allograft and VEGF surface adsorbed and BMP-2 
encapsulated polymer coated allograft. Formation of callus was observed in the VEGF surface 
adsorbed and BMP-2 encapsulated coated allograft at 4 weeks and bone union at the host 8 
weeks. BMP-2 encapsulated coated allograft showed callus around the defect zone at 8 week but 
no callus formation was seen at 4 week. The control group showed the least bone regeneration 
among the three groups. Scale bar = 1 mm 
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Figure 6.3.1.4: MicroCT analysis of femoral bone defect at 4 and 8 weeks post-implantation. 
Representative three-dimensional reconstructed images are shown for control, BMP-2 
encapsulated coated allograft and VEGF surface adsorbed and BMP-2 encapsulated coated 
allograft. Very limited of new bone growth was detected through the defect site in the control 
group, whereas the group treated with VEGF+BMP-2 shows bridging surrounding the defect 
site. The group treated with BMP-2 alone shows some union at the host-graft interface but not as 
robust as VEGF+BMP-2 group. 
 
6.3.2. Histological Analysis  
 
 Histological analysis confirmed the same bone formation trend that was observed in the 
microCT scans. The VEGF+BMP-2-loaded allografts showed extensive bone formation around 
the defect sites and almost full bridging of the cortices (fig.6.3.2.1 and 6.3.2.2). At 4 weeks there 
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was significant difference in bone formation between control group and the groups with growth 
factors (fig. 6.3.2.3 a). At 8 weeks BMP-2 + VEGF group showed enhanced bone formation over 
the other two groups, however it was not statistically significant (fig. 6.3.2.3 b). Allografts 
loaded with no growth factor showed evidence of thin layer of osteoid formation with no 
mineralized tissue and fibrotic tissue along the length of the allograft was observed (fig 6.3.2.1, 
6.3.2.2, 6.3.2.4). The coated and BMP-2 loaded allograft showed callus formation along the 
length of the allograft, however, a closer examination at the allograft revealed that there was no 
sign of remodeling on the cortex of the allograft (6.3.2.5). In contrast, the coated and BMP-2 and 
VEGF loaded allograft demonstrated not only new bony union between the live host bone and 
the allograft surfaces but also partial resorption of the allografts and replacement of the resorbed 
dead bone with viable new bone (fig. 6.3.2.6-8). Figure 6.3.2.8 depicted continuing active 
resorption of the dead cortical bone with new bone.  
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Figure 6.3.2.1: Representative histological images of Goldner’s Trichrome –stained longitudinal 
sections 4 weeks post-implantation imaged under 10X magnification. Goldner’s trichrome stain 
showed no sign of bridging around uncoated/unloaded allograft.  Control and BMP-2 group show 
evidence of unmineralized osteoid within the defect site, peripheral to the allograft while there’s 
evidence of initiation of callus formation surrounding the defect VEGF +BMP-2 loaded allograft.  
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Figure 6.3.2.2: Representative histological images of Goldner’s Trichrome –stained longitudinal 
sections 8 weeks post-implantation imaged under 10x magnification. Goldner’s trichrome stain 
showed limited healing around uncoated/unloaded allograft.  Control group shows evidence of 
unmineralized osteoid within the defect site, peripheral to the allograft while there’s evidence of 
mineralized bone approaching bridging the defect and surrounding the VEGF +BMP-2 loaded 
allograft. The BMP-2 loaded allograft showed some callus formation around the defect site but 
no evidence of bridging.   
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Figure 6.3.2.3: Quantification of new bone area from bridging mineralized calluses of each group. 
Bone area was quantified from the histological slides stained with Golder’s trichrome. * indicates 
p<0.05.  
8 Weeks 4 Weeks 
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Figure 6.3.2.4: Histological section of uncoated/unloaded allograft (A) stained with toluidine blue 
shows fibrotic tissue (f) that covered the periosteal surface of necrotic allograft. Image was taken 
at 5x.  
 
 
 
 
 
 
 
 
 
 
A 
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f 
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Figure 6.3.2.5: Histological section of Allograft (A) encapsulated with BMP-2 alone. Toluidine blue staining  showed 
callus formation around the defect site, indicated by black arrow (a), however the periosteal surface of the allograft (A) 
showed no evidence of remodeling, indicated by * (b). Image (a) was taken at 5x magnification and b) was taken at 20x 
magnification and scale bar= 50 µm 
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Figure 6.3.2.6: Histological section of allograft (A) loaded with BMP-2 and VEGF stained with 
Toluidine blue. Low magnified image of the allograft section stained with toluidine blue showing 
formation of new bone around the cortex of the allograft, indicated by black arrow and evidence 
of remodeling on the cortex of the allograft is indicated by #. Image was taken 5x magnification.  
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Figure 6.3.2.7: Zoom in view of the cortex of the allograft showing cortical bone remodeling is in 
progress where space created by osteoclastic bone resorption is being filled by newly synthesized 
bone in the presence of osteoblast. Image was taken at 40x magnification and scale bar= 20 μm. 
OS=osteoblast, NM= new matrix, A= allograft, OC=osteoclast 
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Figure 6.3.2.8: Toluidine blue stained section of the allograft (A) showing resorption pit created 
by osteoclast (OC) on the surface of the graft (yellow arrow) and formation of new woven bone in 
the resorption lacuna. Image was taken at 40x magnification and scale bar= 20 μm. 
6.4. DISCUSSION 
 
 Despite the advancement of regenerative medicine to overcome the issues associated with 
large segmental defects, effective healing between the host and the allograft implant still remains 
a major challenge. Allograft implants do not initiate the repair processes seen in normal fracture 
healing due to the lack of biological factors. Five-year follow-up studies have demonstrated 
substantial concerns with allograft incorporation into host bone particularly with intact allograft 
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tissue [27, 28]. Incorporation is a series of events leading to gradual replacement of the old 
necrotic bone by living new bone as a result of creeping substitution, a mechanism of 
osteoclastic resorption followed by deposition of new bone. A bone graft is considered to be 
incorporated when there is no abrupt histological change between the host bone and the graft. 
Stevenson et al defined successful incorporation as the graft uniting with the host, with the graft-
host bone construct able to tolerate physiological loads without fracture or pain. From the 
perspective of basic science, the complete incorporation is defined as rapid vascularization and 
substitution of original graft bone with new host bone without substantial loss of strength. In 
short, events that are essential for allograft incorporation are: vascularization, allograft resorption 
and new bone formation. Therefore, we have developed a novel procedure where a very thin 
coating of degradable polymer has been added to both endosteal and periosteal surfaces of long 
bone allografts and loaded with relevant growth factors such that they elute with a temporal 
precision shown to benefit bone repair by stimulating vascularization, osteoclastic and 
osteoblastic activity.  
 In the present study, our main objective was to investigate the efficacy of dual delivery of 
VEGF and BMP-2 in allograft healing over BMP-2 alone, in vivo. First, we sought to determine 
the effect of combined delivery of BMP-2 and VEGF on bone formation. Noteworthy, thought 
there is no significant difference in bone formation between BMP-2 +VEGF and BMP-2 alone, 
however, a trend is evident that shows more new bone formation in the group treated with BMP-
2 and VEGF over the other two groups. There was significant difference between the control 
group and allograft treated with dual growth factors, however, no significant increase in bone 
formation between VEGF+ BMP-2 and BMP-2 alone was noticed. At 8 weeks post-
implantation, the amount of newly formed bone tended to be higher in the VEGF+BMP-2 group 
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compared with defects treated with BMP-2 alone and control with no statistical difference. The 
trend is encouraging and we anticipate by increasing the sample size a significant increase in 
bone formation between VEGF+BMP-2 and BMP-2 alone could have been attained. These data 
correlate with the results of Young et al.,[15] Patel et al.,[16] and Kempen et al.[17] who found 
increase in bone formation by combining BMP-2 with VEGF is more profound at the earlier time 
points of the healing. Peng et al., for instance, have shown that VEGF antagonists actually 
reduce the induction capacity BMP-2 to form bone, while BMP-2 in the presence of VEGF 
showed enhanced bone formation22. Further, the degree of bone formation after exposure to both 
factors was partially dependent on the ratio of one to the other, with higher amounts of BMP-2 
compared to VEGF eliciting more bone formation than the reverse.  Kempen et al. engineered a 
composite scaffold consisting of PLGA microspheres loaded with BMP-2, embedded in a 
poly(propylene) scaffold, surrounded by a VEGF-loaded gelatin hydrogel.  Despite the release of 
98% of the VEGF within the first 14 days, the VEGF+BMP-2 group formed more vessels and 
bone than the other groups. Patel et al. reported that the sequential delivery of VEGF and BMP-2 
accelerates the healing process through a rat cranial critical-size defect model that evaluated the 
angiogenic and osteogenic response to porous poly(propylene fumarate) scaffolds with gelatin 
microparticles that released VEGF and BMP-2. The experimental constructs that released both 
BMP-2 and VEGF showed accelerated bone healing over those releasing BMP-2 or VEGF alone.  
In another study of co-release of VEGF and BMP-2 examining the chemotactic role of each 
molecule, Ramazanoglu et al. examined expressions of collagen type I, Osteocalcin, and 
Osteopontin.  Increased collagen I from VEGF+BMP-2 groups confirmed the chemotactic 
migration behavior elicited by VEGF on osteoblasts.  At week 4, the VEGF+BMP-2 group 
showed higher osteopontin expression.  Since osteopontin regulates bone remodeling by helping 
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osteoclasts bind to bone, an increase in its expression was interpreted as an indication of bone 
remodeling [18].  Thus the physiological basis for delivering both VEGF and BMP-2 from the 
same allograft is well founded given their traditional roles as vasculogenic and osteogenic 
molecules, respectively.  
 The adverse effects of super-physiological dosage of BMP-2 that are currently being used 
clinically is alarming [5,6]. The current therapies utilizing BMP-2, such as INFUSE (contains 1.5 
mg/ml rhBMP-2), exceeds physiological levels of the factor (1 µg/kg) by several orders of 
magnitude [29,30]. In the present study, we used ~ 300 ng/ml of rhBMP-2 which is several 
orders of magnitude lower than what is currently being used clinically (1.5 mg/ml). Using this 
low dose of BMP-2, we were able to show enhanced bone formation over the control groups, 
however none of the animals showed complete bridging in BMP-2 alone group. Literature 
indicates in rodent sub-therapeutic concentrations of BMP-2 with bony nonunion is less than10 
µg/mL; therapeutic concentration with robust bony union, normal trabecular architecture, and 
marrow cellularity is 10-50 µg/ml; and supra-therapeutic concentrations with bony union 
accompanied by cyst-like bone devoid of normal bone structure and cellularity is more than 150 
µg/ml [32]. According to this report, we used concentration of BMP-2 lower than sub-optimal, 
hence, we observed bone formation around the defect site with no complete bridging. However, 
interestingly, in the dual group as we combined low dose of VEGF (~180 ng/ml) with BMP-2 
(~300 ng/ml) we noticed almost complete bridging of the allograft.  For large critical-sized 
defects that cannot heal spontaneously, a burst release of growth factors that recruits progenitor 
cells into the scaffold, followed by a sustained release that promotes osteoblastic differentiation 
has been suggested as the ideal release strategy[31]. Long-term release of BMP-2 might 
stimulate osteoblastic differentiation of osteogenic stem cells or progenitors existing in the 
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surrounding of the implants for a longer time period. To attain dense bone formation with 
bridging we may need to release more BMP-2 (~10 µg/ml) from the coated allograft. Further 
consideration should be taken to study this defect model utilizing a larger defect size, between 7-
10 mm and/or in larger animal models where the distance between the bony ends of the defect 
increases and hemostasis is better controlled. 
In this study, we sought to improve allograft healing by not only creating bony bridging of the 
allograft cortices but also imparting remodeling of the graft. Different approaches to revitalizing 
devitalized allografts have included, creating a synthetic periosteum of cells [19,20], binding and 
releasing genetic vectors to induce host cells to overexpress important growth factors for bone 
repair and remodeling [21,22], modifying the physical structure of the allograft to encourage 
better host cell migration [23,24], and adding a bioactive ceramic coating to the allograft itself 
[25,26].  Each attempt has been moderately successful but also somewhat complex and 
challenging when considering scale-up and the requirements of large-scale manufacturing. 
Noteworthy, researchers have attempted to improve the healing of allograft by either enhancing 
bone formation or imparting remodeling of the allograft. Our hypothesis is stimulating resorption 
of the graft through osteoclast formation and simultaneous induction of new bone formation on 
the periosteal and endosteal surface of allografts is a superior method to improve graft 
incorporation. Our coated allograft demonstrated higher release of VEGF at earlier time points, 
contribute to angiogenesis and osteoclastogenesis followed by sustained release of BMP-2 which 
contributes to new bone formation. Ito et al, performed a similar study where they attempted to 
treat allograft fracture in mice by utilizing gene therapy to deliver VEGF and RANKL [22]. They 
reported, a substantial increase in the release of VEGF at day 4, peaked at day 8 and then started 
to plateau and reached the baseline at week 3. The released amount of RANKL couldn’t be 
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detected as the amount was always lower than the detection limit (30 pg/ml). The histological 
analysis of their study at 4 weeks post-implantation indicated, evidence of continuing 
osteoclastic resorption of the cortical dead bone with new bone formation, however, the 
resorption and subsequent formation of new bone did not occur uniformly on the allograft 
surfaces with parts of some allografts only being resorbed [22]. In the present study, we 
emphasized both on bone formation and the remodeling of the allograft implant. Both microCT 
and histology analysis indicated that BMP-2 and VEGF loaded allograft  demonstrate healing by 
stimulating live, vascularized, remodeled graft with bony union. In contrast, BMP-2 loaded 
allograft depicted bone formation surrounding the defect zone but failed to show any sign of 
bridging or remodeling of the allograft. In the previous chapter we showed VEGF can contribute 
to the enhancement of osteoclast formation in the presence of RANKL in vitro. In this study the 
presence of osteoclastic resorption activity on the surface of the allograft supports our in vitro 
finding. VEGF not only contribute to the invasion of cartilage by blood vessels in endochondral 
ossification but also stimulate the cascade of events that lead to remodeling of the graft by 
inducing osteoclast resorption.  As the old necrotic allograft was resorbed by osteoclastic 
activity, new woven bone matrix, synthesized by sustained release of BMP-2, replaced the site to 
complete the remodeling process. 
6.5. CONCLUSION & FUTURE DIRECTIONS 
 
 In this study we have demonstrated the dual release of VEGF and BMP-2 with temporal 
precision from polymer-coated cortical allograft can stimulate new bone formation as well as 
remodeling of the allograft in a critical-size defect.  The combined release of BMP-2 and VEGF 
showed more promising result in healing allograft fracture than BMP-2 alone. Released VEGF, 
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traditionally tasked with neovascularization, was shown to effect osteoclast progenitor cells and 
induce them to mature, functional osteoclasts capable of resorbing bone and sustained release of 
BMP-2 can stimulate osteoblastic activity which results in synthesis of woven bone hard callus, 
gradually remodeled to lamellar bone.  We recognize that vascularization plays a critical role in 
healing large scale bone defects. Therefore, future studies should be performed to establish the 
technology and protocols for in vivo 3D imaging of vascular ingrowth of allografts for large-animal 
preclinical and clinical trials. In this study we showed remodeling of the allograft qualitatively, 
however, a quantitative assessment of the osteoclast and resorption lacunae is essential to further 
confirm allograft resorption and remodeling. Histological sections should be stained with TRAP 
stain and the number of osteoclast present on the surface of the allograft as well as at the graft-host 
junction should be counted. Finally, since the primary function of structural bone is to support 
loads, the biomechanical properties of coated-loaded allografts must be determined and correlated 
with volumetric parameters determined by micro-CT in auto- and allografts after various healing 
periods. 
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7. SUMMARY AND CONCLUSION 
 
 The ultimate goal of a bone tissue engineer is to design a graft that mimics the tissue it is 
meant to replace while facilitating the regeneration of a patient’s own bone. In the present 
project, we built upon a successful PLGA coated bone allograft design by loading osteogenic 
growth factor, BMP-2, and angiogenic growth factor VEGF. Furthermore, we investigated that 
VEGF, usually associated with angiogenesis can stimulate mature and functional osteoclasts and 
contribute to remodeling of necrotic bone. This study has demonstrated the feasibility of 
imparting biofunctionality to devitalize allograft through the addition of a thin factor-loaded 
polymer coating while maintaining the inherent structure of the allograft. Furthermore, we were 
able to design a polymer coated allograft as a carrier for local and controlled supply of growth 
factors that are imperative to enhance bone remodeling process which may improve the loss of 
functionality of intact allografts. By utilizing two different loading schemes, namely - surface 
adsorption and physical encapsulation, initial burst and gradual release of the growth factors 
were achieved.  Surface adsorption of VEGF resulted in a burst release with almost all of the 
protein being released in the first few days.  Physical encapsulation of BMP-2 showed a 
sustained release throughout the second and third weeks.  Multiple growth factors are able to be 
released in a controlled manner with the ability to load any desired concentration while still 
maintaining the physical structure of the allograft.   
Moving forward, a greater focus needs to be placed on the release of the growth factors and the 
factors that affect their release.  More studies need to be done with different polymer 
concentrations to better understand the extent of its effect on the release of loaded growth factors.  
A protocol must be established to measure the loading efficiency of growth factor. The degree of 
initial burst from the polymer coating depends on the ability of the polymer matrix to encapsulate 
 187 
 
the protein, thereby making it unavailable for immediate diffusion. For this reason, efforts to 
reduce the initial burst have followed the same track as those that were used to increase 
encapsulation efficiency. Although the increase in encapsulation efficiency does not necessarily 
lead to reduction of the burst release, developing a protocol to maximize the encapsulation 
efficiency will be useful in controlling the release profile. Furthermore, impact of varying 
concentration of loaded protein on release kinetics of the growth factors needs to be studied. This 
approach of growth factor incorporation is not limited to VEGF and BMP-2.  Antibiotics, such as 
gentamicin, which may need to be released in a bolus after implantation could be surface adsorbed 
to provide both acute and chronic delivery. This continuous release has great potential with 
antibiotics like gentamicin, which should be released over a 4-6 week period.  Further refinement 
of the coating process is also essential to obtain a continuous coating and more consistent release 
profile of the growth factors. 
In vitro studies demonstrated that both growth factors remained bioactive after being introduced 
to the polymer solution and throughout its release. These findings show the ability to deliver 
growth factors in a way to mimic the natural healing process of bone in the human body. The 
physiological basis for delivering both VEGF and BMP-2 from the same allograft is well 
founded given their traditional roles as vasculogenic and osteogenic molecules, respectively. The 
additional role of VEGF in stimulating osteoclastogenesis, described in chapter 5 is particularly 
beneficial for allograft healing. Allografts show very minimal osteoclast driven remodeling of 
the necrotic bone, resulting in microfractures in the graft area. VEGF, turned out to be the 
common molecule that has the potential of enhancing allograft healing by inducing angiogenesis 
and osteoclastogenesis.  
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 In future, evaluation of secondary structure of the released protein throughout the study would 
further confirm the conformation and denaturation of the protein. In this study, we primarily 
focus on the role of VEGF in osteoclastogenesis, using RAW264.7 cells and Bone Marrow 
Derived Macrophages (BMMS), both are progenitor cells for osteoclasts. Future studies may 
consider evaluating the angiogenesis ability of VEGF, released from the coated allograft. 
Utilizing human umbilical vein endothelial cells (HUVECs) or Endothelial progenitor cells 
(EPCs), Endothelial progenitor cells (EPCs) display high neovascularization, angiogenic, 
proliferative and survival potential in vitro. Detecting antibodies such as vWF, CD31, VE-
Cadherin, PECAM-1 as well as DAPI and actin would be critical in confirming endothelial 
lineage.  To this end, gene expression of Angiopoietin 1, Angiopoietin 2, VEGFA should be 
determined using RT-PCR. Moreover, it will be interesting to examine simultaneous effects of 
BMP-2 and VEGF released from allografts on osteoblast, osteoclast and endothelial progenitor 
cells and depict the crosstalk between growth factor on a cellular level.  
Though the use of allograft is the best alternative to autograft by surgeons, allografts demonstrate 
reduced incorporation, poor mechanical integrity at the interface, poor mechanical properties of 
the allograft as a whole since the tissue is not being remodeled during healing, fracture non-
unions, and poor allograft vascularization. Researchers have attempted different approaches to 
revitalizing devitalized allografts by creating a synthetic periosteum of cells, binding and 
releasing genetic vectors to induce host cells to overexpress important growth factors for bone 
remodeling. Each attempt has their own challenges and shortcomings. In our in vivo study we 
investigated how simultaneous and sequential delivery of BMP-2 and VEGF can induce not only 
bone formation but also graft remodeling which is most essential for overall allograft healing. 
Cortical allograft incorporation occurs via reverse creeping substitution, incorporation initiated 
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by osteoclast resorption followed by new bone formation. A method that allowed for the 
incorporation and controlled delivery of growth factors implicated in fracture healing and bone 
repair would be extremely beneficial in assisting bone-allograft integration and subsequent bone 
repair. Given that unstable bone defects (fractures, segmental defects) undergo endochondral 
ossification, it may be prudent to develop a factor delivery system that can deliver both BMP-2 
and VEGF in temporally controlled patterns specific to that mode of bone repair. To the author’s 
knowledge, this is the first account of the simultaneous delivery of VEGF and BMP-2 from 
coated allograft to enhance overall healing by stimulating bone formation and remodeling. We 
successfully demonstrated that delivering multiple growth factors enhances bone formation over 
single growth factor. We also qualitatively assess remodeling of graft and allograft treated with 
BMP-2 and VEGF and showed allograft healing by generating remodeled, bony union. Total 
number of TRAP positive osteoclasts onto the graft and at graft-host interface would provide us 
a quantitative evaluation of remodeling of the graft, since osteoclast resorption initiates the 
remodeling and incorporation process in cortical allograft. Additional assessment of mechanical 
properties of the structural allografts must be done as these grafts primarily provide immediate 
mechanical support.  
In conclusion, this simple but effective method of delivering two important molecules with 
temporal precision for bone repair may provide the orthopaedic surgeon with a new tool in the 
armamentarium for treating large scale bone injuries brought about by tumor resection and 
trauma, and may serve to reduce or eliminate the long term complications seen with the 
traditional use of devitalized structural allografts 
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APPENDIX: PROTOCOL 
 
PROTEIN LOADING PROTOCOL 
 Encapsulation: 
1. Dissolve 50:50 Polylactide-co-glycolide (PLGA) in tetrahydrofuran with a 1:8 w/v ratio. 
2. Vortex the solution for 30-45 minutes so that the polymer dissolves completely in the 
solvent. 
3. Dissolve 500 ug of BMP-2 into 1ml of 20 mM Acetic Acid. Vortex the protein solution 
to get a homogenous solution. 
4. In order to attain a protein-polymer solution system, add 200 ul of 500 ug/ml 
concentrated BMP-2 to the polymer solution dissolved in THF. 
NOTE:  Do NOT add the full 200 ul of BMP-2 at once to the polymer solution. Add 50 ul 
at once and let it dissolve and then add the next aliquot. Adding the full 200 ul protein 
solution to the polymer causes precipitation. 
5. After adding the 200 ul of protein check the miscibility of the protein-polymer solution, if 
it’s homogenous. 
6. Coat the allograft samples with BMP-2 encapsulated PLGA coating (following the 
coating protocol). 
Surface adsorption: 
1. Dissolve 50:50 Polylactide-co-glycolide (PLGA) in tetrahydrofuran with a 1:8 w/v ratio. 
2. Vortex the solution for 30-45 minutes so that the polymer dissolves completely in the 
solvent. 
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3. Coat the allografts following the coating protocol. 
4. 5 ug of lyophilized protein was provided by sigma. 
M= 5 ug = 5 X 10-3 mg 
5. The loading concentration of the protein to be surface adsorbed on the allograft was chosen 
as 5 ug/ml. In order to attain the concentration add 1 ml of water to the protein vial supplied 
by vendor. 
6. Place the coated allograft in a centrifuge tube. Add 200 -250 ul of the concentrated protein 
solution.  Freeze them in -20C freezer for overnight and the lyophilize them. 
 
ELISA PROTOCOL: 
1. Prepare all reagents, working standards, control, and samples as directed in the previous 
sections. 
2. Remove excess microplate strips from the plate frame, return them to the foil pouch 
containing the desiccant pack, and reseal. 
3. Add 50 µl of Assay Diluent RD1N to each well. 
4. Add 50 µl of Standard, Control, or sample* to each well. Mix by gently tapping the plate 
frame for 1 minute. Cover with the adhesive strip provided. Incubate for 2 hours at room 
temperature. A plate layout is provided to record standards and samples assayed. Aspirate 
each well and wash, repeating the process four times for a total of five washes. 
5. Wash by filling each well with Wash Buffer (400 µl) using a squirt bottle, manifold 
dispenser, or autowasher. Complete removal of liquid at each step is essential to good 
performance. After the last wash, remove any remaining Wash Buffer by aspirating or 
decanting. Invert the plate and blot it against clean paper towels. 
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6. Add 100 µl of Mouse VEGF Conjugate to each well. Cover with a new adhesive strip. 
Incubate for 2 hours at room temperature. 
7. Repeat the aspiration/wash as in step 5. 
8. Add 100 µl of Substrate Solution to each well. Incubate for 30 minutes at room temperature. 
Protect from light. 
9. Add 100 µl of Stop Solution to each well. Gently tap the plate to ensure thorough mixing. 
10. Determine the optical density of each well within 30 minutes, using a microplate reader set to 
450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength 
correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 
nm. This subtraction will correct for optical imperfections in the plate. Readings made 
directly at 450 nm without correction may be higher and less accurate. 
 
CELL FEEDING PROTOCOL 
1. Turn blower and U.V light on in the hood; make sure all supplies needed are in the hood. 
Wait for 15 min. 
2. Warm media in 37 C water bath for 20 min. 
3. Wipe down hood first with Lysol, then with 70% ethanol 
4. Prepare a sterile beaker containing bleach; wipe it down with 70% ethanol. 
5. Remove media from the water bath. Wipe off water with paper towel, and then spray with 
ethanol. 
6. Wipe microscope stand with paper towel spray with 70% ethanol. 
7. Remove cell culture flask from incubator, and wipe down with 70% ethanol. 
8. Using the microscope examine the confluency/ growth of cells in the culture flask. 
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9. Spray ethanol again and place cell culture flask in the hood. 
10. Turn vacuum on. Remove a sterile glass pipette and attach to vacuum pump. 
11. Place cell culture flask vertically. Remove lid from the cell culture flask, place lid button side 
down, and aspirate media. Close cell culture flask. 
12. Aspirate bleach with the glass pipette and dispose of the pipette in the glass container. 
13. Attach 10ml sterile pipette to the dispenser.  
14. Open media, place lid bottom side down, and remove 10ml of media. 
15. Close media bottle. Place cell culture flask vertically. 
16. Open lid of cell culture flask. Add 10 ml of media to the flask and close lid. 
17. Rinse 10 ml pipette by aspirating bleach with it, then dispose the pipette. 
18. Place tissue culture flask back in incubator. 
19. Remove media, and place back in fridge. 
20. Wipe down hood with Lysol and ethanol, turn on U.V light. 
21. Rinse vacuum flask with soap and water. 
CELL SPLITTING PROTOCOL: 
1. Remove cell culture flask from incubator, and wipe down with 70% ethanol. 
2. Since the media contains FBS and FBS and trypsin counter attack, all the media should 
be suctioned out. 
3. Wash the cells with PBS for 2 times. 
4. Add 2 ml of trypsin to detach the cells from the surface of the flask. 
5. Put the flask in the incubator for 2-1 min depending on how efficiently the cells are being 
detached.  
6. Look them under the microscope to see the flow of the unattached cells in the flask. 
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7. Add 4 ml (2X of trypsin) of media to the flask. 
8. Transfer the cell suspension to the centrifuge tube and centrifuge it at 5000 rpm for 10 
min. 
9. As the cells make pallets, take the media out without interrupting the cell pellet.  
10. Add 2 ml of media, vortex it to get a homogenous mixture of cells and media. 
11. Take 90 ul of tryphan blue and 10 ul of media with cells. Mix them well. 
12. Take 1 ul of the solution (trypan+cell) and count them using hematocytometer. 
 
CELL COUNTING PROTOCOL: 
 
USE OF TRYPAN BLUE STAIN AND THE HEMOCYTOMETER TO DETERMINE TOTAL 
CELL COUNTS AND VIABLE CELL NUMBER 
1) Prepare a cell suspension in a balanced salt solution (e.g., Hanks= Balanced Salts [HBSS]) 
2) Transfer 0.5 ml of 0.4% Trypan Blue solution (w/v) to a test tube. Add 0.3 ml of HBSS and 
0.2 ml of the cell suspension (dilution factor = 5) and mix thoroughly. Allow to stand for 5 to 
15 minutes. 
NOTE: If cells are exposed to Trypan Blue for extended periods of time, viable cells, as well as 
nonviable cells, may begin to take up dye. 
3) With the cover-slip in place, use a Pasteur pipette or other suitable device to transfer a small 
amount of Trypan Blue-cell suspension mixture to both chambers of the hemocytometer. 
Carefully touch the edge of the cover-slip with the pipette tip and allow each chamber to fill by 
capillary action. Do not overfill or underfill the chambers. 
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4) Starting with chamber 1 of the hemocytometer, count all the cells in the 1 mm center square 
and four 1 mm corner squares. Non- viable cells will stain blue. Keep a separate count of viable 
and non-viable cells. 
5) Repeat this procedure for chamber 2. 
NOTE: If greater than 10% of the cells appear clustered, repeat entire procedure making sure the 
cells are dispersed by vigorous pipetting in the original cell suspension as well as the Trypan 
Bluecell suspension mixture. If less than 200 or greater than 500 cells (i.e., 20-50 cells/square) 
are observed in the 10 squares, repeat the procedure adjusting to an appropriate dilution factor. 
6) Withdraw a second sample and repeat count procedure to ensure accuracy. 
7) CELL COUNTS: Each square of the hemocytometer, with cover-slip in place, represents a 
total volume of 0.1 mm3. Since 1 cm3 is equivalent to approximately 1 ml, the subsequent cell 
concentration per ml (and the total number of cells) will be determined using the following 
calculations: 
CELLS PER ml = the average count per square X dilution factor X 104 (count 10 squares) 
TOTAL CELLS = cells per ml x the original volume of fluid from which cell sample was 
removed. 
8) CELL VIABILITY (%) = total viable cells (unstained) / total cells (stained and unstained)x 
100. 
 
MTS ASSAY PROTOCOL:  
1. Turn on the plate reader at least 10 minutes before reading results. Use the following settings: 
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 Wavelength/Bandwidth 
Excitation ~480 nm / 20 nm 
Emission ~520 nm / 25 nm 
 
2. Thaw the CellTiter 96® AQueous One Solution Reagent.  
NOTE: It should take approximately 90 minutes at room temperature on the bench top, or 
10 minutes in a water bath at 37°C, to completely thaw the 20 mL size. 
3. Remove well plates from incubators at specified time points (d0, d7, d14, d21). 
4. Replace each well with 1 mL of fresh basal medium. 
5. Pipet 200 µl of CellTiter 96® AQueous One Solution Reagent into each well of the 24-well 
assay plate. 
6. Incubate the plate for 1 hour at 37°C in a humidified, 5% CO2 atmosphere.  
NOTE: To measure the amount of soluble formazan produced by cellular reduction of the 
MTS, proceed immediately to Step 8. Alternatively, to measure the absorbance later, add 
250 µL of 10% SDS to each well to stop the reaction. Store SDS-treated plates protected 
from light in a humidified chamber at room temperature for up to 18 hours. Proceed to 
Step 7. 
7. In a new 24-well plate, make a 1:4 dilution in dIH2O by adding 0.5 mL of MTS/cell medium 
solution from each well to 1.5 mL H2O.   
8. Record the absorbance at 492nm using a UV/V is spectrophotometer plate reader. 
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ALKALINE PHOSPHATASE QUANTIFICATION (BIORAD): 
 
1. Remove well plates at designated time points and remove medium from each well. Rinse each 
well with PBS or Hank’s Balanced Salt Solution and remove. 
2. Add 1 mL of 1% Triton-X 100 to lyse cells. Triton is the detergent to break the cell membrane. 
If necessary, perform additional freeze-thaw cycles or sonicate well plates to ensure cell lysis.  
3. Immediately prior to analysis, mix 1 mL of concentrated diethanolamine buffer and 4 mL of 
dIH2O for each p-Nitrophenylphosphate tablet and dissolve completely. 
NOTE: Calculate the number of samples to analyze and calculate the total volume of 
substrate solution needed. From that, calculate the appropriate number of p-
Nitrophenylphosphate tablets to dissolve. 
4. Remove 100 µl of cell lysate from each well and transfer to a new well plate. 
5. Add 400 µl  of p-Nitrophenylphosphate solution to each well containing cell lysate and 
incubate for 30 min at 37°C in a humidified, 5% CO2 atmosphere. Develop until a bright 
yellow color of reaction product occurs. 
6. Reaction may be stopped by adding 500 µl of 0.4M NaOH to each well. 
7. Record the absorbance at 405-420 nm using a UV/Vis spectrophotometer plate reader. 
NOTE: Volumes of cell lysate, p-Nitrophenylphosphate substrate solution and NaOH may 
be scaled according to the well plate used.  For 24-well plates: 100 µl cell lysate + 400 µl 
substrate solution + 500 µl NaOH 
8. For standard curve: In separate test tubes, prepare a serial dilution of p-Nitrophenol (10 
mol/mL) standard solution (from Sigma-Aldrich, #104-1) with 0.02 N NaOH (as below). 
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Tube 
# 
Diluted p-
Nitrophenyl 
Solution 
 (mL) 
0.02 N 
 NaOH  
(mL) 
Alkaline 
Phosphatase 
Activity 
 (Sigma 
Units/mL) 
1 1 10 1 
2 2 9 2 
3 4 7 4 
4 6 5 6 
5 8 3 8 
6 10 1 10 
 
9. Take a 1mL aliquot from each tube and place in a new well plate. 
10. Record the absorbance at 405-420 nm using a UV/Vis spectrophotometer plate reader using 
0.02N NaOH as a reference.  
11.  Construct a calibration curve of correlating absorbance level with phosphatase activity level 
(sigma unit/mL).  
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ALIZARIN RED STAINING PROTOCOL  
Goal: Calcium deposition 
Mineralized matrix synthesis was analyzed with Alizarin Red staining method for calcium 
deposition. This technique used a colorimetric analysis based on stabilizing the red matrix 
precipitate with Cetylpyridinium Chloride (CPC) to yeild a purple solution. 
Material: 
 4 M Alizarin Red, pH 4.23; add 1.36 g of powder dye to 100 ml of DDI water, use 1N 
NaOH to adjust pH. 
 10% (w/v) Cetylpyridinium Chloride (CPC), pH 7.0; add 10 g of 100 ml of 10 mM 
Sodium phospahte Na2PO4. Use 1N HCL to adjust pH [10 mM Na2PO4; dissolve 0.142 
in 100 ml] 
 70% ethanol 
 PBS w/o Ca or Mg 
Procedure: 
1. Rinse twice culture/sample with PBS to remove any  unattached cells. 
2. Rinse culture sample with DDI H2O. 
3. Fix in 70% Ethanol for 1 hr @ 4C. 
4. Remove ethanol and let air dry for 5-10 minitues. 
5. Wash once with DDI H2O. 
6. Cover sample in 4M (~500 ul) Alzarin Red and incubate for 10 minutes at RT. 
7. Wash samples 5x with DDI H2O (end of stainning assay) 
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8. Wash 1x with PBS and store at RT till ready for the test. 
9. When ready for the test: place 1 ml of 10% CPC on culture and incubate at RT for 15 
mintus. At this point the color will be stable. Samples can be diluted 1:10 in additional 
CPC if necessary (if the machine reads “over” you can dilute.) 
10. Read on a plate reader at 562 nm. 
CULTIVATION OF BONE MARROW MACROPHAGES 
1. Sacrifice mice 4-10 weeks old. 
2. Dissect the hind limbs and clean the muscle tissue from tibia and femur with a scalpel blade. 
3. Separate tibia and femur. Use scalpel blade to chop off the proximal and distal end of each 
bone. 
4. Using 5 ml syringe and 21g needle, flush marrow with complete media (alpha MEM 
supplemented with 10% FBS and 1% pen strep into 50 ml falcon tube.  
5. Spin down the marrow for 5 min at 1200 rpm and resuspend then in ACK buffer (1ml/1 
mouse).  
a. ACK Buffer: Red blood cell lysis buffer: 
For 1 liter of RBC (Red Blood Cell) lysing buffer: 
>>8.3g NH4Cl (ammonium Chloride) 
>>1g NaHCO3 (Sodium bicarbonate) 
>>1mL of EDTA (from a stock of 100mM, pH8.2 in miliQ H2O) 
>>bring to 1 liter with miliQ H2O 
>>filter or autoclave if need sterile 
6. Add complete media and spin the cells down.  
7. Remove the supernatant and resuspend the cells in complete media.  
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8. Seed 100 million of total bone marrow cells in a 10 cm petri dish. 
9. Add 30 ng/ml of MCSF to cell culture. 
10. Change media the very next day and remove the floating cells.  
11. In 3 days the macrophages should form a monolayer of cells and the cells become confluent.  
12. Use accutase to lift the cells.  
13. Add adequate complete media and spin down the cells to collect a pellet.  
14. Resuspend them in complete media.  
15. Culture the macrophages in 24 well plate.  150K /well. 
16. Add adequate RANKL and MCSF for Osteoclast differentiation.  
 
PREPARATION OF CELLS FOR SEM 
1. Fix scaffolds for one hour in 1% (v/v) glutaraldehyde 
2. Followed by 3% (v/v) glutaraldehyde for 24 hours 
3. Dehydrated in ethanol gradient 
    a. begin at 10% (v/v) 
    b. end at 70% (v/v) 
4. Air dry for 24 hours 
5. Sputter coat with gold/palladium 
MODIFIED VON KOSSA FOR HYDROXYAPATITE RESORPTION ASSAY 
1. Plates were washed with 1.2% sodium hypochlorite (bleach) solution for 5 min to remove 
cells. 
a. How to make 1.2% of sodium hypochlorite (bleach) from 10-15% graded sodium 
i. 12.5% (avg) -> 12.5 ml in total 100 ml of solution 
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                          To make 1.2% of solution 100X 1.2/12= 10 ml  
Take 10 ml from 12.5% v/v sodium hypochlorite solution and add 90 ml 
of water.  
2. Rinsed with distilled water and air-dried. No PBS.  
3. For staining, plates were treated in darkness at ambient temperature with 100 ul/well (400 
ul/well in 24 well plates) 5% (w/v) AgNO3 silver nitrate solution for 30 min. 
a. How to make 5% (w/v) AgNO3 
i. 5% (w/v) AgNO3 solution is 5 g in 100 ml 
0.05 g in 1 ml 
1 g in 20 ml - 5% (w/v) 
4. Wells were then aspirated and washed with distilled water and air-dried. No PBS.  
5. Wells were again aspirated, and 100 ul/well 5% (w/v) sodium carbonate in 10% formalin was 
added (400 ul/well for 24 well plates). 
6. After a 5-min incubation at ambient temperature. 
7. The plates were then aspirated and air dried at 500c for 1 hour prior to imaging. Use an 
inverted microscope with 20X objective.   
Note: we tested this procedure on regular well plates where plates aren’t coated with HA. 
The staining procedure doesn’t leave any stains on the regular plates. Therefore under the 
microscope the resorption area will show as white as opposed to black staining on HA coated 
area. 
TRAP assay Protocol: 
1. Prewarm sufficient deionized water for a day’s use to 37°C. Check temperature before use. 
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 2. Bring Fixative Solution to room temperature (18–26°C). Fix slides by immersing in Fixative 
Solution for 30 seconds. Rinse thoroughly in deionized water: Do not allow slides to dry.  
3. To each of 2 test tubes add 0.5 ml Fast Garnet GBC Base Solution and 0.5 ml Sodium Nitrite 
Solution. Mix by gentle inversion for 30 seconds. Let stand 2 minutes. 
 4. Make the following mixture: 
Deionized water prewarmed to 37°C …………………………………………..45 ml  
Diazotized Fast Garnet GBC Solution from Step 3………………………..1.0 ml  
Naphthol AS-Bl Phosphate Solution……………………………………………. 0.5 ml  
Acetate Solution ………………………………………………………………………….2.0 ml  
 Tartrate Solution……………………………………………………………………….. 1.0 ml  
5. Label Coplin jars A and B and transfer solutions from beakers to appropriate Coplin jar. Warm 
solutions in jars to 37°C in water bath. Check that temperature is at 37°C before adding slides.  
6. Add slides to Coplin jars and incubate 1 hour in 37°C water bath protected from light.  
7. After 1 hour, rinse slides thoroughly in deionized water, then counterstain 2 minutes in 
Hematoxylin Solution, Gill No. 3. 
 8. Rinse several minutes in alkaline tap water to blue nuclei.  
9. Air dry and evaluate microscopically.  
 
